Developing a patient-driven, substantive definition of office-based opioid treatment success by Hewell, Valerie Marie
DEVELOPING A PATIENT-DRIVEN, SUBSTANTIVE DEFINITION OF 
OFFICE-BASED OPIOID TREATMENT SUCCESS
By
Valerie Marie Hewell, M. S.
A Dissertation Submitted in Partial Fulfillment of the Requirements
for the Degree of 
Doctor of Philosophy 
in
Clinical-Community Psychology
University of Alaska Fairbanks and Anchorage 
August 2016
APPROVED:
Vivian M. Gonzalez, Ph.D. Committee Co-Chair 
Ellen D.S. Lopez, Ph.D. Committee Co-Chair 
James Fitterling, Ph.D. Committee Member 
Inna Rivkin, Ph.D., Committee Member 
Valerie M. Gifford, Ph.D. UAF Program Director 
Ph.D. Program in Clinical-Community Psychology 
Patricia R. Sandberg, Ph.D., UAA Program Director 
Ph.D. Program in Clinical-Community Psychology 
Todd L. Sherman, M.F.A.
Dean o f the UAF College o f Liberal Arts 
Helena S. Wisniewski, Ph.D.
Vice Provost for Research and Graduate Studies 
Dean o f the UAA Graduate School 
Michael A. Castellini, Ph.D.
Interim Dean o f the UAF Graduate School
Abstract
Patients in office-based opioid treatments’ definitions of treatment success and recovery 
are not well understood. This is important because traditional ways of defining and measuring 
success focus on consumption, and usually abstinence. This definition does not encompass 
medication-assisted treatment, such as office-based opioid treatment, which do not necessitate 
abstinence. Moreover, there is evidence to support the efficacy of office-based opioid treatment 
in reducing the harm associated with opioid misuse, which is important as opioid misuse has 
increased and leads to serious consequences for individuals, families, and society.
To address this gap in the literature, using a qualitative design, this dissertation explored 
patients’ ideas on defining office-based opioid treatment success, recovery, facilitators and 
barriers to treatment success, and recommendations for measuring success. This was achieved by 
conducting a focus group with seven participants and subsequent interviews with seven 
participants, two of whom were also in the focus group, for a total of 12 office-based opioid 
treatment patients in rural Alaska. Grounded theory, directed content analysis, and a community- 
based participatory research approach were used to collect and analyze focus group and 
interview data.
Findings suggest that patients’ definitions of office-based opioid treatment success extend 
beyond consumption and include four main themes: functioning, such as contributing to society 
and living a functional lifestyle; accomplishing, such as reappraising life goals and having an 
intrinsic belief that one can accomplish success; relationships, such as family, friendships, and 
restoring relationships; and psychological factors, such as emotional wellbeing and addiction. 
Recovery was understood as a construct that was related to success, yet distinct, and involved 
healing and growth, a process, and a recovery attitude. Facilitators and barriers to treatment
Ill
success include treatment factors, contextual factors, and psychological factors. Participants also 
recommended measuring success in a way that is individualized and flexible.
This study suggests that providers should take a multifaceted and patient-driven approach 
when attempting to define and measure office-based opioid treatment success. Specifically, 
findings suggest that patients experience success in office-based opioid treatment in ways that 
extend beyond substance consumption. Findings also suggest that contextual barriers, such as 
availability and accessibility of treatment, should be addressed on a systemic level.
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Preface
Like most dissertation undertakings, this project was spawned from a place of passion 
and personal meaning. Through my work as a practicum student and Suboxone® Program 
Director at Turning Point Counseling Services, I was touched by many tragic stories from 
patients. They shared how their lives were negatively impacted by the lack of available or 
sufficient treatment resources for opioid addiction. They shared how they had encountered 
stigma and experienced shame when attempting to seek treatment by those within the very 
system that were supposed to be helping them. They shared powerful stories about perseverance, 
strength, tenacity, and compassion from others that helped them to get the treatment they needed.
These stories prompted me to conduct a mixed-methods research project aimed at 
understanding the factors associated with the use and underutilization of treatment for opioid 
addiction in Alaska by examining the attitudes, perspectives, and knowledge of those who would 
benefit from medication-assisted treatment and of those who deliver services to individuals with 
opioid addiction. From participant’s sharing in this study along with community interpretation of 
the data by the Alaska Advisory Board on Alcohol and Drug Addiction, a need for understanding 
patient’s experiences of success emerged as a relevant future direction. This dissertation is the 
continuation of that study. It is dedicated to the individuals and communities negatively impacted 
by inadequate treatment for opioid addiction.
Along the way, many individuals and groups played integral roles in my ability to 
explore and share this very meaningful work. First, the members of my dissertation committee 
displayed dedication and unwavering commitment to helping me grow as a researcher and to 
helping me make a contribution to informing the direction of office-based opioid treatment in 
Alaska. I especially thank Dr. Ellen Lopez for her support, mentorship, and guidance with
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methodology and Dr. Vivian Gonzalez for providing her expert perspective in the addictions 
literature.
Second, my community partners were essential to the completion of this project. Mr. 
Gunnar Ebbesson and Ms. Cici Schoenberger share the vision I have for increasing access to 
quality services for opioid addiction in the state of Alaska. Mr. Ebbesson supported my vision 
and connected me with individuals and groups that played a role in this project. He continues to 
help me discriminate the work I have done in a way that facilitates its application. Ms. 
Schoenberger was a pleasure to collaborate with and served an integral role in each step of this 
project. She is similarly passionate about increasing access to quality services and is dedicated to 
the wellbeing of her patients. I look forward to continued collaboration with these two in the 
future.
Third, this project was graciously funded by the Alaska Mental Health Trust Authority. 
Other individuals that donated their time and perspective include: Gabriel Cartagena, who 
worked with me on the focus group data collection and analysis; Keri Boyd, Kyle Dexter, and 
Jessica McKay, who helped me pilot the demographics survey and focus group procedures; and 
Mariah Henderson, who donated her graphic design skills to construct a beautiful visual 
representation of the data.
Fourth, my friends, family, and colleagues were vital supports and emotional containers 
for the ups and downs that transgressed during this process. I am endlessly grateful for my cohort 
members and program friends Danielle Giroux, Samantha Bacon, and Keri Boyd, my parents 
including Al and Kathy Hewell, and Chris and the late Nancy Ayotte, and my incredibly 
supportive husband Jared Lundgren.
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Finally, this project is dedicated to the research participants who inspired this study and 
who shared so boldly, along with the patient’s who struggle with opioid addiction only to 
encounter barriers quality treatment. My sincerest goal is that this work will inspire change that 
improves treatment for each of you, and those who have not been able to access treatment. I hope 
what you have shared about office-based opioid treatment success will reach those who are 
involved in service delivery in a way that illuminates the successes that can be experienced in 
this treatment, and in a way that evokes meaningful change.
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Chapter 1: Introduction
Within the field of substance abuse, there are varied views on how success in treatment 
should be defined and measured (Betty Ford Institute Consensus Panel, 2007; Butler Center for 
Research, 2011; Witkiewitz, 2013). Some schools of thought equate success to abstinence, while 
others, specifically the illicit drug abuse literature, view success in terms of a reduction of harm 
and/or a reduction in illicit drug use (Laudet, 2008; MacMaster, 2004). Some treatment options, 
including medication-assisted treatments (defined on p. 4), by definition do not coincide with the 
mainstay assumption that abstinence, the self-denial from all substances, is the desired outcome 
for everyone in treatment (Harm Reduction Coalition [HRC], 2015; Thomas et al., 2014). Instead 
of a predetermined, either-or approach based on the providers’ preferences, treatment should 
concentrate on the patient’s goals, needs, and readiness to change when determining if 
interventions should emphasize a reduction of consumption and the harm associated with use, or 
complete abstinence (MacMaster, 2004).
In addition to inconsistent definitions of treatment success within the substance abuse 
treatment field, little is known regarding patients’ views of what constitutes treatment success. It 
is important to understand the patients’ view of success because their treatment priorities, goals, 
motivation, and sense of control all play important roles in treatment outcomes, such as 
retention, treatment attendance and engagement, negative urinalysis, reduced urges to use, and 
post-treatment abstinence (Brown & Miller, 1993; Cox, Klinger, & Fadardi, 2015; Miller & 
Miller, 2009; Shamloo & Cox, 2014; Zeldman, Ryan, & Fiscella, 2004), as well as other 
functioning, such as employment (Hser, Polinsky, Maglione, & Anglin, 1999). Thus patient 
perspectives are critical considerations for successful treatment implementation. Moreover,
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patients’ views may differ from what is emphasized in standard outcome measures, such as 
substance use and time in treatment (Reisinger, Bush, Colom, Agar, & Batjes, 2003).
This study aimed to build a patient-driven definition of success by qualitatively exploring 
patient-identified aspects of successful treatment among individuals with an opioid use disorder 
who were in an office-based opioid treatment (OBOT) program. OBOT programs use the Food 
and Drug Administration approved pharmaceutical treatments for opioid dependence, 
buprenorphine and the buprenorphine-naloxone combination, Suboxone® in an office-based 
setting as opposed to a structured and regulated medication clinic. It is important to understand 
how OBOT patients understand success because, being approved in 2002, this is a fairly new 
treatment approach in the United States that may deviate from mainstay assumptions about 
treatment success.
Because this study focuses on an opioid-specific treatment, this chapter will provide a 
brief overview of the current prevalence of opioid use in the United States and medication- 
assisted treatment for opioid use disorders. Then, controversies in defining and measuring 
substance misuse treatment success and the current gaps in knowledge regarding patient 
perspectives on these matters will be discussed. Finally, a brief overview of the purpose and 
methodology of this study will be outlined.
Background
Opioid use. Opioid misuse has been deemed a national epidemic due to the recent 
growth in the incidences of opioid initiation (Paulozzi et al., 2012; Substance Abuse and Mental 
Health Services Administration [SAMSHA], 2011) and the harm associated with opioid misuse 
(SAMHSA, 2013 a), including prescription drug addiction and overdose (American Society of 
Addiction Medicine [ASAM], 2016; Bagalman, Sacco, Thaul, & Yeh, 2014; United States
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Department of Health and Human Services [HHS], 2013). In 2010, nearly 5,500 new individuals 
in the United States began using prescription opioids analgesics (painkillers) each day for 
nonmedical reasons, such as experimentation or for recreation (SAMHSA, 2011). Between 2004 
and 2011, emergency medical services associated with opioid use increased by 183%
(SAMSHA, 2013a). Between 1999 and 2010, there was a fourfold increase in death rates caused 
by prescription opioids overdose (Jones, Mack, & Paulozzi, 2013). As of 2012, the average 
number of annual deaths from prescription opioids in the United States was 17,000 (Bagalman et 
al., 2014).
The sudden increase in prescription opioid abuse also appears to be causing an upsurge in 
the rates of heroin use and abuse. Incidences of heroin initiation are 19 times higher in people 
who have previously used prescription opioids for nonmedical purposes (Muhuri, Gfroerer, & 
Davies, 2013), leading many experts to believe that heroin initiation is often precipitated by 
prescription opioid analgesic use (Bagalman et al., 2014; Muhuri et al., 2013). Between 2006 and 
2013, first time heroin use for people in the United States ages 12 and older nearly doubled, 
increasing from 90,000 to 169,000 (SAMHSA, 2013b). Moreover, heroin-related deaths have 
increased significantly in recent years (Rudd et al., 2014).
In Alaska, drug overdose rates, the majority of which include prescription drugs, 
increased by 55% between 1999 and 2010 (Trust for America’s Health, 2013). Notably, the two 
largest ethnic groups in Alaska, Alaska Native/American Indian and non-Hispanic White people, 
have higher death rates from opioids compared with other ethnic groups (Rinaldo & Rinaldo,
2013). Furthermore, 34% of Alaskan citizens live in rural areas (United States Census Bureau, 
2012a), and the literature suggests that higher rates of prescription drug overdose occur in rural
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and impoverished counties (Rinaldo & Rinaldo, 2013). These findings suggest that Alaskans in 
particular are at risk for opioid misuse and the harms associated with it.
To add to this concern, a substantial number of individuals need substance use disorder 
treatment, but they are not receiving it. In 2008-2012, the majority (89.5%) of Alaskan citizens 
who experienced illicit substance use disorders did not receive treatment (SAMHSA, 2013c).
This is comparable to national rates, which suggest that only 1% of Americans receive substance 
use treatment, while 8.6% of Americans need treatment (National Institute on Drug Abuse 
[NIDA], 2015). The treatment gap and the growing rates of opioid-related problems demonstrate 
the need for effective and accessible treatment for Alaskans who are experiencing problems 
related to opioid misuse.
Medication-assisted treatment. Medication-assisted treatment options combine 
pharmacotherapy to treat the physiological symptoms of addiction and behavioral therapy to treat 
the behavioral symptoms associated with addiction (Thomas et al., 2014). In 2002, the Food and 
Drug Administration approved a new medication-assisted treatment for opioid use disorders: 
buprenorphine. Buprenorphine and the buprenorphine and naloxone combination, Suboxone®, 
have been established to be effective, safe, and well-tolerated pharmaceutical treatments for 
opioid dependence (ASAM, 2013; Davids & Gastpar, 2004). They increase patient engagement 
and retention in treatment while reducing symptoms (e.g., cravings, withdrawal, consumption) 
associated with opioid use disorders (ASAM, 2013; Kraus et al., 2011; Rieckmann, Daley,
Fuller, Thomas, & McCarty, 2007). Because this treatment approach uses a partial opioid agonist 
to treat opioid addiction, some do not consider it an abstinence-based approach (Thomas et al., 
2014). The general goal of buprenorphine maintenance treatment is to facilitate either a reduction 
or cessation of illicit opioid use (Thomas et al., 2014).
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Defining and Measuring Success
Defining success and recovery. Measuring substance abuse treatment success is 
challenging due to a disagreement on what constitutes success (Butler Center for Research, 2011; 
McLellan, Chalk, & Bartlett, 2007), which is at least partly informed by the model of addiction 
being ascribed to by different treatment approaches. Additionally, the terms success and recovery 
are frequently entwined, leading to inconsistent and incomprehensive measurement of either 
term.
Recovery is often used as a term synonymous with being in a state of remission or partial 
remission from an addictive disorder across multiple domains of functioning. Individuals are not 
necessarily being “cured” or recovered (past tense) from the given disorder, but are rather in a 
constant process of recovery given the need to actively maintain this status (McLellan et al., 
2007; White, 2007). Because recovery, which typically (although not always) requires 
abstinence, tends to be emphasized in 12-step communities and in many treatment approaches, it 
is important to understand how individuals in non-abstinence based treatments, such as OBOT, 
define both success and recovery.
Identifying attributes of success. Many approaches to defining success and measuring 
treatment outcomes emphasize substance consumption, specifically abstinence (Butler Center for 
Research, 2011; McLellan et al., 2007; Miller & Miller, 2009; Tiffany, Friedman, Greenfield, 
Hasin, & Jackson, 2012; Witkiewitz, 2013). However, there are numerous other categories of 
factors (e.g., biological, psychological, sociocultural) that impact, and are impacted by, the 
development, maintenance, and treatment of addictions. It is argued that improvement across 
multiple domains of functioning, not simply abstinence, is the goal for many individuals in 
substance use treatment and thus should be a consideration for treatment evaluation (McLellan et
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al., 2007). Furthermore, a narrow focus on consumption does not accommodate the goals of all 
patients or treatment approaches, nor does it take into account individual variability in use 
patterns. Therefore, it is also important to understand the multifaceted components that are 
important to patients as outcomes in their treatment beyond consumption.
Evaluating success. Finally, there are established controversies and challenges to 
identifying the outcome domains (i.e., attributes that change as a result of treatment) for 
evaluating substance misuse treatment, particularly when moving beyond consumption. These 
should be chosen based on the setting (e.g., abstinence-only or harm-reduction programs), 
relevancy, and the purpose of evaluation (e.g., clinical, program evaluation, research, societal; 
Carroll et al., 2014; Donovan et al., 2011; Tiffany et al., 2012). In addition to these 
considerations, non-consumption related outcomes might be selected based on sensitivity to 
change due to intervention (Carroll et al., 2014; Tiffany et al., 2012), relationship to consumption 
outcomes over time (Carroll et al., 2014), availability of psychometrically sound measures, 
association with addictive drug use, and generalizability to most substances and users (Tiffany et 
al., 2012). Although some experts have established guidelines for determining outcome domains, 
it remains important to understand and be open to what patients believe should be evaluated, 
given that their goals and motivations have a compelling force in treatment outcomes. 
Patient-Driven Definition of Success
This study uniquely contributes to the literature by exploring an area that has been 
neglected in substance abuse research; specifically, defining successful OBOT from the patient’s 
perspective. Illuminating the patients’ definitions of success may help clinicians, evaluators, and 
researchers to operationally define and concretely measure patient-defined success in OBOT, 
rather than relying on abstinence-based definitions of success that have little applicability to the
6
goals and intended use of this treatment approach. It may also assist health service providers in 
deciding how to intervene with opioid use disorder patients to further improve treatment 
engagement and retention. Although patient-identified outcomes in harm-reduction programs 
have been explored (Lee & Zerai, 2010), successful treatment, the term recovery, and how these 
should be measured according to the patients remain unknown for OBOT.
Study Aims and Research Questions
This study aimed to expand the current understanding of success in substance use 
treatment by developing a patient-driven definition of OBOT success. In collaboration with one 
OBOT program in rural Alaska, this qualitative study was conducted in the following three 
phases:
• Phase I: A focus group with seven active patients was conducted to establish an 
initial framework for OBOT success
• Phase II: Follow-up interviews with seven active patients to refine the initial 
framework were conducted using theoretical sampling techniques
• Phase III: A findings sharing forum was held to share, verify, and further refine 
findings from Phases I and II.
This study adhered to the principles of Community Based Participatory Research 
(CBPR), which is a strengths-based and empowerment approach that engages participants in data 
analysis, interpretation, and dissemination of findings (Israel, Schulz, Parker, & Becker, 1998, 
2001; Kemmis & McTaggart, 2005). Accordingly, the research questions informing the study 
aims included the following:
1) How do OBOT patients define recovery?
2) How do OBOT patients define OBOT success?
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3) What facilitators and barriers do these patients identify as relating to their definition of 
OBOT success?
4) What factors do these patients identify as important for measuring OBOT success? 
Finally, for clarity and ease of reference, acronyms used throughout this dissertation are
included in Table 1.1 below. Four acronyms are referenced in the document, and the rest are 
referenced in the in-text citations.
Table 1.1
List o f Acronyms
Acronym Meaning
APA American Psychiatric Association
ASAM American Society of Addictions Medicine
*
CBPR Community-based Participatory Research
CDC Centers for Disease Control and Prevention
*HIV Human Immunodeficiency Virus
HRC Harm Reduction Coalition
MHALA Mental Health America Los Angeles
NA Narcotics Anonymous
NIDA National Institute on Drug Abuse
*
OBOT Office-based Opioid Treatment
*
SUD Substance Use Disorder
SAMHSA Substance Abuse and Mental Health Service Administration
VHA Veterans Health Administration
-------------------------------------------------------------
Frequently referenced throughout the text.
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Chapter 2: Literature Review
Given the need to expand the established understanding of success in Office-based 
Opioid Treatment OBOT, this chapter will review relevant background that informs this 
dissertation including opioid misuse and treatment (Section A) and defining and measuring 
success (Section B). The first section will cover opioid misuse and treatment options with 
attention to what opioids are, models that inform substance use treatment, substance use 
treatment (including medication-assisted treatment). Then methadone and buprenorphine will be 
reviewed, including the history, recommended uses, and efficacy of each.
Section A: Opioid Misuse and Treatment 
Opioids, Opioid Use, and Opioid Misuse
Opioids. Opioid agonists (chemicals that bind to neuron receptors) can be plant derived 
(e.g., morphine and codeine), semisynthetic (e.g., heroin and oxycodone), or synthetic (e.g., 
fentanyl, methadone, meperidine; Renner, Knapp, Ciraulo, & Epstein, 2014). These substances 
activate the mu opioid neurotransmitter receptor site, which is involved in pain perception and 
reward (NIDA, 2014; Renner et al., 2014), while rare opioid analgesics, like butorphanol, also 
stimulate the kappa opioid neurotransmitter receptor site, which is involved in pain, mood, motor 
control, and consciousness (NIDA, 2014; Renner et al., 2014).
Effects of opioid use. The pharmacological effects of opioids can be sorted into three 
categories: opioid intoxication, opioid withdrawal, and health effects such as opioid overdose. 
Opioid intoxication has a progression of effects, including euphoria, apathy, and an initial burst 
of energy. This is followed by psychomotor retardation, quiescent arousal in a clouded “twilight­
like state”, a sense of warmth and heaviness, constriction of the pupils, dry mouth, hypoactive
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bowels, retarded respiration, slurred speech, and impaired judgment/concentration (Dilts & Dilts, 
2005; NIDA, 2014; Renner et al., 2014).
Prolonged use also may produce changes in a “dose dependent response” which leads to 
physical dependence, whereby withdrawal symptoms are precipitated by the cessation or 
reduction in opioid use (SAMHSA, 2004). Withdrawal symptoms are opposite the symptoms of 
acute opioid agonist use and may include craving, restlessness, cold flashes, kicking of the 
extremities, insomnia, diarrhea, vomiting, and pain (NIDA, 2014). An individual experiencing 
opioid withdrawal will follow three overlapping stages. The first stage peaks 36-72 hours after 
the last dose and involves craving, yawning, sweating, and a runny nose. The second stage 
occurs within 12-72 hours after the last dose and involves sleep disturbance, dilated pupils, 
appetite loss, irritability, and tremors. The third stage occurs within 24-72 hours after the last 
dose and involves an increased severity of the aforementioned symptoms including violent 
yawns, muscle cramps, severe insomnia, chills and fever, nausea, vomiting, and diarrhea (Dilts 
& Dilts, 2005).
In addition to withdrawal, prolonged use of opioid agonists may create tolerance, 
particularly to the effects of euphoria, requiring increasing doses to achieve the desired effects of 
acute intoxication (Renner et al., 2014). Tolerance, dependence, and withdrawal, encompass 
short-term consequences of opioid use. Consequences of long-term use may include deterioration 
in decision-making, behavioral regulation skills, and the ability to adaptively respond to stress 
(NIDA, 2014).
Other consequences of opioid use include negative health effects such as an increased 
risk for contracting infectious diseases like human immunodeficiency virus (HIV) and hepatitis 
and for abscesses with intravenous administration. Further health consequences that can occur,
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regardless of route of administration, include breathing complications, liver disease, kidney 
disease, and risk of overdose (NIDA, 2014). Moreover, opioid use disorders are associated with 
high mortality rates due to infection, suicide, homicide, and accidental overdose (Renner et al., 
2014). One study found that those addicted to opioids experienced premature mortality due to 
factors like injury and disease at rates of approximately six times the rate of the general 
population (Smyth, Hoffman, Fan, & Hser, 2007). Signs of overdose include cardiovascular 
collapse, convulsions, pinpoint pupils, pale skin, apnea, and coma (Dilts & Dilts, 2005). 
Additionally, a serious adverse effect from opioid use is respiratory depression, which is the 
most common effect leading to death from opioids in hospital settings (Jungquist, Karan, & 
Perlis, 2011).
History of opioid use. Opium has been used for medicinal and recreational purposes 
throughout history dating back to the early Greek and Roman eras (Julien, Advokat, & Comaty, 
2011). The use of opioids further materialized in the 1800s when morphine was derived from 
opium to treat pain (Julien et al., 2011). During the Civil War era and with the creation of the 
hypodermic needle, intravenous use of opioids became more common (Julien et al., 2011). In the 
early 20th century, European immigrants, particularly young, troubled, “street criminal” males, 
typified the average user (Courtwright, 2001). With the changing demographic of the typical 
person who misused opioids, the stigma associated with the lower-class immigrants became 
associated with opioid addiction. This, in part, reinforced the cultural assumption in the United 
States that opioid addiction is a product of poor moral character (SAMHSA, 2004).
Opioid use disorder. To meet criteria for an opioid use disorder, a patient must meet at 
least two of the following eleven criteria within a 12-month period (American Psychiatric 
Association [APA], 2013): (a) taking opioids in larger quantities or for longer durations than
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intended; (b) continued use despite desire or attempts to limit or control use; (c) time is 
consumed with opioid use, seeking, or recovery from proximal side effects; (d) presence of 
cravings; (e) failure to fulfill duties (including social, occupational, familial) because of opioid 
use; (f) continued use despite social and interpersonal consequences; (g) other activities are 
given up because of opioid use; (h) recurrent use of opioids in dangerous situations; (i) use 
despite known psychological and physical problems caused or exacerbated by use; (j) presence 
of tolerance; or (k) presence of withdrawal symptoms.
Not everyone who uses opioids as prescribed or recreationally will develop an opioid use 
disorder. There are many factors that are associated with the development of opioid use 
disorders including positive reinforcement associated with opioid use (e.g., experiencing 
pleasure and other positive emotions), negative reinforcement associated with opioid use (e.g., 
reducing pain, anxiety, boredom, depression, aggression, or withdrawals), social approval for 
opioid misuse, environmental cues triggering continued use, experiences of craving, 
psychosocial factors (e.g., availability of opioids and environmental stressors), motivation, drug 
use expectancies, self-efficacy, and opioid receptor disruption (Renner et al., 2014; Tonigan, 
2004). Other factors associated with opioid use disorders include family history and genetic 
predispositions toward substance use disorders, low self-esteem, familial disruption, alcoholism, 
nicotine use, antisocial personality disorder, anxiety, mood disorders, and bipolar disorder 
(Renner et al., 2014; Thombs, 2006). Understanding the etiology and maintaining factors related 
to opioid use disorders are important for determining appropriate treatment approaches.
Although many such factors have been revealed, models of addiction frequently emphasize some 
factors over others.
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Models Informing Treatment Approaches
Moral model. The moral model assumes that addiction is a moral and value-laden 
condition (Thombs, 2006). It suggests that individuals choose to become addicted to substances 
because of personality deficits, such as irresponsibility. Proponents of this model include but are 
not limited to conservative organizations, law enforcement efforts, and fanatical religious groups. 
As such, “treatment” tends to be punitive, to include legal actions, such as jail. Limitations of 
this model include one-dimensional postulations about the multifaceted (e.g., biological, social, 
psychological) factors that influence addiction, the uncertain notion that addiction is a free 
choice, and the erroneous and unsupported assumption that punishment is an effective form of 
treatment (Thombs, 2006).
Disease model. The disease model suggests that addiction stems from a biological 
disposition, such as genetics (Thombs, 2006). This model assumes that individuals with 
addiction are victims of a disease or illness. Proponents of this approach include the field of 
medicine, the industries that produce and market substances (e.g., alcohol and tobacco industries) 
and medications to treat addictions, and the “recovery movement” (e.g., groups of people and 
their families that are “recovering” from addiction). Treatment tends to be compassionate, 
intensive, educationally-based, and medically-managed (Thombs, 2006). For instance, if 
medication-assisted treatment is administered under a disease/medical model, it may be assumed 
that medication alone is adequate and will not emphasize the importance of psychosocial 
treatment or support. However, medication-assisted treatment can be administered in a treatment 
setting that views the medication as a foundation that supports other psychosocial and functional 
changes (Rabinowitz, 2009).
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In the disease model, abstinence is often regarded as a “necessary but not sufficient” 
component for recovery (McLellan et al., 2007). Therefore, someone using medication-assisted 
treatment with a disease explanatory model may have abstinence as the underlying goal. Yet not 
all treatment approaches equate abstinence with improved functioning, and medication-assisted 
treatment approaches need not be synonymous with the disease/medical models of addiction.
This model has normalized addiction as a form of illness, much like any other, which has 
reduced the shame associated with addiction. However some of the underlying assumptions, 
including expectations that abstinence is the only appropriate goal and beliefs that addiction is a 
progressively worsening condition, have been scientifically invalidated (Thombs, 2006). It 
should be noted that a combination of the disease-moral models influence many of the treatment 
approaches currently used in the United States (Thombs, 2006).
Behavioral model. The behavioral model posits that addiction is a maladaptive 
behavioral disorder that an individual learns (Thombs, 2006). This model maintains an objective 
and nonjudgmental stance, and suggests that the behavior of addiction can be shaped by one or 
more factors (e.g., cognition, environment, social circumstances). Psychologists and 
professionals from other similar fields, such as public health, tend to support this model. 
Treatment typically involves behavioral modification, such as changing one’s environment or 
learning skills to prevent relapse, and does not necessitate abstinence. It emphasizes strategies 
that are driven by the evidence of what works, modified according to the evidence, and evaluated 
empirically. Additionally, treatment may include the use of medication, but tends to be 
deemphasized as the main focus (Thombs, 2006).
Biopsychosocial model. Whereas the disease model defines opioid use disorders as a 
disease, primarily emphasizing the biological underpinnings and consequences of the disorder
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(ASAM, 2013), the biopsychosocial model considers biological, psychological, cognitive, and 
sociocultural aspects that lead to and are disrupted by the disorder (Donovan & Marlatt, 2005; 
Tellioglu, 2010). It recognizes that an individual may develop an addiction due to both individual 
and environmental factors (Kosten & George, 2002). Treatment tends to be interdisciplinary in 
nature, recognizing the intricacies of addiction (Donovan & Marlatt, 2005). This treatment model 
informs OBOT, which should attend to the biopsychosocial factors above and beyond opioid use 
without imposing the goal of abstinence (Kraus et al., 2011). These different ways of explaining 
addiction inform how substance use treatment approaches deliver treatment and understand 
treatment success.
Patient-centered models. In addition to the above explanatory models, there has been a 
recent emphasis on patient-centered, strengths-based, and individualized approaches to treating 
chronic conditions, such as substance use (Mental Health America Los Angeles [MHALA],
1995; SAMHSA, 2010a; Veterans Health Administration [VHA], 2011). These systems of 
healthcare (including the Psychosocial Rehabilitation Model [MHALA, 1995], Recovery- 
Oriented Systems of Care [SAMHSA, 2010a], and Psychosocial Rehabilitation and Recovery 
Services [VHA, 2011]) prioritize the patients’ goals, values, culture, and community as 
important elements of treatment and “recovery,” and respect patients’ abilities to direct their 
treatment. Moreover, they veer from the medical models’ definition of recovery by shifting the 
focus away from first treating the symptoms of a patient and toward first viewing the patient as 
the focus of treatment (MHALA, 1995). This is accomplished by listening to the needs and 
desires of the patient while emphasizing the importance of meeting the patient’s functional goals 
(MHALA, 1995). This approach, coupled with the biopsychosocial explanatory model of 
addiction, builds the foundation for this dissertation, which seeks to bring to light the patient’s
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views of success in OBOT. Moreover, this dissertation is patient-centered, strengths-based, 
empowerment-focused, and respects the rights of individuals to direct their own treatment. 
Substance Use Treatment
Most people who need treatment for substance use do not receive it. While it is estimated 
that 8.6% of Americans need substance use treatment, only 1% of the entire population actually 
receive it (NIDA, 2015). Between 2008 and 2012, 89.5% of Alaskan citizens ages 12 and older 
who had illicit substance use disorders did not receive treatment (SAMHSA, 2013c). In general, 
those who do receive treatment for opioid misuse tend to be dependent for two to three years 
before seeking treatment (Renner et al., 2014). Overall, the national rates of those seeking 
treatment for opioid misuse increased between 2002 and 2013, with prescription opioid misuse 
treatment-seeking increasing from approximately 360,000 in 2002 to 746,000 in 2013 and 
treatment-seeking associated with heroin increasing from 277,000 in 2002 to 526,000 in 2013 
(SAMHSA, 2013b), which is likely related to increases in opioid use disorders during this time 
period, rather than increased availability of treatment resources.
Reasons for not seeking substance use treatment include no health care coverage, no 
desire to stop using, not knowing where to receive treatment, belief that treatment was not 
needed to handle the problem, financial costs (even with health care benefits), transportation 
issues, and conflict with employment (e.g., difficulty getting needed time off; SAMHSA, 2015). 
Also, most people with substance use disorders recover spontaneously, or without entering 
treatment (Renner et al., 2014). Those who spontaneously recover tend to have better social 
functioning, less psychopathology, and fewer legal problems (Rounsaville & Kleber, 1985). This 
evidences the important role of resources and motivation for seeking services, and social, 
psychological, and legal factors for overcoming or managing opioid use disorders.
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Evidence-based practices. Since the early 1990s, knowledge related to evidence-based 
practices and treatments for people with substance use disorders has increased, yet 
implementation of these practices has lagged (Power, Nishimi, & Kizer, 2005). Seven practices 
have been recommended as a means to increase evidence-based practices for substance use 
treatment, including: (a) screening patients in medical, primary care, or mental health settings for 
substance use concerns; (b) conducting an initial brief intervention with clients who screen 
positively for substance use concerns; (c) creating a specific treatment plan for those who meets 
diagnostic criteria for a substance use disorder through the assessment process; (d) using 
evidence-based psychosocial interventions for clients who receive specialty care, which may 
include therapies such as motivational enhancement therapy, cognitive-behavioral therapy, 
structured family/couples therapy, contingency management, community reinforcement therapy, 
and 12-step programs; (e) considering pharmacotherapy that is directly linked to psychosocial 
treatment, particularly for individuals with opioid dependence and alcohol disorders; (f) 
encouraging initial engagement and ongoing retention with consideration for the patient’s 
readiness to change; and (g) collaboratively discussing recovery and chronic care management in 
treatment (Power et al., 2005). In summary, substance use treatment should take a patient- 
centered and collaborative approach to screening, intervening, and retaining individuals in a 
treatment, which should include psychosocial interventions and potentially pharmacotherapy 
(Power et al., 2005).
Medication-assisted treatment. Medication-assisted treatment comprises 
pharmacological interventions integrated with counseling, social services, and psychosocial 
treatment, including behavioral approaches. Medication-assisted treatment has been shown to 
have the greatest likelihood of success for people with opioid use disorders (SAMHSA, 2005).
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Medication-assisted treatment approaches for opioid misuse can involve short-term 
detoxification, longer-term opioid replacement therapy, and antagonist treatment with naltrexone 
(Renner, et al., 2014). Medication-assisted treatment can be used in settings like opioid-treatment 
programs using methadone, or as an OBOT using buprenorphine (e.g., Suboxone® and Subutex®; 
SAMHSA, 2005). Many proponents of medication-assisted treatment ascribe to principles of 
harm reduction that recognize “any positive change” as a success (Lee & Zerai, 2010, p. 2411), 
thereby allowing for a range of individualized strategies to be used, from reduced or managed 
use to complete abstinence (HRC, 2015). Incidentally, opioid replacement therapy largely holds 
to a disease model view of addiction.
Historically, there have been challenges preventing the widespread adaptation of 
medication-assisted treatment, including stigma about patients with opioid use disorders (Gordon 
et al., 2011) and about medication-assisted treatment (Roose, Fuentes, & Cheema, 2012), lack of 
education about buprenorphine, and lack of interest in using medication-assisted treatment 
(Gordon et al., 2011). Despite these challenges, because of medication-assisted treatment’s 
effectiveness in improving treatment outcomes for those with opioid use disorders, the National 
Institute of Health has called for state and federal leaders to increase the use of medication- 
assisted treatment through implementing strategies that reduce stigma, decreasing arbitrary 
regulation, and increasing access to treatment (NIH, 1997). In the next section, methadone and 
buprenorphine treatments will be discussed separately with an emphasis on their historical 
context, pharmacological properties, typical treatment structure, and efficacy.
Methadone
Historical context. In 1919, the Supreme Court upheld the Harrison Act, which placed 
regulations on opioids and other substances. This had implications for the existing treatment
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centers that were already dispensing morphine as a means of treating their opioid addicted 
clientele (SAMHSA, 2005). These programs were shut down by the early 1920s, which led to an 
increase in illicit opioid-related crime (SAMHSA, 2005). “Narcotic farms,” which admitted 
voluntary and prison inmates for detoxification services using medical, psychological, and social 
modalities, were instated by 1929 (SAMHSA, 2005). Although these prison-like programs were 
unsuccessful according to high relapse rates (Duvall, Locke, & Brill, 1963; Hunt & Odoroff, 
1962), they did serve as the foundation for new treatment advances, including medication- 
assisted treatment (White, 1998).
The increased rates of opioid use disorders and the harm associated with opioid use, 
coupled with research supporting the efficacy of opioid-treatment programs (but not supporting 
other psychosocial alternatives) led to more support for opioid-treatment programs, such as 
methadone, during the legislative administrative eras of Kennedy and Nixon (SAMHSA, 2005). 
Researchers attempted to find opioids with longer half-lives to treat opioid addiction medically, 
and observed that methadone was effective at reducing opioid cravings and the euphoria 
associated with opioid use with minimal side effects (Dole, 1988). During the 1970s, there was a 
public push to support and fund methadone maintenance treatment in opioid-treatment programs 
settings (SAMHSA, 2005).
Pharmacology. Methadone is a mu opioid agonist that is absorbed orally. It reaches peak 
concentration approximately four hours after it is administered and has a slow half-life (one to 
two days), thereby reducing the euphoric effects and abuse potential (Renner et al., 2014). 
Although adverse reactions are rare, possible side effects of methadone include drowsiness, 
sedation, endocrine effects (or lowered hormonal levels which may result in lowered libido, 
sexual dysfunction, decreased energy, depression, and amenorrhea in women), constipation,
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nausea, vomiting, sleep-disordered breathing, and respiratory depression (Seewald, 2013; 
Webster, 2013). The recommended dose of methadone is between 60-120 mgs/day (Centers for 
Disease Control and Prevention [CDC], 2002). There is evidence to suggest that doses should be 
individualized, yet higher doses generally produce more efficacious results, such as a decrease in 
illicit opioid use as measured by positive urinalysis (Strain, Bigelow, Liebson, & Stiler, 1999).
Treatment structure. Effective methadone maintenance treatment should consider 
individual factors when providing the recommended dose (60-120 mgs/day), retain patients for at 
least 12 months of treatment, consider co-occurring mental and substance use disorders, and 
have realistic expectations of the normal day-to-day variations individuals experience in 
addictions treatment (CDC, 2002). Counseling is often integrated into methadone maintenance 
treatment. However, two randomized controlled trials found no differences between those in 
counseling plus methadone compared with those on just methadone alone (Schwartz, Kelly, 
O’Grady, Gandhi, & Jaffe, 2011, 2012). Despite evidence of methadone being efficacious as a 
standalone treatment, addictions experts continue to recommend the use of methadone in 
conjunction with psychosocial treatment, such as counseling, as the standard of care (Renner et 
al., 2014).
Efficacy. Methadone has demonstrated efficacy in reducing harm and increasing the 
viability of improved functioning (Rieckmann et al., 2007). One critical assessment of the 
evidence that reviewed meta-analyses, systematic reviews, and individual studies established 
methadone maintenance treatment as a highly effective treatment (Fullerton et al., 2014). 
Methadone has been shown to be effective in improving social functioning, including decreasing 
drug-related HIV risk behaviors (Fullerton et al., 2014; Gearing & Schweitzer, 1974; Sees et al., 
2000; Wilson, Schwartz, O’Grady, & Jaffe, 2010), mortality rates (Fullerton et al., 2014),
20
criminality (Fullerton et al., 2014; Schwartz et al., 2011), and financial connections related to 
drugs (i.e., drug-related income and money spent on drugs; Schwartz et al., 2006; Schwartz et al., 
2011). People who used methadone on an interim basis were more likely to be admitted into 
methadone maintenance treatment compared to individuals on a waitlist (Schwartz et al., 2006). 
Additionally, methadone is also associated with better treatment outcomes, including improved 
retention (Fullerton et al., 2014; Sees et al., 2000), decreased illicit opioid (Schwartz et al., 2006; 
Schwartz et al., 2012; Sees et al., 2000) and decreased use of other drug use (Schwartz et al.,
2011).
Through decades of research, methadone maintenance treatment has been established as 
the most effective treatment for opioid dependence (CDC, 2002). However, stigma and other 
systemic barriers have limited the widespread use of methadone maintenance treatment 
(SAMHSA, 2005). Moreover, methadone maintenance treatment may not be the preferred form 
of treatment for all patients. One drawback to methadone maintenance treatment is that it is a 
Drug Enforcement Agency Schedule III drug that must be dispensed, but not prescribed, at 
designated opioid treatment programs (O’Connor & Fiellin, 2000; SAMHSA, 2004). 
Buprenorphine
Historical context. Another medication used in medication-assisted treatment, 
buprenorphine, has also demonstrated efficacy in the treatment of opioid misuse. In 2000, a 
federal law was enacted that, under the Drug Addiction Treatment Act provisions, extended the 
use of medication-assisted treatment from only opioid-treatment programs (e.g., methadone 
maintenance treatment) to qualified general medical facilities providing OBOT (SAMHSA, 
2004). In 2002, the Food and Drug Administration approved a new medication for opioid- 
dependence: buprenorphine. Buprenorphine can be prescribed by a general physician who has
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taken an 8-hour addictions course and applied for a special waiver, and is classified by the Drug 
Enforcement Agency as a Schedule III medication. The office-based administration of 
buprenorphine offers a viable solution to the systemic barrier presented by methadone treatment, 
namely the regulations requiring methadone use only within specific clinics (Phillips & Preston,
2013).
Buprenorphine has been determined to be comparable to methadone treatment, with few 
contraindications (Kraus et al., 2011). Contraindications and considerations that may preclude 
the use of buprenorphine treatment include dependence on sedative-hypnotics (e.g., 
benzodiazepines) or alcohol, untreated psychiatric or medical conditions, active suicidality or 
homicidality, multiple treatment attempts and relapses (specifically poor response to 
buprenorphine), and the physician’s lack of competency (SAMHSA, 2004). Those who may be 
good candidates for buprenorphine treatment have an opioid use disorder, do not have 
contraindications, are motivated, and are aware of all treatment options (SAMHSA, 2004). More 
specifically, patients that have demonstrated positive outcomes in buprenorphine treatment 
include those who are younger and who have shorter opioid abuse histories (Renner et al., 2014).
Pharmacology. Buprenorphine is a partial mu opioid agonist with a high affinity for 
opioid receptors, meaning that it fully binds with the mu opioid receptor site to deter withdrawal 
symptoms (by means of its partial agonist properties) and effectively block other agonists 
(SAMHSA, 2004). It is also a strong kappa opioid receptor agonists (by virtue of its high 
receptor affinity; Renner et al., 2014; Washington & Fanciullo, 2013) and a nociception agonist 
(Washington & Fanciullo, 2013).
The various receptor-binding properties at these different sites create the side effect 
profile, and the analgesic properties (Washington & Fanciullo, 2013). Because buprenorphine is
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a partial, not a full, opioid agonist, the side effect profile is milder than that of full agonists with 
similar side effects including dizziness, headache, constipation, nausea, vomiting, rare 
respiratory depression (typically when used in conjunction with sedative-hypnotics), 
precipitation of hypotension, rare cases of allergic reaction, endocrine effects (e.g., lowered 
libido), and psychiatric effects (e.g., insomnia, fatigue, anxiety, vertigo, and confusion; 
Washington & Fanciullo, 2013). Moreover, because it only partially agonizes the mu opioid 
receptor, a ceiling effect occurs by which limited agonal properties occur, even with increased 
doses (SAMHSA, 2004). Two forms of buprenorphine are available: Subutex® (buprenorphine) 
and Suboxone® (a combination of buprenorphine and naloxone). Naloxone is an opioid 
antagonist, meaning it blocks opioid receptors (SAMHSA, 2004) and produces unpleasant 
precipitated withdrawal when injected.
The general recommended dose for stabilizing patients on buprenorphine is 8-24 mgs/day 
with the recognition that some patients may need 32 mgs/day (Kraus et al., 2011). Studies have 
found that 8 mg and 16 mg groups have better retention than 1 mg groups (Ling et al., 1998). An 
8 mg dose also outperforms 1 mg groups on global rating (by clients and staff) of drug problems, 
drug use (based on urine drug screens), and cravings (Ling et al., 1998). Nevertheless, patients 
should be in opioid withdrawal before being given the first dose of buprenorphine to avoid 
precipitating withdrawal (Renner et al., 2014; SAMHSA, 2004). Moreover, buprenorphine 
requires sustained use to reach its full therapeutic benefit (Kraus et al., 2011).
The abuse properties of buprenorphine have been evaluated (Bazazi, Yokell, Fu, Rich, & 
Zaller, 2011; Comer et al., 2010). One study that evaluated the abuse of buprenorphine, 
buprenorphine-naloxone, and heroin found that the buprenorphine-naloxone combination had the 
lowest intravenous abuse rates and the lowest self-reported rating of desire to take the drug again
23
(Comer et al., 2010). Another study that examined self-reports from 100 opioid users found that 
opioid users who injected as a route of administration were more likely to report illicit diversion 
of buprenorphine/naloxone to “get high.” Thus it appears intravenous opioid users have a higher 
potential for diverting the intended use of buprenorphine/naloxone, such as using it illicitly. 
However, those who report past illicit use of buprenorphine/naloxone described primarily using 
it illicitly to avoid withdrawal symptoms (74%), to deter opioid use (66%), and because of 
financial barriers to treatment (64%; Bazazi et al., 2011). This suggests that illicit buprenorphine 
use may be more motivated by attempts to self-treat addiction than an indicator of addictive 
behavior. Overall, these findings suggest that, despite the reservations of some who oppose 
buprenorphine, evidence of abuse potential of buprenorphine/naloxone when used as prescribed 
is nonexistent. Further, the rate of those who misuse, abuse and divert this medication to get high 
is relatively low.
Treatment structure. Typical OBOT involves three phases: (a) induction, including 
discontinuing the use of other opioids and determining the appropriate dose of buprenorphine;
(b) stabilization, which initiates once withdrawal symptoms are managed; and (c) maintenance, 
which focuses on psychosocial issues related to opioid use disorder (SAMHSA, 2004). No 
standard length for treatment has been established. Patients in buprenorphine treatment may 
engage in short term treatment (i.e., less than 12 months) or indefinitely depending on the agreed 
upon treatment plan between client and provider (SAMHSA, 2005).
The recommendations for buprenorphine maintenance treatment suggest the following 
factors should be considered when designing individual treatment plans to address opioid use 
disorders: biopsychosocial needs; comorbidity of psychiatric, medical and other substance use 
disorders; legal issues; employment/financial issues; social and familial support; and somatic
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impacts of drug use (Kraus et al., 2011; SAMHSA, 2005). These recommendations are important 
as they suggest that treatment should address factors above and beyond opioid use, for instance, 
biopsychosocial considerations. As such, it has been recommended that buprenorphine 
maintenance treatment include a psychosocial component (Kraus et al., 2011). However, based 
on standard outcome measurements such as retention and illicit opioid use, randomized 
controlled trials have not consistently found better treatment outcomes for buprenorphine plus 
psychosocial treatment (Amato, Minozzi, Davoli, & Vecchi, 2011; Moore et al., 2012; Weiss et 
al., 2011). Some evidence suggests that psychosocial treatment (e.g., cognitive behavioral 
therapy, supportive counseling) has no effect on retention (Amato et al., 2011; Moore et al.,
2012), illicit drug use (Amato et al., 2011; Moore et al., 2012; Weiss et al., 2011), psychiatric 
symptoms, or treatment compliance (Amato et al., 2011). However, other evidence suggests 
buprenorphine plus psychosocial treatment and/or mutual support groups are associated with 
longer treatment retention (Stein, Cioe, & Friedmann, 2005), higher session attendance (Moore 
et al., 2012), and abstinence the week after treatment (e.g., a cognitive-behavioral therapy 
session; Moore et al., 2012) and at follow up (Amato et al., 2011). For example, in one study, 
buprenorphine maintenance treatment patients believed psychosocial treatment was important 
even when it was not required as a means to help them with psychosocial concerns (e.g., self 
esteem) and to share and connect with others with similar stories (Egan, Netherland, Gass, 
Finkelstein, & Weiss, 2011).
Some may interpret these results to suggest that physician monitoring may be sufficient 
for successful implementation of buprenorphine (Renner et al., 2014). Yet, when considered, 
psychosocial treatment has been shown to be effective in some studies. Still, many studies 
evaluate standard outcome measures (i.e., retention and consumption) and do not consider the
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multifaceted benefits that may result from buprenorphine plus psychosocial treatment, such as 
improved coping and psychosocial functioning. Nevertheless, treatment recommendations often 
advise psychosocial treatment as a necessary component of buprenorphine maintenance 
treatment (Kraus et al., 2011; SAMHSA, 2005).
Efficacy. Buprenorphine has been established as an effective, safe, and well-tolerated 
drug (Davids & Gastpar, 2004) that increases client engagement and retention while reducing 
withdrawal effects and opioid use (ASAM, 2013; Kraus et al., 2011; Rieckmann et al., 2007; 
SAMHSA, 2004). Buprenorphine outperforms placebos for reducing cravings (Fudala et al.,
2003), illicit opioid use (Fudala et al., 2003; Johnson et al., 1995; Kakko, Svanborg, Kreek, & 
Heilig, 2003), illicit use of other drugs (Kakko et al., 2003), requests for dose increases (Johnson 
et al., 1995), and treatment retention one year after initiating treatment (Kakko et al., 2003). 
Methadone Compared to Buprenorphine
A nationwide analysis of medication-assisted treatment trends found that from 2002 to 
2011, buprenorphine replaced methadone as the most commonly used medication-assisted 
treatment for opioid use disorders (Riksheim, Gossop, & Clausen, 2014). Moreover, attrition 
rates decreased and patients enrolled in treatment increased during this time (Riksheim et al., 
2014). This illustrates that buprenorphine is increasingly becoming an important treatment option 
for those with opioid use disorders.
The clinical efficacy of buprenorphine compared with methadone has been mixed. Some 
studies have found that buprenorphine and methadone are similar in clinical efficacy as 
determined by urinalysis and illicit use of opioids (Kakko et al., 2007), heroin, and other drugs 
(Mattick et al., 2003). Similarly, studies comparing methadone and buprenorphine treatment 
outcomes, such as retention, abstinence, and illicit opioid use, have found comparable results
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(Kakko et al., 2007; Johnson et al., 2000; Marsch et al., 2005; Sullivan, Chawarski, O’Connor, 
Schottenfeld, & Fiellin, 2005). Moreover, one study found that the higher dose of buprenorphine 
outperformed lower (but not higher) doses of methadone in retention and illicit opioid use (as 
measured by urinalysis; Johnson et al., 2000). However, another study found that higher doses of 
methadone (80 mgs/day) outperformed low-dose methadone (30 mgs/day) and fixed-dose 
buprenorphine (8 mgs/day) for treatment retention (Ling, Wesson, Charuvastra, & Kett, 1996). 
These results suggest that buprenorphine, especially at higher doses, is as effective or close to as 
effective as methadone in reducing risky behaviors associated with contracting infectious 
diseases (e.g., hepatitis and HIV), decreasing the use of illicit opioids, and retaining patients in 
treatment (Kraus et al., 2011). It should be noted that, while some studies have found Suboxone® 
and Subutex® are both effective in treating pregnant women (Debelak, Morrone, O’Grady, & 
Jones, 2013), Subutex® (buprenorphine without naloxone) tends to be prescribed because of 
naloxone’s property of precipitating withdrawal symptoms.
Empirical evidence comparing buprenorphine and methadone treatment in pregnant 
women precludes a clear advantage for methadone and suggests that buprenorphine may be the 
medication-assisted treatment of choice with this population (Coyle et al., 2012; Fischer et al., 
2006; Jones et al., 2005; Jones, O’Grady, Johnson, Velez, & Jansson, 2010; Pritham, Paul, & 
Hayes, 2012). One study found no difference in neonate abstinence syndrome and illicit opioid 
use (Jones et al., 2005). However, neonates who were exposed to buprenorphine stayed in the 
hospital for shorter periods of time than those who were exposed to methadone (Jones et al., 
2005, 2010), required a smaller dose of morphine (Jones et al., 2010), had shorter treatment for 
neonate abstinence syndrome (Jones et al., 2010; Pritham et al., 2012), and had milder behavioral 
effects (e.g., excitability, overarousal, hypertonic symptoms, stress from abstinence, and self­
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regulation; Coyle et al., 2012). When considering the outcomes for pregnant woman, one study 
found no differences in retention rates, but found that pregnant women in methadone treatment 
had less illicit opioid use than those in buprenorphine treatment (Fischer et al., 2006). Even 
though empirical support suggests buprenorphine performs well in treating pregnant women, 
further research is needed to establish the clinical efficacy of buprenorphine in special 
populations including pregnant women and adolescents (Kraus et al., 2011).
Patient preferences are another important consideration when comparing methadone to 
buprenorphine. In one qualitative study conducted in the United Kingdom, patients reported 
clearer thinking with buprenorphine compared to methadone, which in turn led to the need for 
more psychosocial treatment (Tanner, Bordon, Conroy, & Best, 2011). Individuals in 
buprenorphine maintenance treatment also reported higher confidence and less stigma compared 
to methadone maintenance treatment (Tanner et al., 2011). Another study found that patients 
perceived buprenorphine maintenance treatment to be effective at controlling opioid use, 
reducing cravings, improving their quality of life, allowing them to feel more normal, and 
prompting them to engage in treatment (Egan et al., 2011). Patients preferred buprenorphine 
maintenance treatment to methadone maintenance treatment because of the ability for autonomy, 
self-directedness of treatment and less rigid regulations (Egan et al., 2011). However, those with 
chronic pain and more severe opioid dependence may be less successful in buprenorphine 
treatment, and thus methadone is the recommended treatment for these populations given its 
properties as a full agonist (Renner et al., 2014).
Overall, evidence suggests that buprenorphine is as or more effective than methadone in 
treating opioid use disorders. When rapidly inducing treatment with flexible and sufficient 
dosing, buprenorphine is as effective as methadone (Maremmani & Gerra, 2010). Moreover,
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buprenorphine is empirically recognized as superior to methadone in its safety profile (Kraus et 
al., 2011; Maremmani & Gerra, 2010). Further, mounting evidence suggests that buprenorphine 
is safe for pregnant women and provides some clear benefits (Coyle et al., 2012; Fischer et al., 
2006; Jones et al., 2005; Jones et al., 2010; Maremmani & Gerra, 2010; Pritham et al., 2012). 
Additionally, buprenorphine offers an advantage to methadone treatment in terms of improving 
the access to care (Kraus et al., 2011; Maremmani & Gerra, 2010; Phillips & Preston, 2013).
In sum, there is a place for both methadone and buprenorphine treatments, as each have 
indicated uses and populations (Maremmani & Gerra, 2010). Because of its safety profile, 
administrative regulations, and patient preferences, buprenorphine may be a more useful option 
for early intervention of opioid use disorders (Renner et al., 2014). It may also be a useful 
treatment for those who do not wish to use methadone (Davids & Gastpar, 2004). Given that this 
medication is gaining popularity, has demonstrated efficacy, and is more accessible than 
methadone treatment, patients in buprenorphine treatment are a good target population for 
developing a patient-driven definition of success in medication-assisted treatment. Moreover, the 
different regulatory standards for buprenorphine treatment, compared to methadone treatment, 
may result in different experiences of success for those in OBOT programs compared to those in 
other opioid-treatment programs.
Treatment in Alaska
In the preceding sections, the efficacy of medication-assisted treatment for opioid use 
disorders was established. However, opioid-treatment programs and OBOT programs using 
buprenorphine are sparse in Alaska. In a single day in 2012, an average of 148 clients in Alaska 
were receiving methadone compared to 20 clients receiving buprenorphine (SAMHSA, 2013c). 
Although there are no statistics available to review current medication-assisted treatment in
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Alaska, there are 41 physicians in 17 Alaskan communities on an Internet directory 
(Buprenorphine Doctors, March 27, 2015) who are providing OBOT. Nevertheless, both 
Alaskans that would benefit from medication-assisted treatment and Alaskan healthcare 
providers have identified a gap in services and a need for better access to medication-assisted 
treatment (Hewell, Vasquez, & Rivkin, 2016a). Additionally, the growing rates of opioid use and 
the efficacy of medication-assisted treatment, particularly buprenorphine, evidences the need for 
effective and accessible medication-assisted treatment in Alaska.
Conclusion
This section reviewed opioid misuse and the effective medication-assisted treatments. 
However, the criteria used to evaluate how treatment outcomes are defined and measured are 
contingent on how success in treatment is defined. The next section will review the variability in 
the way outcomes are measured and defined in the field of substance abuse. This will exemplify 
how historical ways of defining success and measuring outcomes in substance use treatment may 
be limited for understanding success for clients in buprenorphine treatment. Furthermore, this 
section will make the case that outcomes research would benefit from understanding how those 
in treatment define success.
Section B: Defining and Measuring Success
The field of substance abuse lacks agreement on what constitutes treatment success. 
Furthermore, treatment success often gets interchanged with the term recovery, which is also not 
clearly defined. Inconsistent definitions of treatment success and recovery from substance use 
disorders are established concerns in the field because they create challenges for measuring 
outcomes (Betty Ford Institute Consensus Panel, 2007; Butler Center for Research, 2011; Dodge, 
Krantz, & Kenny, 2010; Laudet, 2008; Laudet, Morgen, & White, 2006; White, 2007;
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Witkiewitz, 2013), which thwarts progress in research and clinical practice (Betty Ford Institute 
Consensus Panel, 2007).
The following sections will review definitions of and issues with the construct of 
recovery. Then, features associated with treatment success will be discussed, including how 
success is traditionally measured, and issues associated with the typically narrow views of 
success. Finally, a case will be made for qualitatively exploring success from the patient’s 
perspective of treatment success by reviewing qualitative literature on the subject.
Recovery
The term recovery has been historically associated with returning to health after trauma 
or illness in the medical field and within the 12-step community, yet has recently extended to 
other organizations, agencies, policies, and treatment efforts (Laudet, 2007, 2008; White, 2007). 
Particularly in 12-step programs such as Narcotics Anonymous (NA), this term, recovery, is used 
with the assumption that every individual with substance use disorders is powerless over the 
substances and must desire complete cessation of use to be a member (NA, 1988).
In the United States, 12-step program philosophy and the recovery construct have 
prevailing influences on substance misuse treatment. The 12-step model has substantially 
influenced the field of substance abuse’s adherence to the disease model, and consequently 
frames most of the commonly available substance use treatment in the United States (Yalisove, 
1998). Therefore, to understand success in treatment, it is also important to explore the term 
recovery. Although the construct, recovery is ambiguous some of the defining features are 
described below.
Defining features. One of the primary features of many definitions of recovery is that it 
is an active process or state of being, without a fixed endpoint (ASAM, 1982; Galanter, 2007;
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Laudet, 2008; McLellan et al., 2007; SAMHSA, 2012; White, 2007). This assumes recovery is a 
moving target that requires constant maintenance and attention (McLellan et al., 2007; White, 
2007). Additionally, the majority of the definitions of recovery involve abstinence, or the 
complete cessation of all psychoactive substances, as a prerequisite (ASAM, 1982; Dodge et al., 
2010; Galanter, 2007; Laudet, 2008; McLellan et al., 2007).
Another aspect of recovery is the improvement of health/wellness (Dodge et al., 2010; 
SAMHSA, 2012; White, 2007) and physical or biomedical functioning (ASAM, 1982; Dodge et 
al., 2010). Many of the definitions of recovery also include relational elements, including family 
relationships (ASAM, 1982; Dodge et al., 2010; SAMHSA, 2012) and social functioning (Dodge 
et al., 2010; SAMHSA, 2012). Some even consider allegiance to those in recovery (e.g., through 
membership in NA) to be an important aspect of recovery (NA, 1988), and believe it is important 
to share one’s recovery status with others (ASAM, 1982).
Improvements in psychiatric functioning, such as a mental disorder diagnosis (Dodge et 
al., 2010) and psychological functioning, such as emotional and cognitive difficulties (ASAM, 
1982; Dodge et al., 2010; SAHMSA, 2012), are included in some recovery definitions. Healing 
from traumas caused by addiction (White, 2007) and working towards personal growth (Laudet, 
2007, 2008) are included in others.
Similarly, the notion that recovery involves movement towards self-actualization and 
cultivating a sense of purpose or meaning in life is sometimes emphasized (Galanter, 2007; 
SAMHSA, 2012; White, 2007). Moreover, spirituality is a heavily emphasized element in many 
recovery communities (Dodge et al., 2010; Galanter, 2007; NA, 1988). For example, NA 
endorses the belief that individuals must admit they are powerless over substances and surrender 
their will to a Higher Power to absolve character deficits (NA, 1992). Consequently, some, but
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not all, emphasize self-determination (e.g., “voluntarily choosing” recovery) as an important 
element of recovery (SAMHSA, 2012; White, 2007).
Other features that are included in many recovery definitions include acquiring life skills, 
engaging in self-care practices, and having stability in one’s core needs, such as safety (ASAM, 
1982; SAMHSA, 2012). Additionally, some suggest that moving towards recovery involves 
improvements in quality of life (Laudet, 2008; McLellan et al., 2007). In addition to 
improvements in ones’ individual functioning, productively contributing to society (Dodge et al., 
2010; SAMHSA, 2012; White, 2007) and adapting to life (Galanter, 2007) are also discussed as 
features of the recovery construct. In summary, the term recovery is used inconsistently. 
However, a key feature includes the assumption that abstinence is a requisite to a continual 
process of improving one’s physical, social, psychological, and spiritual self.
Challenges with recovery. These inconsistent definitions of recovery tend to share three 
commonalities which pose challenges for professionals in the field trying to assess this construct, 
and for those in buprenorphine maintenance treatment: (a) the view that individuals with 
substance use disorders will continually struggle with addiction, (b) adherence to an abstinence- 
only model, and (c) lack of clarity and specificity.
An unclear, never-ending definition of recovery perpetuates the stigma associated with 
substance abuse by deemphasizing the genuine possibility of overcoming addiction and 
maintaining the message that addiction is a loss of control (Laudet, 2008). Additionally, this 
definition suggests an adherence to the medical model of addiction that explains addiction as a 
chronic, relapsing disease that is biologically based according to medical communities, and 
spiritually based according to 12-step communities, as opposed to a compilation of dynamic and 
interactive biological, psychological, sociocultural, and environmental factors (Thombs, 2006).
33
In consequence, this excludes some individuals, such as those in OBOT, from ever being able to 
enter into recovery given their use of a medication that has (or opponents to its use believe it has) 
the potential for abuse. This attitude is highlighted by the proposed criticism of medication- 
assisted treatments as “trading one drug for another.”
Another apparent problem with the conceptualization of recovery is the emphasis placed 
on requiring abstinence, as this may not be the goal for all people with substance use disorders. 
For instance, it has been established that many individuals seek alcohol treatment with a goal of 
reducing their use, rather than completely abstaining (Dunn & Strain, 2013). However, 
identifying non-abstinence based goals becomes more complicated for illicit drug use given the 
often illegal and unregulated nature of these substances.
Abstinence as a requirement for recovery marginalizes individuals in replacement 
therapy, such as OBOT, by assuming they would never be able to attain recovery given their use 
of this medication. Additionally, recovery communities that require abstinence tend to perpetuate 
the stigma associated with the use of prescribed psychoactive substances, including the 
medication-assisted treatments methadone and buprenorphine, by discouraging medication- 
assisted treatment patients from speaking during support group meetings because they are “not 
clean” (White, 2007). It remains important to understand how OBOT patients understand the 
construct of recovery. Keeping in mind that they may have experienced stigma related to the 
term recovery, they may assume it is what they should strive for because it is the prevailing view 
in many treatment structures and that abstinence (complete cessation of all substances) is likely 
not a goal (at least short term) for these individuals.
Finally, attempting to create a single definition of recovery may be challenging because it 
is used in various ways, such as describing the actual lived experiences of an individual or
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associating the term with treatment outcomes or organizational goals (White, 2007). Notably, the 
various uses of the term recovery present issues for operationally defining and measuring this 
construct. Some have defined recovery in terms of treatment outcomes, which attempts to add 
some clarity (McLellan et al., 2007). However, if outcome domains differ from how individuals 
attempting to overcome a substance use disorder define recovery, this approach still neglects to 
capture what is important to the individuals themselves. Although it is important to understand 
how patients define recovery, it may be more important to understand how they define tangible 
and achievable gains, such as treatment success. As such, factors associated with treatment 
success, how it is measured, and controversies in defining and measuring success will now be 
reviewed.
Success
The field of substance abuse noticeably lacks consensus on what comprises recovery, 
which makes measuring the “process of recovery” problematic. A clearer way of measuring 
improvements in substance use disorder treatment may be to define treatment success and to 
assess treatment outcomes accordingly. However, instead of evaluating the multidimensional 
factors related to substance use, standard outcome domains tend to have a narrow focus on 
consumption (Butler Center for Research, 2011; Miller & Miller, 2009; Tiffany et al., 2012) and 
even more narrowly on abstinence, or the complete cessation of all substances (Carroll et al., 
2014; Miller & Miller, 2009; Tiffany et al., 2012; Witkiewitz, 2013). A focus solely on 
abstinence is problematic because it lacks sensitivity to other changes that may be made in 
treatment, and overlooks positive changes that are made if one reduces their use (e.g., using a 
few times would be considered a “treatment failure”; Carroll et al., 2014).
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In addition to inconsistent and overly demanding definitions of recovery that emphasize 
abstinence, the field of substance abuse also lacks consensus regarding what constitutes 
“clinically significant change” in illicit drug use treatment beyond abstinence. This is, in part, 
because it is challenging to define “normative” or “low-risk” drug use (Carroll et al., 2014; 
Witkiewitz, 2013). Moreover, current approaches to defining and measuring success may neglect 
to address key concerns the patient has beyond consumption (Miller & Miller, 2009).
Inconsistent and narrow (i.e., abstinence-only) standards for defining and measuring 
illicit drug use treatment success impedes researchers’ abilities to measure differences between 
treatments, our abilities to measure attributes of effective treatment programs, clinicians’ abilities 
to understand and apply “what works” in treatment, and patients’ abilities to demonstrate and be 
recognized for the gains they make in treatment if they do not achieve abstinence.
Multidimensional factors related to substance use. Empirical research demonstrates 
that there are several factors above and beyond consumption that impact addiction and treatment 
success. This is in line with the biopsychosocial model of addiction, which considers the 
biological (e.g., neurobiology, brain structure, genetics), psychological (e.g., emotional 
problems, social stigma, comorbidity, motivation), and sociocultural (e.g., age, race, gender, 
family, social contexts) elements that impact addiction’s development, progression, maintenance, 
and indicated treatment (Miller & Carroll, 2006). Specifically, motivation, pain, substance use 
expectancies, physical and psychological functioning, stress, craving, self-efficacy, and social 
support related to opioid misuse will be briefly reviewed below.
Motivation has demonstrated impacts on substance misuse treatment (Miller & Carroll,
2006) and is an important consideration for substance misuse assessment (Tonigan, 2004). For 
opioid misuse, motivations for use that are associated with opioid-related problems include pain,
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social pressures, coping with emotional distress, and enhancement expectancies, or the belief that 
substance use will enhance a desired experience (Jones, Spradlin, Robinson, Tragesser, & Tusel,
2014). Pain intensity and the expectations for pain relief in particular play an important role in 
opioid misuse (Ashrafioun, Bohnert, Jannausch, & Ilgen, 2015; Jones et al., 2014).
Physical and psychological functioning are also associated with opioid misuse 
(Ashrafioun et al., 2015). In particular, stress plays a role in opioid addiction. Opioid dependent 
individuals have been found to report more stress (Hyman et al., 2009; Jaremko, Sterling, & Van 
Bockstaele, 2015) and less use of adaptive coping (Hyman et al., 2009) compared with those 
who are not dependent on opioids. Additionally, abnormal and high cortisol levels are found 
more often in opioid-dependent individuals compared to controls, and these abnormal cortisol 
levels have been associated with an increase in the likelihood that an individual will discontinue 
methadone maintenance treatment by nearly 8 times (Jaremko et al., 2015). Moreover, the 
medication lofexidine, which reduces opioid-seeking behavior in animals, has also been found to 
reduce stress and opioid cravings in individuals who are dependent on opioids (Sinha, 
Kimmerling, Doebrick, & Kosten, 2007). Importantly, substance craving is especially profound 
in addiction (Tiffany et al., 2012) and predicts opioid use for those in buprenorphine 
maintenance treatment (Tsui, Anderson, Strong, & Stein, 2014).
Two other important constructs related to treatment outcomes in substance use disorders 
include self-efficacy (Ilgen, McKellar, & Tiet, 2005; Tiffany et al., 2012), defined as confidence 
in one’s ability to do something (e.g., be abstinent or not use), and perceived locus of control 
(Tonigan, 2004), which is the belief that change is within one’s power. In one study, self­
efficacy about participant’s perceived ability to abstain from using heroin in specific situations 
predicted a reduction in illicit opioid use for those in methadone maintenance treatment at 30 and
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90 days into treatment (Reilly et al., 1995), while abstinence self-efficacy was found to be highly 
associated with successful abstinence at a one-year post-discharge follow up for participants in 
substance use disorder treatment (Ilgen et al., 2005).
Family history and social support are recognized as important external factors that impact 
addiction and treatment (Tonigan, 2004). For those with opioid use disorders, lower quality of 
social support relates to higher perceived stress, which in turn is associated with greater opioid 
misuse (Hyman et al., 2009).
Clearly, several factors impact addictive behavior and treatment success, yet these factors 
are not consistently evaluated as outcomes. The ways outcomes tend to be measured in substance 
use treatment will now be reviewed.
Measuring Success
Outcome domains. Outcome domains and outcome measures are used to assess changes 
in the patient that occur due to treatment (McLellan et al., 2007; SAMHSA, 2010b; Tonigan,
2004). Three outcome domains have been commonly used since the 1960s to assess treatment 
outcomes, including substance consumption (SAMHSA, 2010b; White, 2007), employment 
status/the ability to support oneself, and criminal activity (Donovan et al., 2011; McClellan et al., 
2007; SAMHSA, 2010b). Other domains that are also deemed to be important will be reviewed 
below.
Consumption. The most standard measure of outcomes is the quantity and frequency of 
substance use within a specific time-period (Butler Center for Research, 2011; Donovan et al., 
2011). Abstinence tends to be used as the “gold standard” in measuring substance use outcomes, 
likely because if an individual is not using at all, they do not meet criteria for a substance use 
disorder. Additionally, abstinence is assumed by many to be vital for improvements in other
38
domains (McLellan et al., 2007). Moreover, it is notably difficult to define “low risk” drug use, 
even for alcohol, a legal substance with a large body of research (Witkiewitz, 2013).
Additionally, providers tend to conceive abstinence as the desirable intermediate and short-term 
goal for illicit drug use treatment, compared to alcohol and cannabis where a reduction in harm is 
more acceptable (Rosenberg, 2014). These provider perspectives likely impact the treatment 
emphasis and subsequent target outcomes for those in illicit drug use treatment.
The consumption-related outcome of abstinence is not applicable for all patients, given 
that not all individuals have the goal of abstinence. Also, by using an opioid to treat opioid use 
disorders, proponents of abstinence-only medical models, including some 12-step organizations, 
would argue that individuals in this treatment are not abstinent. These issues are compounded in 
terms of defining success for illicit opioid use, where defining constructs such as “low risk” use 
are especially difficult than with alcohol because of the challenge in defining “normative” illicit 
drug use (Carroll et al., 2014; Witkiewitz, 2013).
In addition to abstinence, other ways to measure consumption include frequency of drug 
positive urinalysis and self-reported reductions in frequency of use (Carroll et al., 2014). Even 
though consumption-related outcomes do not fully capture the intricacies of substance use 
treatment, drug-taking behaviors (measured by both biological screens, such as urinalysis, and 
self-report) continue to be recommended as primary outcomes for randomized controlled trials 
(Donovan et al., 2011). However, this does not capture a comprehensive snapshot of treatment 
success. Additionally, the assumption that reduced quantity and frequency of an abused 
substance is what all patients deem as successful treatment is unfounded (further discussed in 
OBOT outcomes subsection).
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Other outcomes. Establishing commonly agreed upon outcome domains and measures 
that focus on factors above and beyond consumption is challenging (Tiffany et al., 2012; 
Witkiewitz, 2013). Yet they are essential to research and evaluation (Butler Center for Research,
2011). Employment status and functioning (Butler Center for Research, 2011; SAMHSA, 
2010b), citizenship (e.g., contribution to society and service; White, 2007), stability in one’s 
housing environment (SAMHSA, 2010b; White, 2007), and criminal activity are some outcomes 
that have been used for evaluation. Health, both physical (Butler Center for Research, 2011; 
McLellan et al., 2007; White, 2007) and mental (McLellan et al., 2007; White, 2007), are also 
used and recommended outcome variables. Psychosocial (McLellan et al., 2007; SAMHSA, 
2010b; Tiffany et al., 2012) and family functioning (McLellan et al., 2007), relationships (White,
2007), and social support (Tiffany et al., 2012) have been used and are recommended as 
important substance use disorder outcomes. Craving and self-efficacy are also recommended for 
consistent use as outcome variables based on their empirical relationship to substance misuse 
(Tiffany et al., 2012).
More recently, quality of life has been recognized as an important outcome (Butler 
Center for Research, 2011; Miller & Miller, 2009; Tiffany et al., 2012; White, 2007), which 
predicts the maintenance of treatment gains like remission at 1 and 2 years post-treatment 
(Laudet, Becker, & White, 2009). Quality of life can be assessed based on an individual’s 
subjective report across wellbeing domains, including: safety and security, relationships, health, 
connectedness with the community, spirituality, self-esteem, sense of meaning, and creativity 
(Cummins, Eckersley, Pallant, Van Vugt, & Misajon, 2003; Wasserman, Sorensen, Delucchi, 
Masson, & Hall, 2006). Relatedly, subjective wellbeing is accentuated as something that should
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be measured given that the patient’s subjective happiness should be better after treatment than 
when they were addicted (Miller & Miller, 2009).
Treatment process outcomes. In addition to the outcome domains reviewed above, some 
outcomes measure the process of treatment, including access to services, quality of services, 
treatment retention, engagement, and the therapeutic alliance. Access to services and the quality 
of services may be important outcomes for organizations and systems to monitor their treatment 
performance (McLellan et al., 2007; SAMHSA, 2010b).
Treatment retention, or an individual’s continued attendance in treatment (i.e., duration 
and frequency), is one of the most frequently used outcome measures related to the process of 
treatment (McLellan et al., 2007; SAMHSA, 2010b), even though it may be less sensitive to 
therapeutic change than other outcome measures (Carroll et al., 2014). Although treatment 
retention may be an important consideration related to treatment process outcomes, treatment 
engagement may be even more important (Lee & Zerai, 2010; Reisinger et al., 2003). In fact, 
based on hundreds of empirical findings across 40 years of research, engagement has been found 
to be one of the best predictors of treatment success (Mee-lee, McLellan, & Miller, 2010; 
Orlinsky, Grawe, & Parks, 1994).
Treatment engagement has been described as motivation and participation in treatment 
(Mee-lee et al., 2010; Orlinsky et al., 1994; Reisinger et al., 2003). Harm-reduction programs 
emphasize the importance of demarginalization (including being treated with respect by 
providers and developing trust) as a requisite to engagement (that is, patient-identified treatment 
outcomes begin to be articulated as trust is deepened) and successful treatment (Lee & Zerai, 
2010).
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The therapeutic alliance is another fundamental attribute of effective treatment that 
involves agreement between therapist and patient on the goals, task, and their therapeutic bond 
(Bordin, 1979). The therapeutic alliance has been demonstrated to play an important role in 
substance use disorder treatment outcomes, accounting for 50-66% of the variance in outcomes 
for alcohol use (Miller, Willbourne, & Hettema, 2002; Luborsky, Barber, Siqueland, McLellan, 
& Woody, 1997). Therapeutic alliance has been found to predict better outcomes by impacting 
drinking behavior, consumption, and participation in alcohol use disorder treatment (Connors, 
Carroll, DiClemente, Longabaugh, & Donovan, 1997) and improving outcomes for those with 
opioid dependence (Luborsky et al., 1997). Clearly, therapeutic alliance and treatment 
engagement are well established as important treatment process outcomes that should be 
considered in addition to other commonly measured variables of treatment retention. It should be 
noted that five outcome domains reviewed above including change in self-efficacy, drug craving, 
social support, quality of life, and psychosocial functioning were recommended for evaluation in 
substance misuse treatment based on one assessment of critical outcome measures (Tiffany et al.,
2012), while retention, reduction in frequency of substance use, and complete abstinence were 
identified as outcomes that should be eliminated from illicit drug use treatment evaluation as 
these variables lack sensitivity to therapeutic change (Carroll et al., 2014).
OBOT outcomes. Standard outcomes, such as long-term abstinence, traditionally 
measured by continuous, prolonged, point prevalence, and repeated point prevalence, have been 
established for the legal drug nicotine (Carroll et al., 2014; Donovan et al., 2011). Even though 
consumption is the primary outcome for another legal drug, alcohol, attempts have been made to 
narrow in on the issues of abstinence versus “low risk” alcohol use by integrating measures that
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encapsulate both (Donovan et al., 2011). No known standards or efforts have been proposed for 
medication-assisted treatments, such as OBOT.
In a qualitative study which used interviews with 18 staff members and 32 patients in two 
harm-reduction programs, participants identified the following positive treatment outcomes: 
feeling respected and engaged in treatment, improvements in quality of life, social functioning, 
goal reappraisal, and symptom reduction (Lee & Zerai, 2010). Meanwhile, these patients’ 
providers defined positive outcomes as “any positive change” (p. 2411) in the patient and 
“planting a seed” (p. 2433) by instilling lessons that could inspire change at a later date (Lee & 
Zerai, 2010).
Specific to opioid use, some measures have been developed to assess domains relevant to 
opioid misuse, such as The Opiate Treatment Index (Darke, Hall, Wodak, Heather, & Ward, 
1992), The Current Opioid Misuse Measure (Ashrafioun et al., 2015), and The Opioid 
Prescription Medication Motives Questionnaire (Jones et al., 2014). These measures comprise 
domains that include: drug intoxication; HIV risk-taking behavior; healthcare use patterns; 
criminality; psychological adjustment, coping, and emotional volatility; health and social 
functioning/pressures; pain; poor response to medication; addiction and problematic medication 
use; and enhancement expectancies (Ashrafioun et al., 2015; Darke et al., 1992; Jones et al.,
2014). Nevertheless, many buprenorphine maintenance treatment studies use only standard 
outcome measures, including retention (Amato et al., 2011; Kakko et al., 2003; Moore et al., 
2012; Stein et al., 2005), illicit drug consumption (Amato et al., 2011; Fudala et al., 2003; 
Johnson et al., 1995; Kakko et al., 2003; Moore et al., 2012; Weiss et al., 2011), craving (Fudala 
et al., 2003), psychiatric symptoms, and treatment compliance (Amato et al., 2011).
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Although a few published studies have qualitatively explored patient perspectives about 
factors related to treatment success in general harm reduction programs (Lee & Zerai, 2010) and 
methadone maintenance treatment (Redden, Tracy, & Shafer, 2013), no known studies have 
explored what is involved in treatment success from the perspective of patients in OBOT. In one 
qualitative study that conducted eight focus groups with 68 medication-assisted treatment 
patients, treatment was described by some participants as “liquid handcuffs” and a “crutch” that 
leaves them still dependent (Redden et al., 2013). These findings suggest that patients had fairly 
negative views of methadone maintenance treatment, but the study did not extensively elucidate 
what patients believed constituted success in this treatment. Further, given that methadone 
maintenance treatment has a different treatment structure and regulatory requirements than 
OBOT (that is, methadone maintenance treatment must be dispensed in a regulated dispensary as 
opposed to in a primary care office by a physician), it is important to investigate the factors 
OBOT patients identify as being important for their success.
Another preliminary study, which established the foundation for this dissertation’s aims, 
qualitatively explored how individuals who would benefit from medication-assisted treatment 
described a process of success in substance use treatment and recovery from opioid misuse 
(Hewell et al., 2016b). Participants in this study described success as involving intrapsychic 
factors (e.g., being open-minded, having self-acceptance, taking responsibility for changing), 
interpersonal factors (e.g., feeling connected and having healthy social support), reaching a 
critical mass point (e.g., a point when the person starts to shift and begin making changes), and 
engaging in a “living program of recovery” (e.g., individualized treatment plans, continuing to 
fight for recovery). Although these findings began to illuminate some potential factors that may 
be important in OBOT patients’ definitions of success, it was not the primary focus of the study.
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Further, it included a sample of “people who would benefit from medication-assisted treatment,” 
and were not necessarily already in treatment. Therefore, a comprehensive study that explores 
how patients in an OBOT program define success will provide a more complete understanding of 
successful treatment that is specific to OBOT.
A Case for a Patient-Informed Definition of Success
There appears to be the beginnings of a paradigm shift encouraging researchers, 
evaluators, and treatment providers to consider outcome domains above and beyond 
consumption-related measures (Carroll et al., 2014; Tiffany et al., 2012; Tonigan, 2004; 
Witkiewitz, 2013). In addition to suggestions based on research, this effort also needs to be 
driven by the factors that patients deem important. Although Tiffany and colleagues (2012) 
recommend domains be empirically established as related to substance misuse broadly, patients 
may illuminate domains that are not already established in the literature, or they may afford more 
weight to some domains over others. For instance, factors beyond consumption tend to be 
important to individuals in treatment, and to the significant people in their lives (Witkiewitz,
2013). Moreover, if the patient’s goal is “low risk” use, it is important to define what this means 
from his or her perspective. We currently have a poor understanding of what constitutes 
meaningful change from patients’ perspectives and more specifically what are important 
domains for measuring success for individual in OBOT.
It is important to understand the factors that are important to patients in treatment, as 
these likely relate to motivation to change, successful treatment outcomes, retention, and 
engagement (Miller & Miller, 2009). A qualitative design that explores patients’ perspectives has 
the potential to enlighten researchers, evaluators, and treatment providers about how patients
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define success and recovery, the factors they believe are barriers and facilitators to their success, 
and the qualities that should be evaluated to assess success in treatment outcomes.
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Chapter 3: Research Design and Methodology 
Overarching Study Design
This qualitative study explored patients’ perspectives on treatment success in an in 
Office-based Opioid Treatment (OBOT) program. This was achieved by conducting a focus 
group with seven participants and subsequent interviews with seven participants, two of which 
were also in the focus group, for a total of twelve OBOT patients in rural Alaska. This section 
will outline the study’s rationale and the theoretical assumptions.
Project rationale. As discussed in Chapter Two, there remains uncertainty regarding 
how treatment success should be defined and measured for Suboxone®. This study aimed to 
build a patient-driven definition of successful treatment that identified the factors patients deem 
important to treatment success. To achieve this aim, a qualitative design was employed, and the 
study drew from the techniques of grounded theory (Charmaz, 2006), directed content analysis 
(Hsieh & Shannon, 2005), and the principles of community based participatory research (CBPR; 
Israel et al., 1998; Kemmis & McTaggart, 2005). Accordingly, the research questions included 
the following:
1) How do OBOT patients define OBOT success?
2) How do OBOT patients define recovery?
3) What facilitators and barriers do these patients identify as relating to their definition of
OBOT success?
4) What factors do these patients identify as important for measuring OBOT success?
Theoretical assumptions. The following outlines the theories and approaches that
informed this study, including constructivism, community based participatory research (CBPR), 
grounded theory, and directed content analysis. Elucidating assumptions about the nature of
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knowledge (ontology), the relationship between the researcher and participants (epistemology), 
and about how knowledge is acquired (methodology) builds qualitative rigor, or trustworthiness 
(Morrow, 2005; Roulston, 2010).
Constructivistic assumptions. This study is based on the constructivistic paradigm with 
an emphasis on symbolic interactionism. The ontological assumption of constructivism is that 
multiple realities exist (Charmaz, 2006; Israel et al., 1998). The symbolic interactionism 
emphasis assumes that individual behavior is developed agentically in a social context and not 
mechanically produced (Charmaz, 2006). As such, the researchers and the research participants 
(OBOT patients) are expected to bring their subjective experiences and symbolic meanings into 
shared interactions. These assumptions helped to inform the design, data collection, and data 
analyses of this study.
Specifically, this study intended to interpret the dynamics and subtleties of how 
individuals make meaning of OBOT treatment success (Charmaz, 2006). The researchers 
endeavored to enter into the reality of the OBOT patients in attempts to iteratively interpret and 
reconstruct their subjective meaning of success (Charmaz & Belgrave, 2012; Israel et al., 1998).
CBPR principles. This study adhered to the principles of CBPR (see Table 3.1, Column 
1, Principles) as defined by Israel and colleagues (2001) and Kemmis and McTaggart (2005). As 
illustrated in Table 3.1, Column 2 (Study Adherence), this study was grounded in a reflexive- 
dialectical CBPR approach (Kemmis & McTaggart, 2005). This CBPR approach is 
ontologically, epistemologically, and methodologically consistent with the assumptions of 
constructivism. Specifically, it assumes there is no one truth that can be known (ontology), 
suggests that the process of studying a phenomenon creates change (epistemology), and purports
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that the research should explore basic assumptions about truth in a reflexive and intersubjective 
manner (methodology).
CBPR Principles Informing the Current Study_____________________________________
Table 3.1
Principles Study adherence
1. Shared Ownership
2. Community 
Analysis of Social 
Problems
3. Strength-based and 
Empowerment Focus
4. Community Action
5. Iterative and 
Cyclical Process
This study was founded on a long-term commitment and 
collaboration between the lead researcher and the professional 
advisors. This included sharing the following: involvement 
throughout the study, establishment of study priorities, voice in 
data interpretation, determinants for the dissemination of 
findings, and benefits of integrating knowledge with action.
This study’s focus emerged from a preliminary CBPR study 
aimed at identifying and addressing barriers to buprenorphine 
treatment in the Interior region of Alaska (Hewell et al., 2016a). 
Multiple stakeholders, including the current professional 
advisors, study participants, and the Alaska Advisory Board for 
Alcohol and Drug Abuse, were involved in interpreting findings 
and determining future directions, which included the current 
study.
This study focused on the strengths of patients in OBOT. It also 
intended to empower professional advisors to promote OBOT 
success in their community.
This study was committed to identifying the needs of patients in 
the community through its consideration of contextual variables 
(Israel et al., 2001). Involving participants in interpreting 
findings helped evoke community change determined necessary 
by patients (Kemmis & McTaggart, 2005).
Data were collected, analyzed, and interpreted with OBOT 
patients and professional advisors throughout the project to co- 
create a shared understanding. Regular communication with a 
professional advisor supported the iterative and cyclical process.
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A discovery-oriented approach, such as CBPR, has been identified as the most effective 
approach to understanding local perspectives, identifying culturally grounded priorities, and 
determining interventions and evaluation strategies based on this knowledge (Lau, Chang, & 
Okazaki, 2010). This approach emphasizes practice-based evidence (Lau et al., 2010). The ethics 
of CBPR will be further discussed in the Ethics section.
Grounded theory. This study was rooted in a constructivistic grounded theory approach 
as outlined by Charmaz (2006). Grounded theory explores phenomena with limited theoretical or 
empirical information, such as success in OBOT. The goal was to generate theory (Charmaz & 
Belgrave, 2012) by using investigative, non-speculative empirical observation, with a focus on 
substantive face-valid data (Dey, 2007).
This study moved away from post-positivism (a philosophical research stance that 
acknowledges the researcher’s bias, yet still seeks objectivity) by affording a flexible, meaning- 
focused stance. Data were gathered inductively, analyzed comparatively and iteratively, and 
interpreted interactively (Charmaz, 2006). The goal was to understand how participants create 
meaning of a particular phenomenon—success in OBOT—by attempting to get as close to the 
study participants’ experience as possible (Charmaz & Belgrave, 2012). The end product is a 
substantive, context-dependent definition of success in OBOT (Bryant & Charmaz, 2007).
Directed content analysis. In addition to grounded theory, this study also used techniques 
of directed content analysis as outlined by Hsieh and Shannon (2005) to frame and analyze the 
data. Qualitative content analysis is focused on clarifying the content and contextual meaning of 
the language within a text (Hsieh & Shannon, 2005). This approach to data analysis still assumes 
a naturalistic orientation, yet it uses both deductive and inductive approaches. Therefore, it is 
useful when there is a priori knowledge, but researchers are open to expanding upon the existing
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theory. Analysis began by using a systematic process to sort data into themes based on existing 
theory with flexibility to refine, add, or omit constructs and concepts that were not grounded in 
the data. As such, analysis started with a clear framework (Hsieh & Shannon, 2005) with the 
goal to further elucidate the studied phenomenon (Downe-Wamboldt, 1992).
Detailed Methodological Approach
This study was conducted in three phases, including a focus group, semi-structured 
interviews, and a findings forum. Accompanying aims and methods of each phase are 
summarized in Table 3.2.
Table 3.2
Summary o f Study Phases, Aims, and Methods_______________________________________
Phase I. Focus group
Aim: Refine the descriptive framework of patient success in OBOT.
Method: Eligible participants were invited to participate in an initial focus group.
The focus group protocol and questions can be found in Appendix D. Findings that
emerged from this phase informed recruitment for Phase II.
Phase II. Semi-structured telephone interviews
Aim: Enhance the framework of OBOT success and develop a substantive patient-
driven definition of OBOT success.
Method: Semi-structured, in-depth telephone interviews were conducted with 
participants who were recruited through theoretical sampling. Telephone interviews 
were conducted until saturation was achieved.
Phase III. Findings forum
Aim: Verify and further refine the findings from Phases I and II.
Method: Using grounded theory techniques of member checking (Charmaz, 2006) 
and CBPR principles of shared ownership, strength-based and empowerment focus, 
and community action (Israel et al., 2001; Kemmis & McTaggart, 2005), study 
participants were invited to co-interpret findings from Phases I and II.
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Research team. The backgrounds of the research team are discussed to increase 
transparency and qualitative trustworthiness. As the author of this dissertation and a PhD student 
in a Clinical-Community Psychology program, I (Valerie Hewell) led this team. I have 
background knowledge in substance abuse through research and clinical practice. Therefore, to 
minimize the influence of biases, Gabriel Cartagena, a UAF undergraduate student, assisted with 
focus group data collection and the data analysis. The dissertation study was co-chaired by Ellen 
Lopez, MPH, PhD, trained in public health, with expertise in cancer prevention and control, 
qualitative methods, and CBPR, and Vivian Gonzalez, PhD, trained in clinical psychology, with 
expertise in substance abuse and quantitative methods.
Consistent with the CBPR principles outlined by Israel and colleagues (1998), the 
research team also included two professional advisors. These two masters-level substance abuse 
counselors offered extensive knowledge and understanding of the challenges and successes 
related to OBOT and have long-standing positive working relationship with me. One advisor, 
Gunnar Ebbesson, assisted in informing project conceptualization and pilot testing study 
processes and instruments. The other advisor, Cici Schoenberger, assisted in identifying the 
project aims. Ms. Schoenberger was readily available throughout the study for consultation, 
which encouraged collaborative and transparent decision-making (Mikesell, Bromley, & 
Khodyakov, 2013). Partner communications involved discussing the study protocols, cultural 
and ethical issues, participant recruitment, data interpretation, and future directions. For a 
detailed synopsis of their roles and responsibilities, see Appendix B.
Setting. This study was conducted within a partnership between Sunshine Community 
Health Center: an integrated health clinic in the rural Alaskan village of Talkeetna, and myself. 
Talkeetna is located approximately 114 miles from Anchorage within the Matanuska-Susitna
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Borough. Located at the base of Denali (North America’s highest peak), Talkeetna is the “jump 
off point” for climbing Denali and the Alaska Range. The village is a historic site marked by 
natural beauty (including the meeting of three rivers) and home to outdoor activities, such as 
fishing and hunting (Talkeetna Chamber of Commerce, 2012). In 2010, the census population 
was 876: 91% were Caucasian, almost 4% were Alaska Native, and slightly over 3% were two or 
more races. In terms of gender, 51.7% were male and 48.3% were female (United States Census 
Bureau, 2012b).
Program details. Sunshine Community Health Center (Sunshine) offers an OBOT 
program, which combines the use of Suboxone® with psychosocial substance abuse counseling. 
Their program encompasses several principles of comprehensive substance abuse treatment as 
defined by the National Institute of Drug Abuse, such as providing intake processing, treatment 
planning, substance abuse monitoring, peer-support groups, mental health services, behavioral 
therapy and counseling, clinical and case management, educational services, continuing care, 
medical services, and pharmacotherapy (NIDA, 2012).
The OBOT program was established in November 2009 and has had a total of three 
treatment providers: (a) one medical doctor from start of program in 2009 until June 2013; (b) a 
second medical doctor from November 2013 until present; and (c) one Licensed Clinical Social 
Worker, from start of program in 2009 until the beginning of the study (June, 2015). During the 
process of data collection, a new Licensed Clinical Social Worker was hired and began leading 
patient groups.
From the initiation of the OBOT program, there have been a total of 90 admissions, 35 of 
which are currently active. Fourteen patients left the program in good standing, 18 were
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terminated by the clinic, five were suspended and may return with close supervision, and 17 
dropped out.
Sunshine conducts two “beginning” groups that meet every other Thursday, one 
“advanced” group that meets the third Friday of the month, and “individualized” programs for 
those who meet criteria for the advanced group, but cannot attend the scheduled group due to 
external conflicts. Criteria for participating in the advanced group includes the following: (a) a 
minimum of six months abstinence from all substances (except Suboxone® and nicotine); (b) 
regular compliance with the program expectations; and (c) evidence of recovery thinking. Ms. 
Schoenberger, Sunshine’s OBOT program director, defined recovery thinking as:
Thinking that involves healthy choice-making, thoughtful rather than impulsive 
decision-making, thinking based on feelings rather than the avoidance o f feelings, 
and thinking about the impact o f one’s behavior on others rather than on just the 
self. Recovery thinking is both a process and a goal for a person who has stopped 
actively using substances and is learning to shed the unhealthy thinking that was 
required to maintain the addiction (C. Schoenberger, personal communication,
May 24, 2015).
When data collection began (June, 2015), there were 21 patients in the advanced group 
or in individualized treatment and 14 patients in the beginner group. When the study ended 
(February, 2016), there were 16 patients in the beginner groups, 15 patients in the advanced 
group, and 11 in the individualized treatment.
I visited the clinic and sat in on the beginning and advanced groups in April 2015 to 
observe, build relationships, and gauge the feasibility of the study. Patients expressed enthusiasm
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for the study and described their hopes that the study would positively impact future patients by 
educating providers.
Ethical considerations and human subjects protection. This study was approved by 
the University of Alaska Institutional Review Board. Study procedures were developed with 
consideration for specific ethical concerns, such as voluntary participation, confidentiality, and 
participant welfare.
Voluntary participation was emphasized during the informed consent process.
Participants were asked to sign the Informed Consent Form before participating. Highlights from 
the form, including voluntary participation and confidentiality, were discussed verbally.
All physical data were stored behind a locked door in a locked cabinet. Confidential 
identifying information including names, contact information, and signatures on the informed 
consent were stored separately from the raw data. Each participant was assigned a random 
identification number to preserve confidentiality. All study-related material, such as Informed 
Consent Forms and demographic surveys, used this identification number. Paperwork was 
deidentified using these numeric identifiers. Qualitative data were de-identified by omitting 
names, dates, places, or other identifying information during the transcription process. All 
findings are reported in an aggregate format to protect confidentiality.
Data were shared among research team members using secure flash drives or the 
University of Alaska Fairbanks Life Science Informatics Secure File Share Service, a service that 
offers an operating system neutral file system. Electronic files were backed up onto the shared 
drive within 48 hours of modification. Project-related files were accessible only to team 
researchers who have successfully applied for a password protected account. Each researcher had 
access to the data used a password-protected computer.
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To ensure participant welfare, researchers monitored participant distress throughout the 
study. Participants were told that they could stop the study at any time for any reason, and were 
encouraged to inform the researcher if the conversation became too distressing. At the end of the 
study, an empowerment debriefing procedure was taken to check for distress, and participants 
were offered a referral list.
Moreover, ethical conduct as set forth by the Belmont Report may not be sufficient in 
CBPR research (Mikesell et al., 2013). Therefore, this study was designed to adhere to the 
reflective-dialectical CBPR approach that attends to additional ethical considerations, including: 
collaboration, mutuality, shared decision-making, empowerment, transparency, and negotiation. 
By partnering with professional advisors, the study strived to enhance ethical standing by 
increasing cultural sensitivity, protecting participants, and minimizing the risk to the community 
(Mikesell et al., 2013). Moreover, this study prioritized each participant’s confidentiality, in part, 
by only reporting results using aggregated or de-identified format. Even though participants and 
professional advisors had a role in data interpretation, they only had access to aggregate (not 
raw) data.
Funding. To compensate focus group, interview, and findings forum participants for 
their time and transportation costs, I successfully sought a small project grant from the Alaska 
Mental Health Trust Authority. This grant funded costs associated with transportation, 
participant compensation, data transcription, and data analysis software.
Eligibility, Recruitment, and Sampling Considerations
Inclusion criteria required that study participants be: (a) a patient in Sunshine’s OBOT 
program, and (b) 18 years or older. In addition, participants would have been excluded if they 
were not willing to have the focus group, telephone interview, or findings forum audio-recorded.
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The following section will describe considerations that were made for recruitment and sampling, 
while participant characteristics will be described on page 61.
Considerations for recruitment. In qualitative research, variation exists regarding 
recommended sample sizes. For focus groups, more than 12 participants may present challenges 
to moderating the focus group and allowing for full exploration, while less than six participants 
may present challenges in sustaining a conversation (Morgan, 1997; Onwuebuzie & Leech, 
2007). However, it is suggested that researchers should over-recruit by approximately 25% 
(Powell & Single, 1996). Therefore, we aimed for a sample of six to twelve participants for the 
focus group, with a maximum of 18 participants.
For interviews, it is important to consider the homogeneity of the population when 
determining how many participants to sample (Onwuebuzie & Leech, 2007). In addition to 
considering the homogeneity of the population (e.g., Sunshine OBOT program), this study drew 
from insights gained in another qualitative study that used similar sampling approaches 
(nonprobalistic purposive sampling) and reached saturation (Guest, Bunce, & Johnson, 2006). 
Therefore, we aimed for an ideal telephone interview sample size range of six to twelve. 
Accordingly, between the focus group and the interviews, a maximum of thirty (n = 30) 
participants could have been recruited into this study.
Recruitment process. Participants were recruited for study Phases I and II by the 
Sunshine’s OBOT program director, Ms. Schoenberger, via informational flyers and through 
word-of-mouth. Consistent with the theoretical sampling procedures outlined by Charmaz 
(2006), the recruitment and sampling process for the Phase II telephone interviews was data- 
driven, meaning that participants were sampled based on emerging thematic categories from 
Phase I that required clarification. For example, after Phase I was completed, it was determined
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that an increased representation of patients in the beginner group was needed. In response, the 
beginner group was intentionally sampled for Phase II interviews.
Sampling approach. In qualitative research, sampling plays a vital role in establishing 
the parameters for a study. This study considered the setting, data collection processes, time of 
data collection, purpose, types of participants being sampled (e.g., heterogenic vs. 
homogeneous), and ability for saturation to be reached in the sampling process (Onwuegbuzie & 
Leech, 2007).
Multi-stage purposive sampling. This study used multi-stage, purposive sampling 
procedures combining criterion-based purposive sampling, theoretical sampling, and mixed 
purposive sampling techniques. As illustrated in Figure 3.1, the multi-stage purposive sampling 
techniques were used (left) with examples of the corresponding data collection and analysis 
processes (right). The second and third rows of this process (theoretical sampling, mixed 
purposive sampling and interviewing) were continued until no new themes emerged.
Phase I:
criterion-based and 
homogenous sampling
theoretical sampling
Phase II:
mixed purposive sampling
Focus Group
Focus Group Themes
(not enough beginner group 
representation)
1
Focus Group Themes
(functioning/normalcy’)
interview
participant
(beginner group)
interview
participant
(beginner group)
Figure 3.1. Multi-Stage Purposive Sampling Process. This figure outlines the process for 
sampling participants using theoretical sampling procedures.
Criterion-based and homogenous sampling. The Phase I focus group utilized criterion-
based and homogenous purposive sampling to ensure only those participants that met inclusion
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criterion were recruited for participation. This sample was homogenous in that the majority of 
participants (86%) were in the advanced group (discussed in detail on p. 61). This served as a 
“jumping off point” for informing emerging theoretical sampling techniques during Phase II 
(Draucker, Martsolf, Ross, & Rusk, 2007). As outlined by Glaser (1978), the initial sampling for 
the Phase I focus group was determined based on the community-identified problem and the 
research questions. Once data collection and analysis began, further sampling followed the lead 
of the emergent data using theoretical and mixed purposive sampling.
Theoretical and mixed purposive sampling. After Phase I focus group data were 
collected and analyzed, subsequent participants were selected for Phase II in-depth semi­
structured telephone interviews based on the process of theoretical sampling. Theoretical 
sampling is used to expand, clarify, and refine data until saturation is reached, that is, until no 
new themes emerge (Charmaz, 2006). Using this process, themes that emerged from Phase I 
along with gaps in the data were used to inform the selection of participants for the next data 
collection phase. Participants were selected based on their ability to provide detail or 
clarification on specific topics. Additional participants were selected until data saturation was 
reached (Charmaz, 2006). For example, Phase I focus group participants described 
functioning/normalcy as an important theme, so Phase II telephone interview participants were 
asked probing questions to clarify, refine, and confirm/disconfirm attributes of this theme. 
Additionally, during Phase I, it became apparent that there was not sufficient representation from 
individuals in the beginner group, so theoretical sampling was used to select participants from 
the beginner group for Phase II interviews. This simultaneous process of collecting and 
analyzing data was used to explore and refine the definition of success in OBOT until a
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comprehensive and accurate understanding of success and recovery was developed based on 
participants’ perspectives and experiences (Charmaz & Belgrave, 2012; Dey, 2007).
Based on the theoretical sampling process described above, the research team used mixed 
purposive sampling to select and recruit participants, assist in theory development, and 
triangulate data (Onwuegbuzie & Leech, 2007; Patton, 2002). Mixed purposive sampling uses a 
combination of purposive sampling strategies to acquire the desired sample (Patton, 2002).
Based on Patton’s (2002) techniques, this study specifically used snowball sampling, extreme 
case sampling, maximum variation sampling, critical case sampling, and 
confirming/disconfirming cases sampling. Snowball sampling was used to recruit participants 
that were harder to access, such as clients in the beginner group. Extreme case sampling was 
used to understand the perspectives of those who were struggling to obtain success and those 
who did not adhere to an abstinence-only orientation. Maximum variation sampling was used to 
expand on initial data collection to obtain a representative sample, including targeted recruitment 
of beginner (as opposed to advanced) patients and those who were struggling (as opposed to 
being successful) in treatment. Critical case sampling was used to get the perspective of someone 
who was in the individual program and did not attend group. Finally, confirming/disconfirming 
cases sampling was used to sample a young beginner client who was struggling to be successful. 
Definitions of purposive sampling techniques can be found in Appendix A.
Compensation. Focus group participants were offered light refreshments and a $20 gift 
card to a local grocery store after completion of the focus group. Telephone interview 
participants and findings forum participants were offered a $20 gift card to a local grocery store. 
To protect participant confidentiality, telephone interview participants were asked to inform Ms. 
Schoenberger when they completed the interview. Ms. Schoenberger then provided them with
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their gift card, a copy of the Informed Consent Form, and a Referral Sheet if they had not already 
received these forms through email.
Participant Characteristics
Of the 12 total participants in this study, seven participated in the Phase I focus group and 
seven participated in the Phase II telephone interviews. Two Phase II participants also 
participated in the focus group. Demographic information for each phase, and for the entire 
sample of this study, is outlined below and detailed in Table 3.3.
Focus group. Seven Sunshine OBOT patients participated in the focus group. The 
majority (86%, n = 6) were in the advanced group and female (57%, n = 4). Ages ranged from 
30-72 years (M = 39, SD = 20). Fourteen percent (n = 1) were in the beginner group. Participants 
in this focus group had been in outpatient treatment from 3 to 65 months, that is five years (M = 
41 months, SD = 23.2).
Interviews. Those who chose to participate in Phase I were also eligible to participate in 
Phase II. Therefore, two of the seven interviews were conducted with participants who also 
participated in the Phase I focus group. As a sample, interview participants were younger and 
more similar in age compared with focus group participants. Ages ranged from 22-57 years (M = 
35, SD = 10.9). More of this sample was unemployed compared to focus group (71%, n = 5), 
with the remaining 14% being a student (n = 1) and 14% being retired (n = 1). Additionally, 
more of this sample was in the beginning group (71%, n = 5). Interview participants in this group 
had been in outpatient treatment from 2 to 108 months, that is nine years (M = 34 months, SD = 
39.4).
Combined. Of the combined 12 participants from Phases I and II, 58% identified as 
male, and 100% identified as Caucasian. Ages ranged from 22 to 72 years (M = 39,
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SD = 14). The combined sample is comparable to the program director’s report of the population 
(patients in Sunshine Clinic’s OBOT program), of which 58% were also male and 95% were 
Caucasian (with the remaining 5% being Alaska Native or mixed). Ages in the total population 
ranges from 21 to 72 years (M = 38, SD = 12).
Participants from the total sample had been in outpatient treatment from 2 months to 96 
months, that is nine years (M = 39.7 months, SD = 32.3). Twenty-five percent (three of the 
twelve) combined participants indicated they had tried Narcotics Anonymous meetings, but are 
no longer attending because it was “not very helpful,” there were “too many drugs at the 
meetings,” or they “didn’t like it.”
The majority (58%) reported living in rural areas while 25% lived in an urban area and 
17% lived between a rural and urban area. More than half of the participants (58%) reported 
having children. In terms of marital status, 42% reported being married, 25% were single, 17% 
were divorced, and 17% were in a relationship. Half of the participants reported being 
unemployed or laid off, 33% worked full time or were students, and 17% were retired or 
disabled. In terms of income, most reported having enough money to meet their needs (67%) 
while 33% struggled to meet their needs.
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Table 3.3
FG n (%) Interviews n (%) Total N (%)
Sample 7 (-) 7 (-) 12 (-)
Gender
Male 3 (43%) 5 (71%) 7 (58%)
Female 4 (57%) 2 (29%) 5 (42%)
Ethnicity
Caucasian 7 (100%) 7 (100%) 12 (100%)
Age
18-30 1 (14%) 2 (29%) 2 (17%)
31-48 3 (43%) 4 (57%) 7 (58%)
49-72 3 (43%) 1 (14%) 3 (25%)
Lifestyle
Geography
Rural 3 (43%) 4 (57%) 7 (58%)
Urban 2 (29%) 2 (29%) 3 (25%)
Rural/Urban 2 (29%) 1 (14%) 2 (17%)
Relationship Status/Family
Married 3 (43%) 3 (43%) 5 (42%)
Single 1 (14%) 2 (29%) 3 (25%)
Divorced 2 (29%) 1 (14%) 2 (17%)
In a relationship 1 (14%) 1 (14%) 2 (17%)
Have children 5 (71%) 4 (57%) 7 (58%)
Employment
Unemployed 1 (14%) 5 (71%) 5 (42%)
Employed full time or student 3 (43%) 1 (14%) 4 (33%)
Retired or disabled 3 (43%) 1 (14%) 2 (17%)
Financial Stability
Have enough to meet their needs 4 (57%) 4 (57%) 8 (67%)
Struggle to meet their needs 4 (57%) 3 (43%) 5 (42%)
Treatment Group
Beginning Group 1 (14%) 5 (71%) 5 (42%)
Advanced Group 6 (86%) 1 (14%) 6 (50%)
Individual Program 0 (0%) 1 (14%) 1 (8%)
Note. FG = focus group
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Data Collection
Instruments. Demographic data were collected using a pen-and-paper survey for the 
focus group. Demographic questions were asked verbally during the interviews. Qualitative data 
were collected during the Phase I focus group and Phase II in-depth telephone interviews using a 
semi-structured interview guide. As stipulated in the Informed Consent Forms, the focus group 
and telephone interviews were audio-recorded for the purposes of review and transcription.
Demographic survey. After providing their informed consent, participants completed a 
demographics questionnaire. The survey began with demographic questions such as age, 
residence, and ethnicity. Then, questions about past and current health, including mental health, 
physical health, social functioning, and spiritual wellbeing, were asked. Questions were informed 
by those used in national surveys such as the Behavioral Risk Factor Surveillance System 2014 
Questionnaire and other studies (CDC, 2013; Mee-Lee, 2013). The next questions asked about 
opioid use and treatment history (informed by, Mee-Lee, 2013; Miller & Appel, n. d.). Finally, 
participants were asked about their perspectives related to substance abuse recovery (e.g., if they 
consider themselves in recovery and why; informed by Laudet, 2007; Luke, Ribisi, Walton, & 
Davidson, 2002). The demographic survey was reviewed and pilot tested by professional 
advisors, researchers, a Ph.D. student with clinical experience in working with people with 
substance use disorders, and individuals without a background in substance misuse research or 
treatment.
Phase I: Focus group. This study’s focus group protocol development— including the 
process and procedures for conducting focus groups, establishing ground rules, facilitating 
discussion, and taking notes—was informed by the Toolkit for Conducting Focus Groups (Omni 
Research and Training, 2015) and processes used by Sharma, Lopez, Mekiana, Ctibor, & Church
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(2013). The focus group questions were informed by the key structural components outlined in 
Table 3.4 (Charmaz, 2006; Charmaz & Belgrave, 2012).
Table 3.4
Structure _ for Focus Group Question Guide
Section Interview structure
Initial Section
Intermediate Section
Closing Questions
Post-interview Debriefing
Open-ended to facilitate non-prompted and unanticipated 
themes.
Prompted participants to provide an open and nuanced 
understanding of their perception of OBOT success. 
Directed questions to focus the interview and collect 
missing data about OBOT success.
Positively framed questions to increase participants’ 
comfort.
The second to last question asked if there was “something” 
more the participant might add. This allowed room for 
more detail instead of abruptly closing the dialogue. 
Empowerment-based debriefing: recapped the interview, 
highlighted the importance of the participants’ 
contributions, discussed potential implications (such as 
providing insight to treatment providers, researchers, and 
evaluators), and asked what participants hoped would come 
from the study.
Two close-ended questions to assess how the participant 
felt after, compared to when they began, the interview 
(DeCou, Skewes, Lopez, & Skanis, 2013).
The procedure for collecting focus group data was interactive and collaborative. Focus 
group questions were developed using an open-ended and collaborative structure to balance the 
needs of addressing the research questions while still capturing the participants’ perspective
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outside of what was queried (Charmaz & Belgrave, 2012). Additionally, an “All-on-the-wall” 
(Sharma et al., 2013) procedure was used to encourage participants to co-interpret and analyze 
data as it was collected. The focus group questions and “All-on-the-wall” procedures are detailed 
in Appendix D.
To answer the study’s research questions, three blocks of questions were posed during the 
focus group. The first question block queried participants’ definitions of success and recovery, 
and responses were recorded on a flip chart. The second question block queried factors related to 
treatment success, including facilitators and barriers. Participants were asked to write down their 
thoughts about what contributes to “feeling successful” in treatment on yellow sticky notes, and 
their thoughts about what contributes to “not feeling successful” in treatment on green sticky 
notes. They were then asked to share their responses, collaboratively sort the sticky notes into 
groupings (domains), and name each identified domain. Figure 3.2 includes two photos to 
illustrate how the sticky notes were assembled into domains. The third question block queried 
participants’ beliefs about how OBOT success should be measured. Responses were 
collaboratively discussed.
visible, these two images depict a visual representation of how participants’ responses were 
sorted into domains using the “All-on-the-wall” procedure.
66
Professional advisors, researchers, and individuals who did not have a background in 
substance misuse research or treatment reviewed the study protocol to encourage 
comprehensiveness and accessibility of the instrument. In addition, three PhD students with 
clinical experience working with people with substance use disorders pilot tested the focus group 
process. Outcomes from the pilot-test included omitting items that were deemed unnecessary 
(e.g., “When I say the word success, what comes to your mind? What words, images, and 
connections come up for you?”), and rewording other items to enhance clarity (e.g., changing 
“How do treatment providers define recovery? How is this the same, or different, than your 
understanding?” to “How did you come to define success and recovery like this? [prompt: 
providers, family, support groups, friend]”). Pilot-testing also determined the focus group 
procedures to be feasible.
Phase II: In-depth, semi-structured telephone interviews. After the focus group was 
conducted and data were analyzed, it was determined that the same interview questions should 
be asked during the Phase II interviews. However, specific probes were added to further explore 
themes and domains that emerged from the Phase I focus group (Charmaz, 2006; Glaser & 
Strauss, 1967).
Conducting the focus group. Potential participants were screened for eligibility by Ms. 
Schoenberger. They were then invited to participate in the focus group, which was conducted at 
Sunshine’s clinic in Willow, Alaska. The focus group comprised three stages: (1) welcoming and 
study orientation, (2) break and decision to sign the Informed Consent Form, and (3) data 
collection.
Stage one. Individuals were welcomed with light refreshments and offered two copies of 
the Informed Consent Form. I oriented the group with an opening script (see Appendix D),
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which outlined the purpose of the study. The Informed Consent Form was read aloud and 
questions were answered. It was emphasized that disclosing illegal activities such as drug use 
would not warrant breaking confidentiality.
Stage two. Individuals took a brief break during which they could either decide to sign 
the Informed Consent Form and remain for the focus group or refrain from participating and 
leave before the focus group began. Individuals still interested in participating in the study were 
asked to sign the Informed Consent Form, return it to me, and keep a second copy for their 
records.
Stage three. Data collection involved participants completing the demographic survey 
(see Appendix C), establishing ground rules for the focus group (see Appendix D), and taking 
part in the focus group discussion. I facilitated the group during which probes and follow-up 
questions were used to refine the participants’ understandings of success (Charmaz & Belgrave, 
2012). During the focus group, Mr. Cartagena recorded copious notes based on behavioral 
observations using Onwuegbuzie, Leech, and Collins (2010) strategies for behavioral and 
nonverbal communication.
After Stage I data were collected, researchers and participants engaged in an empowerment 
approach to debriefing. This involved recapping the focus group discussion, highlighting the 
importance of the participants’ contributions, discussing potential implications (such as 
providing insight into how success can be measured in Suboxone® treatment), and asking what 
participants hoped would come from the study. Finally, participants were asked two close-ended 
questions to assess how they felt after, compared to before, taking part in the focus group. In 
another qualitative interview study that entailed participants discussing past traumas involving a 
loved one’s suicide or suicide attempt (DeCou et al., 2013), these debriefing questions revealed
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participation in the study had a therapeutic effect. As participants left the focus group, they were 
offered a resource sheet (see Appendix F).
Conducting the telephone interviews. Ms. Schoenberger advised that travel costs would 
be a major barrier to participation and engagement for the patients in the Sunshine OBOT. 
Therefore, I conducted Phase II interviews via telephone to reduce travel costs and other 
obstacles to participation. After potential participants were identified based on the theoretical 
sampling process, Ms. Schoenberger provided the contact information for individuals who were 
interested in conducting an interview. Ms. Schoenberger provided potential participants with a 
copy of the Informed Consent Form, or I provided them with an electronic copy of the Informed 
Consent Form.
Prior to initiating an interview, I described the study, read through the Informed Consent 
Form, and emphasized that disclosing illegal activities such as drug use would not warrant 
breaking confidentiality. Each individual’s oral consent was captured on the audio-recording. 
This process of obtaining verbal informed consent was successfully accomplished by Gifford 
(2013) who conducted telephone interviews with rural behavioral health care providers. I then 
conducted a telephone administration of the demographics survey previously described, and 
concluded with conducting the semi-structured interview.
The telephone interviews were completed using a conversational manner to increase 
flexibility, and to build rapport (Bazeley, 2013; Charmaz & Belgrave, 2012; Morrow, 2005). 
Consistent with constructivist grounded theory, I drew from themes that emerged during Stage I, 
while also remaining flexible in terms of exploring new and emergent topics (Charmaz, 2006; 
Charmaz & Belgrave, 2012; Doody & Noonan, 2013). After completing the telephone interview, 
I debriefed with participants and offered them an electronic version of the resource sheet
69
(debriefing procedures included in Appendix F). Ms. Schoenberger also made hard copies of the 
resource sheet available at Sunshine for individuals who may not have had Internet access.
Conducting the findings forum. To verify the findings from Phases I and II, this study 
used grounded theory techniques of member checking (Charmaz, 2006) while adhering to CBPR 
values such as shared ownership (Israel et al., 2001; Kemmis & McTaggart, 2005) to conduct a 
findings forum. After all of the data were collected and analyzed by researchers, a preliminary 
presentation of findings was developed for study participants. All participants were contacted to 
invite them to the findings forum. Eligible findings forum participants were those who had: (a) 
completed Phase I and/or II, and (b) indicated that they were interested in participating in the 
findings forum on their Phase I or II Informed Consent Form. Participants who could not attend a 
forum were offered an electronic copy of the presentation (PowerPoint) and the opportunity to 
discuss the findings individually with me.
Due to geographic constraints, I conducted the findings forum via conference using a 
secure computer connection in a private setting that connected with Sunshine’s telebehavioral 
technology equipment. The Sunshine program director, Ms. Cici Schoenberg, approved this 
approach to facilitate the forum.
We used Meeting to Go: an Internet meeting forum that provided a secure connection 
(e.g., end-to-end encryption, strong passwords). The findings forum was conducted in four 
stages: (1) welcome, (2) presentation, (3) discussion, and (4) closing.
Stage one (welcome). Participants were welcomed to the findings forum by reintroducing 
them to the purpose of the study and their involvement in the study (e.g., participation in the 
focus group or in an interview). The importance of confidentiality was established and 
participants were reminded of how the study protects their privacy. Specifically, participants
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were reminded that we would not disclose their identity unless there was an indicated threat to 
themselves or others and that findings will only be reported in aggregate form. Additionally, the 
purpose of the findings forum—to present and verify findings—was accentuated. During this 
stage, Ms. Schoenberger welcomed participants and provided them with a hard copy of the 
findings forum Informed Consent. In addition to signing the consent form, participants were 
asked to give their verbal consent. During a brief break, individuals were given the opportunity 
to decline participation and leave the forum. Nobody chose to leave.
Stage two (presentation). The findings of the study were presented to participants. 
Participants were given a handout of the PowerPoint presentation (see Appendix M). They were 
encouraged to take notes to denote findings with which they agreed, disagreed, or wanted 
clarification.
Stage three (discussion). Participants were invited to share their reactions to the findings 
and engage in a discussion about the presentation. This provided a means for verifying findings 
via member checking (Charmaz, 2006). To guide the discussion, participants were asked to share 
how they wanted to see the findings used, and to determine if and how they wanted to initiate an 
action plan (Israel et al., 2001; Kemmis & McTaggart, 2005). Specific discussion questions are 
provided in Table 3.5.
Stage fo u r  (closing). At the end of the findings forum, I summarized what was discussed. 
Participants were also provided the opportunity to debrief and process their experience in the 
findings forum. To thank participants for their time and compensate them for travel expenses, 
they were offered a $20 gift card to a local grocery store (given to them by Ms. Schoenberger).
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Table 3.5
Findings Forum Questions
Stage Questions
Stage III. Discussion
Stage IV. Closing
1) What are your general impressions of the findings?
2) What was most interesting? Did anything surprise you?
3) Are there findings you may not agree with and would like to 
clarify?
4) Are there findings you particularly agree with and would like 
to highlight?
5) How would you like to use this research?
6) How did you feel about this method? If you were a part of 
the original focus group, how did you feel about the process 
of using the sticky-notes?
1) How helpful was it to hear other people’s stories?
2) How was it to participate in this forum using distance 
technology?
Data Analysis
Demographic survey management and analysis. Completed demographic surveys were 
coded and entered into an excel document for descriptive statistical analysis. Continuous 
variables (e.g., age, length of opioid misuse) were analyzed for mean, median, mode, standard 
deviation, and range, while categorical variables (e.g., “Please rate your current health”) were 
analyzed to examine frequencies. I did not explore relationships or differences between variables 
(e.g., using ANOVA) because of the small sample size.
The qualitative items (e.g., “What is/was your opioid of choice”) that yielded quantifiable 
responses were quantified and analyzed as categorical variables using descriptive statistical 
analyses, that is, frequencies. Qualitative items that yielded rich and varied responses (e.g.,
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“Why do you feel like you are or are not in recovery?”) were analyzed using directed content 
analysis. All demographic survey analyses are reported in an aggregate format that describes 
participants as a group.
Approach to qualitative analysis. As previously described, inductive and deductive 
qualitative analysis approaches were used. Since I have a background in substance abuse 
research and clinical work, a deductive approach of directed content analysis was used to frame a 
priori knowledge and assumptions (Hsieh & Shannon, 2005). To balance the constraints of a 
deductive approach, analysis maintained a theoretically sensitive stance to encourage openness to 
emergent data (Charmaz, 2006; Glaser & Strauss, 1967; Kelle, 2007). A second researcher, Mr. 
Cartagena (who had no formal background in substance abuse research) assisted with data 
collection and analysis, and with avoiding an unintentional push towards already established,
“pet theories” (Kelle, 2007). Both researchers openly discussed their biases and assumptions 
throughout the study, including during data analysis. Finally, as recommended by Strauss and 
Corbin (1990), a theoretically sensitive stance was encouraged by: (a) taking a step back from 
the data to reflect, (b) remaining skeptical and inquisitive, and (c) sticking to the research 
protocol. As analysis moved toward data saturation, researchers took a flexible, thoughtful, 
community-informed (e.g., by conducting the findings forum), and data-grounded approach in 
efforts to avoid premature foreclosure of categories (Charmaz, 2006).
Exploring the data. To explore the qualitative data, analysis included a preliminary 
analysis, theoretical sampling, and finally a comprehensive analysis. Data included transcripts 
created from audio-recordings of the focus group and interviews, visual diagrams of participant- 
defined categories that emerged during the focus group, behavioral observations documented 
during the focus group, and notes recorded during data collection sessions.
73
Preliminary analysis. Adhering to the principles of CBPR (Israel et al., 1998; Israel et 
al., 2001), focus group participants were regarded as co-researchers who interpreted and verified 
the analysis as data were collected (Sharma et al., 2013). After the focus group, photos were 
taken of the “All-on-the-wall” (see Appendix D) procedure to capture participant-generated 
findings as one form of data. In addition, the audio-recorded focus group was transcribed. Using 
these sources of data, researchers conducted a preliminary analysis using initial coding 
(described next).
Specifically, we started broadly by developing codes that closely represented the data (in 
this study, the categories initially developed by focus group participants during the All-on-the- 
wall procedure; Charmaz, 2006). Initial coding was also used to capture ideas that were 
discussed in other stages of the focus group. Progressively, we scrutinized and explored the 
relationships between identified or emerging categories (Draucker et al., 2007; Kelle, 2007). 
Codes that were symbolic markers of the language participants used (in-vivo codes) were used to 
represent the meaning of participants’ perspectives (Charmaz, 2006). In-vivo codes were derived 
from participant-defined categories that emerged during the focus group and from reviewing the 
transcripts. Then, we used selective coding, diagrams, and theme-development to begin moving 
the initial codes towards broader categories (Charmaz, 2003, 2006). At this stage, individuals 
were theoretically sampled for telephone interviews based on themes that required deeper 
exploration (Draucker et al., 2007).
Theoretical sampling. Conducting the initial and selective coding of the focus group 
transcript created a snapshot of the data. The researchers then examined the emergent themes to 
identify those requiring expansion and clarification. Subsequently, theoretical sampling was 
conducted in an effort to elaborate meaning, discover variation, identify gaps, and reach
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saturation (Charmaz, 2006; Patton, 2002). Mixed purposive sampling techniques guided the 
theoretical sampling decision-making process. For example, typical cases emerged from the 
focus group, such as people who were doing well and were in the “advanced group.” In response, 
the researchers decided to sample atypical cases to gain a different perspective, such as people 
who were struggling in the group, and those in the “beginner group”).
Comprehensive analysis. Telephone interview recordings were transcribed to become 
raw data for data analysis. The coding process involved a progression that moved understanding 
from discrete and literal (initial coding), to conceptual and abstract (selective coding), to a higher 
level of abstraction and relational representation of the data (theoretical coding). After all of the 
data from Phases I and II were collected and coded, theoretical coding was conducted to “weave 
the fractured story back together” (Glaser, 1978, p. 72). That is, theoretical coding relied on 
selective coding to develop categories that subsumed initial codes in efforts to develop an 
analytic framework (Charmaz, 2003).
Categories earned their way into the analysis (Charmaz, 2006) through emerging from 
the constant comparison method (Draucker et al., 2007). The constant comparison method 
enabled the following comparisons: (a) data/categories between people, (b) the same person at 
different points during the focus group and/or telephone interview, (c) incidents with other 
incidents, (d) data with categories, (e) categories with other categories, and (f) the team-based 
codebook with emerging data. Nvivo10 software (described below) is a qualitative data 
management and analysis software program that facilitated the constant comparison method. For 
example, through running Nvivo10queries, nodes (codes) were compared, and visual models of 
the data were created (Bazeley & Jackson, 2013).
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Organizing the data. The process of memo writing, developing a codebook, and using 
Nvivo10 software program was employed to organize the data. Data were securely stored in 
accordance with the Institutional Review Board protocol.
Memo writing. To increase trustworthiness of theoretical sampling and the constant 
comparison method, informative memos were written and curated. Memos were written during 
and after data collection (focus group and telephone interviews), meetings with Ms. 
Schoenberger and researchers, data analysis and synthesis, and draft paper writing to abstractly 
develop and analyze data, categories, and concepts (Bryant & Charmaz, 2007).
Codebook. Glaser and Strauss (1967) suggest that analytic codes should emerge from the 
data, not from a deductive or preconceived assumption about the theory. Nevertheless, Strauss 
and Corbin’s (1990, 1994) approach to grounded theory allows for a less fundamentalist and 
more pragmatic approach to analysis. An a priori codebook (see Appendix G) was developed per 
the literature. The primary purpose of this codebook was to frame researchers’ expectations, 
biases and assumptions. This a priori codebook was compared with those codebooks that were 
later developed based on the data collected from participants.
Nvivo10. Nvivo10, a software program for qualitative data analysis (Nvivo10 for Mac, 
2015), was used to store, organize, and analyze qualitative data, including transcripts, pictures, 
notes, and codebooks. An audit trail comprising memos and notes from meetings were also 
stored in this program.
Rigor
Qualitative research ascribes to a different standard from quantitative research for 
establishing rigor or trustworthiness. In this study, criteria for trustworthiness as identified by 
Morrow (2005) was established in the manner described in Table 3.6.
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Table 3.6
Establishing Trustworthiness
Rigor criteria 
Credibility
Transferability
Dependability
Triangulation
Praxis
How it was established 
Definition: Similar to “internal validity” in quantitative research. Refers 
to the communication of internal rigor in the research process. 
Application: This study used participants as peer-investigators during 
the focus group, theoretically sampled for negative cases, conducted a 
findings forum where participants co-interpreted findings, and remained 
reflexive.
Definition: Similar to “external validity” in quantitative research. Refers 
to how far the findings of a qualitative study can be generalized. 
Application: Researchers provided detailed information about the 
researchers, the instruments, the context, and the participants to increase 
the opportunity for transferability of study findings to other settings. 
Definition: Similar to “reliability” in quantitative research. Refers to 
having a systematic plan that can lead to study replication.
Application: Study design applied “planned flexibility” (Bazeley, 2013, 
p. 31) through a detailed, systematic plan using a protocol, a codebook, 
diligent memo writing, and directed content analysis approach. 
Definition: The process of taking multiple perspectives.
Application: Study used various investigators (professional advisor, two 
coders), methods (inductive grounded theory approach and deductive 
directed content analysis), and multiple sources of data (notes from 
professional advisors, focus group, telephone interviews, and the 
literature). Participants were encouraged to verify findings, or “member 
check” (Charmaz, 2006; Israel et al., 1998).
Definition: Integrating practice with theory (Patton, 2002).
Application: Study aimed to expand upon existing knowledge of success 
in substance abuse treatment in a practical way based on the 
perspectives of the patients.
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Table 3.6 continued
Verstehen
Dialogue
Context, 
Culture, and 
Rapport
Reflexivity, 
Representation, 
and Fairness
Consequential
Validity
Definition: Obtaining a deep understanding of study findings. 
Application: Gained a broad focus (with a focus group) and then 
obtained in-depth perspectives via the telephone interviews.
Definition: Mutually constructed theory based on multiple perspectives. 
Application: Study intended to encourage dialogue through adhering to 
a CBPR approach, specifically via collaborative involvement from Ms. 
Schoenberger and study participants throughout the study.
Definition: “Recontextualizing” participants’ experiences.
Application: Attention paid to building rapport while being cognizant of 
the “slippery slope” of blending research with clinical practice. Ms. 
Schoenberger oversaw process and facilitated entry into the treatment 
culture.
Definition: The process of explicating inherent biases through 
acknowledging the subjective nature of research and striving to 
accurately represent participants’ perspectives.
Application: Researchers explicated their assumptions and backgrounds, 
and explored them throughout the study. Diverse perspectives included 
in the research team. The team remained flexible to the needs of 
stakeholders, reflexive throughout data collection, followed the lead of 
participants, and remained theoretically sensitive during data analysis 
(Bazeley, 2013; Charmaz, 2006). Member checks during Phases I and 
III encouraged accurate representation of the findings.
Definition: Building the capacity for social and political change. 
Application: Adhered to CBPR principles to enhance the relevance and 
usefulness of the data, create rigor by using local knowledge and 
practical social experiences, bridge cultural gaps by engaging and 
empowering marginalized populations, and improve the well-being of 
communities through the strength-based approach which encourages 
participant buy-in (Israel et al., 1998).
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Chapter 4: Findings
Findings from this study will be discussed based on descriptive analysis of participants’ 
responses to the demographic survey and qualitative analysis of the Phase I focus group, Phase II 
interviews, and Phase III findings forum. The categories that emerged during the initial focus 
group, during which participants developed categories related to their definitions of success, 
were further clarified and revised through conducting subsequent in-depth interviews. Findings 
that emerged through the qualitative analysis were discussed and clarified during a findings 
forum. The findings presented below are based on the final analysis that integrates data from the 
focus group, in-depth interviews and findings forum. Appendix L includes three analysis tables 
providing detail about how the analysis evolved from the focus group through the subsequent 
interviews and findings forum.
Descriptive Analysis
After consenting to the study, participants completed a demographics questionnaire, 
which included questions about their health, addiction, treatment experience, and recovery. Table 
4.1 details participants’ health, wellbeing and opioid use ratings, including frequencies and the 
mean, standard deviation, and ranges when applicable.
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Health, Wellbeing, and Opioid Use______________________________________________________________
FG n (%) Interviews n (%) Total N (%)
Table 4.1
Health and Wellbeing 
Current Health 
Physical Health 
Fair/Poor
Good/Very Good/Excellent 
Mental Health 
Fair/Poor
Good/Very Good/Excellent 
Spiritual Wellbeing 
Fair/Poor
Good/Very Good/Excellent 
Not Applicable 
Social Functioning 
Fair/Poor
Good/Very Good/Excellent 
Current Psychological Concerns 
Depression 
Anxiety 
Stress 
None
Current Health Concerns 
Breathing 
Chronic Pain 
None 
Arthritis 
Liver/Kidney
Abscesses/Collapsed Veins 
High Blood Pressure and Smoking 
Heart Health 
Infectious Disease
1 (14%) 1 (14%) 1 (8%)
6 (86%) 6 (86%) 11 (92%)
0 (0%) 1 (14%) 1 (8%)
7 (100%) 6 (86%) 11 (92%)
1 (14%) 0 (0%) 1 (8%)
6 (86%) 5 (71%) 9 (75%)
0 (0%) 2 (29%) 2 (17%)
1 (14%) 2 (29%) 3 (25%)
6 (86%) 5 (71%) 9 (75%)
2 (29%) 1 (14%) 3 (25%)
0 (0%) 3 (43%) 3 (25%)
1 (14%) 1 (14%) 2 (17%)
5 (71%) 3 (43%) 5 (71%)
3 (43%) 2 (29%) 4 (33%)
1 (14%) 4 (57%) 4 (33%)
2 (29%) 3 (43%) 4 (33%)
2 (29%) 0 (0%) 2 (17%)
2 (29%) 1 (14%) 2 (17%)
1 (14%) 1 (14%) 2 (17%)
2 (29%) 0 (0%) 2 (17%)
1 (14%) 1 (14%) 1 (8%)
1 (14%) 1 (14%) 1 (8%)
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Table 4.1 continued
Opioid Use
Introduction to Opioids
Prescribed by Doctor 
Fun/Enhance Mood 
To get “High”
To Manage Pain 
To Cope with Stress 
To Escape Something Negative 
To Cope with Psychological Issue 
Because they were Available 
To Fit In
To Cope with Certain Social Encounters 
Opioids Used
Medication-assisted Treatment (as prescribed) 
Prescription Opioids (not as prescribed) 
Heroin
Prescription Opioids (as prescribed) 
Methadone (not as prescribed)
Morphine (not as prescribed) 
Medication-assisted Treatment (not as 
prescribed)
Morphine (as prescribed)
Methadone (as prescribed)
Opioids of Choice
Prescription Opioids 
Heroin 
Methadone 
Preferred Route of Administration 
Intravenously 
Orally
Multiple Routes 
Smoking
FG n (%) Interviews n (%) Total N (%)
6 (86%) 6 (86%) 10 (83%)
4 (57%) 6 (86%) 9 (75%)
4 (57%) 6 (86%) 9 (75%)
5 (71%) 6 (86%) 9 (75%)
4 (57%) 5 (71%) 8 (67%)
4 (57%) 4 (57%) 7 (58%)
3 (43%) 4 (57%) 6 (50%)
3 (43%) 4 (57%) 6 (50%)
3 (43%) 2 (29%) 4 (33%)
0 (0%) 1 (14%) 1 (8%)
7 (100%) 7 (100%) 12 (100%)
7 (100%) 6 (86%) 11 (92%)
5 (71%) 6 (86%) 10 (83%)
6 (86%) 5 (71%) 10 (83%)
6 (86%) 5 (71%) 9 (75%)
5 (71%) 4 (57%) 8 (67%)
3 (43%) 3 (43%) 6 (50%)
2 (29%) 2 (29%) 3 (25%)
1 (14%) 0 (0%) 1 (8%)
5 (71%) 3 (43%) 6 (50%)
3 (43%) 4 (57%) 6 (50%)
1 (14%) 1 (14%) 2 (17%)
2 (29%) 4 (57%) 5 (42%)
2 (29%) 2 (29%) 3 (25%)
3 (43%) 0 (0%) 3 (25%)
0 (0%) 1 (14%) 1 (8%)
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Health and wellbeing. Regarding current health, most participants described their health 
as good, very good, or excellent with regard to their physical (91%), mental (91%), spiritual 
(75%), and social health/functioning (75%). Current psychological concerns reported included 
depression (25%), anxiety (25%), and stress (17%), while the most common current health 
concerns included breathing (33%), and chronic pain (33%).
Opioid use. All of the participants reported experiencing withdrawal symptoms at some 
point, and also considered their opioid use problematic or addictive at some point. Participants 
reported that their average length of addiction ranged from 2-20 years (M = 9, SD = 5), while 
average length of recovery ranged from 2 to 108 months (M = 38.25, SD = 32.8), that is zero to 
nine years.
Participants reported origins or reasons for beginning to use opioids and the types of 
opioids used are listed in Table 4.1. Most participants were introduced to opioids by their doctor 
(83%), and used to enhance their mood (75%), to get high (75%), to manage pain (75%), to cope 
with stress (67%), and/or to escape from something negative (58%). The primary opioids that 
were used include medication-assisted treatment, as prescribed (100%); prescription opioids, not 
as prescribed (92%) and as prescribed (83%); and heroin (83%). Half of the participants reported 
having used medication-assisted treatment, not as prescribed.
Participants’ reported opioids of choice included: prescription pills such as oxycodone, 
tramadol, codeine, and oxymorphone (58%), heroin (50%), or methadone and/or 
methadone/morphine, (17%). In terms of preferred methods for taking opioids, 42% preferred 
taking opioids intravenously, 25% preferred taking opioids orally, 25% preferred multiple routes 
of administration, and 8% preferred smoking/inhalation.
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Table 4.2
Current Substance Use and Goals
Focus Group Interviews Total
Current Goals Current Goals Goals Current
n (%) n (%) n (%) n (%) N (%) N (%)
Nicotine
No Use 2 (29%) 7 (100%) 3 (43%) 6 (86%) 11 (92%) 4 (33%)
Moderate/Controlled 4 (57%) 0 (0%) 2 (29%) 1 (14%) 1 (8%) 5 (42%)
Unrestricted/Heavy 1 (14%) 0 (0%) 2 (29%) 0 (0%) 0 (0%) 3 (25%)
Alcohol
No Use 7 (100%) 7 (100%) 4 (57%) 4 (57%) 9 (75%) 9 (75%)
Moderate/Controlled 0 (0%) 0 (0%) 3 (43%) 3 (43%) 3 (25%) 3 (25%)
Unrestricted/Heavy 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Marijuana
No Use 7 (100%) 7 (100%) 6 (86%) 5 (71%) 10 (83%) 11 (92%)
Moderate/Controlled 0 (0%) 0 (0%) 1 (14%) 2 (29%) 2 (17%) 1 (8%)
Unrestricted/Heavy 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Opioids (not Suboxone®)
No Use 7 (100%) 7 (100%) 6 (86%) 7 (100%) 12 (100%) 11 (92%)
Moderate/Controlled 0 (0%) 0 (0%) 1 (14%) 0 (0%) 0 (0%) 1 (8%)
Unrestricted/Heavy 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Stimulants
No Use 7 (100%) 7 (100%) 6 (86%) 7 (100%) 12 (100%) 11 (92%)
Moderate/Controlled 0 (0%) 0 (0%) 1 (14%) 0 (0%) 0 (0%) 1 (8%)
Unrestricted/Heavy 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Current substance use and goals. Current use and goals related to substance use are 
reported in Table 4.2. Some participants were still moderately using substances, and a minority 
of participants had the goal of moderate use of some substances, such as marijuana, alcohol, and 
nicotine. None of the participants had a goal of heavy/unregulated use of any substance, or of 
any use of stimulants or opioids (excluding Suboxone®).
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Regarding current Suboxone® treatment, 50% were in the Sunshine Clinic’s advanced 
group (a minimum of 6 months of abstinence, evidence of recovery thinking, and compliance 
with the program), 42% were in the beginner group (did not qualify for the advanced group), and 
8% were in the individual group (met criteria for the advanced group but are not able to attend). 
None of the participants considered themselves to be in active addiction at the time of the study, 
and all of the participants considered themselves to be in recovery. Participants’ reported 
believing they were in recovery due to cessation of substance use disorder (SUD) symptoms 
(e.g., reduction in relapse, cravings, and heroin addiction), their ability to function, and having 
motivation to be in treatment. For example, one participant stated, “While on Suboxone®, you 
are able to be a fully functioning member of society and as long as I'm on Suboxone® everything 
is fine with no to minimal danger of relapse” (Participant [P]7). Participant five described how 
stability and progress contribute to feeling like they are in recovery:
I  am at a really good place in my life right now. I  have been sober for a very long 
time. Everything in my life seems to keep getting better and better. I  have a good 
job, I  graduated college. I  have strong/healthy relationships.
Qualitative Findings
The qualitative findings will be described in terms of a hierarchy of broader categories, 
descriptive themes, and subsumed concepts. For ease of reference, categories are bolded, themes 
are underlined, and concepts are italicized. The four overarching categories were established 
based on the research questions (see p. 8): Success, Recovery, Facilitators & Barriers, and 
Measurement of Success. Themes represent the salient groupings of data that characterize each 
category. Concepts provide more detail and context, and help tell the story of each theme.
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Analyses of the categories are presented in the following sections, including: definitions 
of categories and affiliated themes and concepts, frequency of endorsement, and the number of 
interview participants endorsing each theme. It should be noted that although providing the 
frequency of endorsement is not common practice in qualitative research, it is in accordance with 
the directed content analysis approach used in this dissertation (Curtis et al., 2001; Hsieh & 
Shannon 2005). Additionally, this enables the reader to recognize the most referenced content 
and adds transparency to the analytical process.
The final section of this chapter (see Participants’ Experiences of being in the Study) 
focuses on how participants felt about participating in the study. This section also introduces a 
metaphorical, integrated conceptual model of the cumulative findings. The model emerged 
during the Phase I focus group, and continued to become refined during the Phase II interviews 
and analysis process. The following section describes the success category and associated themes 
and concepts.
Success. Success, which includes participants’ definitions of success, was the category 
that participants discussed with highest frequency. Analysis revealed four primary themes within 
success, including: lifestyle, accomplishments, relationships, and psychological factors. Table 
4.3 provides definitions, frequencies, and data collection sources for each theme and concept 
comprising the category success. Although all themes and concepts were referenced in the focus 
group, concepts that were specifically named by participants during the focus group All-on-the- 
wall procedure are represented with (a). A table of initial themes identified and named by 
participants during the Phase I focus group is provided in Appendix 5.K-1.
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Table 4.3
Themes and Concepts Related to Success
No. ref. No. interviews
Lifestyle
Functional Lifestyle a
Fulfilling responsibilities; functioning in work/school 
Living a healthy and sustainable lifestyle (e.g., taking care of self) 
Cessation of Substance Use Disorder (SUD) Symptoms
Reducing symptoms related to substance disorder (e.g., withdrawal, 
stealing, cravings, tolerance, drug-seeking)
Living Life
Living life to the fullest
Seeing contrast to life when using (e.g., numbing)
Accomplishing 
Progress a
Making “small successes” and moving toward goals 
“Bettering yourself’ and reappraisal of life goals 
Seeing past to present difference in regards to progress 
Self-efficacy
Believing one can manage life; learning to cope/deal with life 
“Doing it for myself”
Relationships 
Family a
Referring to family and close relationships/significant others 
Restoring Relationships
Making amends; healing lost social connections 
Social Functioning a
Improving social relationships
Ending relationships that did not foster success/social functioning 
Psychological
Emotional Wellbeing a
Feeling happiness, peace, self-esteem, self-worth 
Mental Health a
Recovering from mental health symptoms (e.g., depression, anxiety) 
Having a clear head and better decision-making process 
Character
Feeling like a “new person”; being more open and honest
99
45
37
17
60
37
24
59
34
15
10
46
18
15
13
1 Concepts that were also identified by participants in the focus group.
7
5
5
5
3
3
5
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Lifestyle. Lifestyle emerged as a prominent theme of success that included concepts of 
having a functional lifestyle, cessation o f SUD symptoms, and living life (to the fullest). This 
theme incorporates how one lives day-to-day and how daily lifestyle behaviors relate to success.
Participants described living a functional lifestyle when describing success. This concept 
emerged during the focus group, and was further elaborated upon during subsequent interviews. 
Participants believed they were functional when they were able to contribute to society and do 
“normal” things. For example, participant nine described how success includes living a 
sustainable lifestyle:
...things like going to work and keeping a regular schedule and paying bills.
Maintaining a safe place to stay. Being able to keep possessions that are 
necessary to maintain a lifestyle, like a car or work equipment...andsustainable 
lifestyle.
Another theme of living a successful lifestyle described by participants during the focus 
group and interviews was cessation o f SUD symptoms. Although participants referenced 
reduction in symptoms, such as cravings (e.g., “I don’t have any cravings or anything”, P5), most 
participants also described behavioral changes, such as a reduction in drug seeking. For example, 
one participant described how Suboxone® relieves behavioral symptoms of SUD by noting,
“with Suboxone®, you take it and... I’m not always chasing drugs like I was before. That 
stopped” (P3). Likewise, another participant shared, “I’m not constantly looking for some way to 
feel better and I’m not going about the wrong things to get that” (P11).
A final theme emerging within lifestyle was living life. This involved doing and 
experiencing things that were not experienced before, such as actively engaging in relationships 
(as opposed to being a “warm body”, P2), going on vacation, practicing self-care, and not
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“numbing” themselves like they did in active addiction. One participant described how success 
means being more emotionally present and engaged in life by stating, “Now when I cry I’m 
actually crying because I’m hurt. When I’m happy, I’m not just crying to fit the emotion that’s 
going on around me” (P4). This same participant also stated, “...before.it was just day to day, 
and now I live everyday” (P4). Finally, participant ten described how living life involved having 
a sense of purpose:
Doing drugs like that, when y o u ’re lost, it will give you a sense ofpurpose. Like, 
oh I  got something to do today... And especially in Alaska, people get bored and 
what not... but like, when I ’m on Suboxone®, that gives me like... it kind o f fills 
it... I ’m trying to get into this school... But even when I ’m sitting at home alone 
all day, it gives me more o f a sense ofpurpose...it makes me feel better about 
myself than going and running around and playing the game.
Accomplishing. When defining success, participants discussed the theme of 
accomplishing things. Two concepts (reported in Table 4.3) comprising accomplishing included 
progress and self-efficacy.
Progress was the most frequently endorsed concept of accomplishing. One participant 
aptly demonstrated the growth component of progress by explaining, “I think there’s this 
growth in every way. Everything I do every day is showing something successful” (P6). For 
another participant, progress was “Bettering Yourself’, or the notion that success involved some 
degree of becoming a better version of oneself. Notably, this was so relevant to focus group 
participants that they referenced Bettering Yourself as a theme during the All-on-the-wall 
procedure, which was later integrated into the progress concept. Thus, accomplishing is in part
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demonstrated by making progress towards one’s goals and growing into a better version of 
oneself.
While progress described the active changes participants were making in their lives and 
the momentum required to make these changes, another concept, self-efficacy, related to intrinsic 
beliefs related to one’s motivation and ability to change. Participant ten discussed their 
experience of self-efficacy:
I  know in my head right now, a week from now, I ’m not going to be screwed 
u p . I  don’t want to be screwed up on the street doing drugs again. I  know right 
now. I  tr u s t .I  trust myself more. I  trust myself when I ’m on Suboxone® more, as 
o f right now. In a year from now, I ’ll trust myself without.
As demonstrated above, self-efficacy related to a sense of trust and believing in oneself. It 
also related to what drives participants to change, which tended to include intrinsic, versus 
extrinsic, motivators. One participant notably illustrated how important an intrinsic motivation to 
change is when they suggested, “For me for success I had to do it for myself finally. Because I 
tried it for everybody else and it never worked that way” (P3). These intrinsic processes emerged 
as being important for participants to be able to make progress toward their goals.
In sum, one participant particularly captured the accomplishing theme when they stated:
“I am able to accomplish the things that I want to and direct the course of my life” (P9). This 
encompasses a belief in being able to accomplish things, as well as a focus on progress.
Relationships. Participants identified relationships with family, the process of restoring 
relationships, and social functioning as concepts of success in Suboxone® treatment (reported in 
Table 4.3). Family was by far the most referenced relationship concept noted by participants 
during both the Phase I focus group and Phase II interviews, suggesting it plays an important role
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in how they define success in Suboxone® treatment. For example, one participant shared how 
treatment success contributed to better relationships: “Just having better relationships in general. 
Number one, my kids, my family, gaining all that trust back and everything really started with 
group and being on Suboxone® and being in recovery” (P2).
Another relationship concept of success was social functioning, which was 
operationalized as being the ability to function socially and to have healthy social relationships. 
Participant ten explained how overcoming their addiction impacted their relationships: 
[Treatment success has] improved [my relationships] obviously, because when 
yo u ’re a junkie not a lot ofpeople want to be your friend. I t ’s about keeping good 
company I  guess. I f  you want to keep good company, then hang out with people 
that are successful.
Finally, restoring relationships included participants’ discussion of making amends and 
mending relational connections that were lost due to their addiction. Participants’ endorsement of 
restoring relationships with family and social functioning commonly co-occurred, suggesting 
that treatment success facilitated a process of having healthier relationships. For example, 
participants discussed regaining custody of children, having closer emotional connections to 
family members, spending more time with family and friends, and having improved relationships 
because treatment success helped them to refrain from risky activities and behaviors associated 
with their addiction, such as stealing, lying, being emotionally disconnected.
Psychological. The psychological concepts of success elucidate the way thought- 
processes, emotions, and participants’ sense of self changed in relation to recognizing their 
treatment successes. Psychological concepts that emerged from the focus group and interviews 
include emotional wellbeing (e.g., “feeling happy for no reason.. .where I was miserable before”,
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P6), mental health (e.g., “my mind is a lot more clear. I think more positively”, P11), and 
character (e.g., “feel(ing) like a whole new person”, P4). Additionally, the concept of character 
was described in the initial focus group as morality (e.g., “it’s about that moral compass”, P7).
Within the psychological theme, participants accentuated that success involved more than 
just the cessation of symptoms. One participant highlighted the importance of seeking treatment 
in order to heal psychologically to achieve success by describing their experience with people 
who were not psychologically healthy: “I mean you could have someone who’s been sober for 
twenty years and they’re mentally not there. They’re mentally sick. Because they haven’t seeked 
any help” (P6). Relatedly, another participant noted how they have been able to achieve 
psychological wellbeing after the cessation of opioid abuse by noting, “I no longer crave drugs or 
even desire them. I no longer need that to make me happy. I’m finding my happiness without 
them” (P3).
Beginner compared to advanced group membership. In addition to the analysis 
conducted to achieve study aims, an analysis was conducted to identify how definitions of 
success might differ between participants in the beginner and those in the advanced group. This 
analysis provides greater context to the themes that emerged from this study. Table 4.4 outlines 
the total number of references to themes of success (times each concept was endorsed by a 
participant, or group of participants as in the focus group) for participants in the beginner (42%, 
n = 5) and the advanced and independent (58%, n = 7) group. It should be noted that it would not 
be meaningful to determine the statistical significance of this comparison. This comparison was 
not the focus of this study, and participants were not invited to interpret possible reasons for any 
differences in theme endorsement found between the two groups. Nevertheless, interpretation of 
what may account for the variation between groups follows.
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Table 4.4
Success References_ for Beginner versus Advanced Group
Beginner Advanced
Lifestyle
Cessation o f SUD 26 11
Functioning 22 23
Living Life 14 3
Accomplishing
Progress 24 13
Self-efficacy 7 17
Relationships
Family 20 14
Restoring Relationships 12 3
Social Functioning 5 5
Psychological Factors
Character 9 4
Emotional Wellbeing 11 7
Mental Health 9 6
For the theme lifestyle, beginner group participants more often referenced cessation o f 
substance use disorder symptoms and living life than those in the advanced or independent 
group. One possible reason for these differences is that those in the beginner group may place 
more emphasis on these concepts because these are new and salient to their experience of 
success. For instance, someone who is new to treatment may be feeling more successful due to 
the reduction in substance use disorder symptoms and the freedom to live life to the fullest that 
follows because these experiences are in stark contrast to their recent experiences in addiction.
Regarding accomplishing, participants in the beginner group had a greater number of 
references regarding progress, while those in the advanced/independent group more often
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endorsed self-efficacy. Similar to the lifestyle concepts, it could be that those who are new to 
treatment experience success when they notice progress toward their goals, while those who have 
been in treatment for longer may find that having an internalized sense of their ability to continue 
reaching goals is more relevant for success.
Across the beginner and advanced groups, relationship concepts were similar or not 
drastically different regarding references to family and social functioning. However, beginner 
participants referenced restoring relationships more often than those in the 
advanced/independent group. Participants newer to treatment may find it more important to 
mend ruptures caused by their addiction. This may not be as important to those who have been in 
treatment for longer because they may have already mended important relationships.
Finally, there were not very dramatic differences between the two groups for 
psychological concepts. While character was referenced more often in the beginner group, the 
references were longer in the advanced group. That is, several individuals had a lot to say. As 
such, it appears that character was a salient concept across groups. It is possible that perceived 
changes in participants’ character made them feel successful. Alternatively, perhaps participants 
believe character is an important factor in success because of what they have heard from others, 
including treatment providers and society in general.
Recovery. Participants defined recovery as embodying similar elements as success. 
Nevertheless, when describing their recovery, participants further described a process of 
healing/growth with a specific recovery attitude. Table 4.5 outlines the themes related to 
recovery. All themes were referenced by participants in the focus group and expanded upon in 
the subsequent interviews.
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Table 4.5
Themes Related to Recovery
Themes Conceptualization
No.
references
No.
interviews
Healing/Growth 43 7
Holistic Healing (from the past) 
Growing into a better person 
Overcoming difficulty/fears 
Actively working on oneself 
Living according to one’s own values 
Connecting with others 
Having more freedom in life 
Living life to the fullest
17 6
Process
Involving time, phases, stages 
Reflecting on life - past, present, 
future
13 5
Recovery Attitude
Having a sense of peace re: life 
Accepting oneself and others 
Having a desire to change 
Making the decision to change
12 5
In contrast to success, which was described by participants in terms of measurable and 
observable outcomes and changes, participants described recovery as a healing and growth 
process. This understanding of recovery began to emerge during the Phase I focus group where 
participants endorsed healing and the notion that recovery is “more than” sobriety. Nevertheless, 
healing/growth does parallel the success concept of living life in that through the process of 
healing, participants are able to actively engage in life and live it to the fullest.
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To illustrate the holistic properties of healing/growth, one participant stated: “I think it’s 
a chain reaction of positive -  it happens in your life because once you start remaining in recovery 
then your health gets better mentally, physically” (P6). This participant further shared their ideas 
about recovery as being, “A mental, physical, spiritual part of you that all comes in and 
somewhat works together.”
Healing and growth were described as involving elements of one’s self-development, and 
a connection with important people and forces in one’s life. Participant eight shared their 
recovery goals related to a secure sense of self:
For me to be recovered... I  would like to find  a way to be confident or 
comfortable enough in myself to not have to get high... confident or comfortable 
enough in my own situation, my own family or whatever it is I  got going on now.
As demonstrated with this quote, participants described a path towards interpersonal and 
psychological growth.This parallels some elements of success, including relational and 
psychological themes. While success themes were often described in terms of noticeable 
changes, recovery themes appeared to involve a deeper level of awareness of change over time 
in terms of where one is today, how they have overcome adversity in the past, and where they 
want to be in the future. As participant 11 explained:
Basically recovering from all the wear and tear that you put on your body and 
your mental status and then success is more that yo u ’re actually doing what 
yo u ’re supposed to do and living your life for yourself.
Recovery was described as a process, including a progressive movement toward the 
healing/growth described above. One participant illustrated the developmental nature of recovery
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by describing it as a, “transition between one lifestyle and the other.. .[with] a series of false 
starts” (P9).
In addition to the primary notion that recovery involves a healing/growth process, 
participants also described a specific recovery attitude, which included desire and decision to 
change. One participant exemplified the role of decision-making in recovery by stating,
“Actually recovery starts when you make the decision to get healthy” (P4). Another participant 
concurred, stating, “You have to set your mind into it” (P3). Notably, a recovery attitude 
parallels the concept of self-efficacy in the accomplishing theme of success in that both involve 
making a decision to change.
Participants discussed recovery attitude as including a more balanced and acceptance- 
based orientation to the world. For example, one participant explained, “yah I am [at peace]. But 
it took time” (P3). While this is similar to psychological concepts such as emotional wellbeing, 
when discussing success, participants described observed changes that had occurred in their 
emotional state rather than focusing on the path it took to get there.
As indicated above, some of the recovery themes paralleled success themes and concepts 
including healing and growth as related to living life, and a recovery attitude as related to self­
efficacy and emotional wellbeing. Nevertheless, participants were adamant that recovery and 
success were related, yet distinct, constructs. Perhaps the most prominent distinction of how 
these categories differ includes the notion that success precedes recovery. As noted by one 
participant, “Once you have success your recovery starts, you start healing emotionally, 
physically, mentally” (P3). This suggests that even though these categories parallel each other, 
they become distinct because of the longevity of recovery. Additionally, recovery was described 
as a deeper level of commitment as exemplified by this participant: “You’ve got to set your heart
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into it, not just your mind” (P3). Finally, the process element of recovery is the most distinctive 
component, suggesting that recovery as a process might be an important defining characteristic 
of this category.
Facilitators and barriers. Three themes emerged from participants’ discussions 
regarding what makes it easier and or harder to achieve success in Suboxone® treatment. These 
themes included treatment factors, contextual factors, and psychological factors. Table 4.6 
outlines facilitator and barrier themes and concepts, all of which were also referenced in the 
focus group.
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Table 4.6
Themes and Concepts Related to Facilitators and Barriers
Themes & No. No.
Concepts Facilitators Barriers ref interviews
Treatment Factors 73 7
Psychosocial Group, support, Feeling judged by 46 7
Treatment acceptance, valuing 
patients, encouraging 
accountability, being 
flexible
providers, not patient- 
centered, having a 
mismatch between patient 
goals & treatment goals, 
treatment
regulations/policies
Suboxone® Increasing motivation, 
reducing cravings, and 
eliminating option to 
abuse opioids
Suboxone® contrasting with 
values; physical 
dependence to Suboxone®
35 7
Availability and - Waiting lists, limited 11 3
Accessibility treatment options, finances, 
individuals’ 
awareness/literacy re: 
Suboxone® treatment
Contextual Factors 55 7
Social Relationship When relationships 
support/ facilitate 
success
How relationships can get 
in the way or distract from 
success
24 6
Life Life circumstances 
bringing happiness
Balancing life tasks, 
stressors, and life events
20 6
External - Others’ judgment, stigma, 11 5
Assumptions and expectations about 
behavior
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Table 4.6 continued
Psychological Factors 46 7
Mindset Insight, awareness, or 
wake-up calls; 
decision/desire to 
change; doing what is 
right for participant
19 7
Self-concept and 
Feelings
Confidence, hope, 
satisfaction with life, 
and self acceptance
Guilt, shame, internalized-
stigma
17 5
Addiction - Cravings, denial, being an 
“addict”, reasons for using
12 6
Treatment Factors. Participants discussed treatment factors that made it both easier and 
harder for them to achieve success in treatment, including psychosocial treatment, Suboxone®, 
and availability and accessibility o f treatment (defined in Table 4.6). Participants described 
being grateful and appreciative for treatments that facilitated success, and described these 
treatments with words like “accountable”, “support”, “love”, “empathy”, “helpful”, “comfort”, 
and “encouragement”. In contrast, participants discussed the distress they encountered when 
treatment posed barriers, using descriptive words and phrases like “horrible”, “another drug 
dealer”, “bitter”, “judgmental”, “awful”, “struggle”, “cookie-cutter”, “have to lie”, and “didn’t 
pay attention”. Notably, facilitative treatment involved support and compassion, while treatment 
that inhibits treatment success involved judgmental and inattentive treatment.
Participants also discussed some barriers to success when treatment programs did not 
meet the patient where they were in terms of goals and readiness to change. Participant nine 
highlighted this by noting:
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I  don’t care w ho’s telling you or what restrictions they ’re putting on you [...] 
treatment does not work as far as quitting unless you want it to work. [...] So 
being forced to—I  entered the Suboxone® program because I  was ready to quit 
using drugs. So even though I  want to quit smoking, somebody telling me that I  
have to; it worries me because I  don’t want to end up losing the rest o f my success 
by messing up my Suboxone® script because I  didn’t quit smoking in time for her 
so it goes back to that whole lying to your treatment program.
As this participant described, a mismatch in treatment philosophy and patient readiness 
and goals can create a barrier to feeling successful. Another consideration, the fine line between 
programs that facilitate success and those that pose barriers, is illustrated by participant eight’s 
description of the issue of providers overprescribing opioids (not Suboxone®):
The problem is, there is a very fine balance between prescribing and treating 
people properly and prescribing what they need, and overprescribing and helping 
to enable an addict. I  know there ’s a fine line. I  mean that’s a problem for  
someone, not me obviously, to solve. But hopefully things like this will help with 
that.
While participants expressed both gratitude and accolades for how Suboxone® has helped 
them, some participants acknowledged how Suboxone® conflicted with their beliefs that success 
equates with abstinence. On one hand, this participant described their gratitude: “The 
Suboxone®. I’m telling you that it’s an amazing medication, and if it wasn’t for the medication 
I’d be dead” (P4). Likewise, another shared, “If I had to take it the rest of my life, I’d be willing 
to do it” (P6). Conversely, some described getting off Suboxone® as being the “ultimate”
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success. As explained by one participant: “If I could just get off Suboxone® and have children 
and not go back to where I was. That would be a real success in my eyes and heart” (P11).
Analysis revealed how getting off Suboxone® was often tied into participants’ beliefs 
about abstinence. Some participants equated success with being abstinent from all substances, 
including Suboxone®. For example, one participant explained: “I’d like to be abstinent on my 
own ability, not on Suboxone®” (P3). Additionally, some participants believed abstinence to be 
the ultimate success because it “feels right”, because of internalized shame, and because they see 
Suboxone® as being in contradiction to their future goals and values (e.g., not being dependent 
on a drug, being free, having children).
In contrast, others believed that success could go hand-in-hand with being on Suboxone® 
and other substances. As another participant articulated, “I wouldn’t like to say that I’m not 
successful because I haven’t stopped smoking weed, but I think that I’m successful because I’m 
not doing heroin” (P10). Likewise, participants believed Suboxone® could correspond with 
success when they were able to compare themselves to their past and observe their progress.
Participants described barriers related to treatment availability and accessibility. This 
encompassed the time required to get into treatment, availability of treatments in Alaska, 
financial barriers (including insurance), waiting lists, and misinformation about Suboxone® given 
by providers. Participant eight expressed the availability barriers he or she encountered:
And [treatment is] not made readily available. Like I  live in [rural town] and I  
drive all the way to [another rural town] for treatment. So just availability, 
misunderstanding about how to get into them, or advertising for them.
Contextual factors. Participants also described contextual facilitators and barriers, 
including social relationships, life, and external assumptions. Participants noted that social
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relationships could support and facilitate, or get in the way of success. One participant explained 
how family and friends might facilitate success by providing support: “You need somebody you 
can go to. You always need somebody you can call and go to so they can say, “okay, I’m here 
for you. Talk to me” (P7). Interestingly, many of these positive social influences were noted to 
be from individuals in the OBOT program. One participant demonstrated how positive and 
reciprocal peer interactions in the OBOT group have facilitated their success: “For group it’s the 
encouragement I get from other people’s success.. .and them encouraging me” (P4). Participant 
eight discussed the importance of cutting ties with some old social contacts, which could pose 
barriers to success if they were still in contact:
I ’m still seeing those shady characters which is just going to make it that much 
harder to su cceed .I don’t need to start buying Suboxone® o ff o f the streets 
because I ’d  still be seeing the same people everyday from buying the Suboxone® 
o ff o f the streets and therefore I  wouldn’t be able to get away from them.
Life was discussed as both a barrier and facilitator to treatment. Life was considered a 
barrier to furthering success when it comes to juggling daily responsibilities as revealed in this 
participant’s statement: “It’s been hard to balance, work, life and kids with this group and doing 
both” (P3). Conversely, life was also understood as facilitating success when life circumstances 
bring happiness and peace, as seen with this participant’s statement: “Another thing that helps 
me, we live on a ranch and I’m around horses, animals” (P4).
An interesting component of life that emerged during the interviews related to living in 
Alaska. Living in Alaska was noted to be a barrier to success when people misused substances 
due to boredom, the extreme seasonal variations, or having the money to spend. To exemplify 
how fluctuations in season can be a barrier to treatment, participant 12 noted:
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I  think the difference [between a successful treatment experience and a not so 
successful treatment experience] is just the season. When I  was with [successful 
treatment], it was through the summer, starting like in March and to have that all 
through the summer [...] I  was working a lot more. And then the light at midnight 
helped with my [life tasks]. Now that i t ’s winter [...] I  basically went backwards. 
Additionally, one participant described how Alaska’s economy and financial industries 
might contribute to drug use by noting, “drug use has always been an issue in Alaska because 
people have the money or money is more easily to come by [than] for people in other states” 
(P8). However, living in Alaska was also described as a facilitator of success in terms of being 
able to move to rural locations to remove oneself from triggers. This participant explained:
I  mean that’s why we moved to (rural, AK), we used to live in (more urban area) 
or (outside o f urban area). We moved out here because I  wanted to get away from  
all o f the people that... we were trying to get where I  didn’t know anybody so that 
I  could get away from the people so that I  could stay away from the drugs. I t ’s 
actually worked really well.
Finally, external assumptions primarily included barriers such as judgment, stigma, and 
societal assumptions about how individuals should behave. Participant three characterized these 
external assumption barriers among healthcare providers:
There’s a stigma that’s grown on the physician’s side o f it, the doctors ’ side o f it.
As they become aware o f Suboxone®; they looked at the notes and see that we 
were addicts, there’s a stigma as far as our character.
In turn, participant suggested that if education could be provided to treatment providers, 
doctors, and pharmacists, it could counteract the negative effects of judgment and stigma. Some
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described the stigma as being due to not understanding Suboxone®, and many expressed a desire 
to educate providers so they are not perpetrating harm caused by stigma.
Psychological factors. Analysis also identified three specific concepts within 
psychological factors that made it both easier and harder for participants to achieve success in 
treatment, including mindset, addiction, and feelings/self-concept. Mindset was often described 
as being a motivator that included a decision and desire to change. Participants conveyed the 
necessity of desiring success. They noted that this desire could be sparked internally (e.g., 
insight, awareness), externally (e.g., from God or kids/family), or from a combination of the two 
(e.g., wake-up calls). Participant 11 exemplified how wake-up calls comprise both internal and 
external factors that lead to one having the desire to change:
It definitely was a struggle. But in the end I  just had to put mind over matter and 
just put my willpower in there... my mom passed away and she passed away from  
drug use. And it really kicked me in the butt and made me think, do I  want to die 
like that? And it really, really, really put a point in my mind that I  don’t want to 
die.
Another psychological facilitator and barrier discussed by participants included feelings 
and self-concept. As described, when participants’ self-concept and feelings become negative, it 
can act as barriers to success. For example, one participant shared, “The only thing time I have 
not felt successful in this program is when I was doubting myself for being on Suboxone®” (P6). 
Another participant admitted, “I was shameful to even come to this group” (P2). Still another 
participant shared how negative self-concept could act as a barrier given the shame associated 
with pre-treatment behaviors: “You feel like a dirty person when you start. You get off the
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streets, you’ve been doing all kinds of drugs, and I guess that could make you feel unsuccessful 
at the beginning” (P10).
Although most feelings and self-concept factors were described as negative, some 
participants explained that positive feelings and self-concept facilitated their treatment success. 
One participant shared, “I do have hope that I can be not dependent on anything” (P3).
Finally, addiction was primarily discussed as a barrier. With a tone of gratefulness, 
psychosocial treatment and Suboxone® were described by participants as antidotes to addiction 
that can facilitate success. For instance, one participant stated, “[Suboxone®] helps with the 
cravings too” (P12), while another noted the helpfulness of, “go(ing) to group every month and 
[having providers] ask specifically about relapse or cravings” (P4).
Measurement. In addition to seeking an understanding of how participants define 
success and recovery, this study also sought to understand what factors would be important for 
measuring success in Suboxone® treatment. To address this question, participants were asked, 
“How do we as in researchers and counselors know when there has been success? Are there 
specific things we could be asking to measure and look at i f  this person has been successful or 
not?” In response, participants primarily provided advice about the ways success in Suboxone® 
treatment should be measured, rather than informing specific factors. Themes related to 
Measurement are outlined in Table 4.7.
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Table 4.7
Themes Related to Measurement o f Success
Themes Conceptualization No. ref No. interviews a
Individualized and Success varies across patients 9 5
Flexible Definition Asking patients re: their ideas of 
success
Measures need to be flexible and align 
with patient goals
Understanding “who’s definition of 
success” is being used - patients or 
societies?
Recognizing Physical and mental addiction 8 4
Needs/Traits of Accurate measurement - difficult
People who are because people may be dishonest
Addicted
Pay Attention and Recognizing small successes, progress 7 3
Recognize Progress Attending to how patients carry 
themselves (Do they look “normal”? 
Are they positive? Are they 
consistent?)
Other Specific Cravings, personality changes, 6 4
Factors to Consider appearance of good health, financial 
stability, relationships 
Assessing if patients are meeting their 
treatment goals
a Focus group participants were not asked this question.
Participants indicated that when measuring success, treatment providers and/or 
researchers should have an individualized and flexible definition. Specifically, participants 
recommended that treatment providers remain cognizant that success varies from person to
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person. As such, providers should base their measurements of success on how their patients 
define success, and should develop flexible treatment planning to follow accordingly.
Participants also discussed the need to consider which definition(s) of success are being used: the 
patient’s, society’s or the provider’s?
Likewise, participants advised that what providers or researchers measure regarding 
success should be realistic and obtainable for the individual, and should align with the patient’s 
goals for treatment. For example, one participant highlighted: “The questions that you ask to find 
out if anyone is going to be successful are also going to be a little different based on the needs of 
the individual” (P8).
Although participants did not specify exact factors that should be measured, they did 
suggest that providers and researchers should keep in mind the specific traits of people who 
struggle with addiction when measuring success, including considering physical and mental 
features of addiction. One specific trait that participants suggested might make it difficult to 
measure success was patient honesty; that is, patients providing inconsistent or conflicting 
reports. For instance, one participant shared, “when you’re not staying sober your stories are 
completely different the next time around” (P4). Another participant elaborated on how honesty 
would impact the ability to measure success by noting, “you can only tell [that there has been 
success] if the people are being honest around you because I’ve seen a lot of people not be so 
honest” (P11).
Additionally, participants suggested it is important for providers and/or researchers to pay 
attention to how patients carry themselves, and to recognize progress. Paying attention could 
include noticing “small successes” and recognizing progress towards treatment goals as 
explained by participant 11:
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I  think just the small successes that people have in the beginning are really 
helpful, or are ...just that [counselor] would say, ‘I  can see you can make it. You 
used to do this much, but now yo u ’re only getting through enough’.
Alternatively, it could include observing if they look “normal,” if they are realistically 
positive-minded (for example, not denying challenges), and if their story illogically changes over 
time. To this end, one participant elaborated by recommending, “Doctors and counselors that 
really pay attention to exactly what you’re saying and remember what you say or write it down”
(P4).
Other factors participants suggested should be considered to when measuring success 
included the following: cravings, personality change, appearance of health, financial stability, if 
the person is meeting the goals they initially set, and their relationships with people in their lives. 
These were not described as specific aspects of success that should be measured per say, but 
were more so recommended as considerations for treatment providers in subjectively monitoring 
progress.
Although participants did not identify specific factors that should be measured, they did 
note that success should be measured based on the participant’s definition of success. 
Accordingly, treatment providers and/or researchers may consider assessing the success themes 
and concepts listed above when measuring success.
Participants’ Experiences of Being in the Study
In addition to the topics addressed during the Phase I focus group and Phase II 
interviews, participants were asked about their experiences of being in the study. Participants 
were also asked to assist with the analysis process during Phase I and to verify the findings 
during Phase III (discussed later in this chapter). Involving participants in the analysis process is
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consistent with the CBPR approach (Israel et al., 1998). It also serves as a means to triangulate 
data and findings through member-checking (Charmaz, 2006).
Phases I and II. At the end of the focus group and each interview, participants were 
asked how they felt after participating in the study and if there was anything else they wanted to 
share. When discussing how they felt after participating in the study, participants reported having 
a positive mood, particularly because they had the opportunity to share, and because they wanted 
to help others through their own experiences. Participant twelve’s response echoes such 
commonly expressed responses:
I  feel better. I  honestly want... to see other people succeed too, so i f  I  can help 
other people succeed, that’s going to make me feel even better. That’s what I ’m 
about now a-days so... it makes me feel good. So I  hope this survey helps.
Another participant noted the benefits they received from participating in the study by 
stating, “It’s like a therapy session a lm o st, it gets my feelings out into the air to myself.. .I’m in 
a positive mood” (P10).
Participants were also asked if there was anything else they wanted to share. Responses 
reflected participants’ desires for the research to make an impact on treatment delivery. They 
shared additional views about treatment and drug use. Primarily, participants expressed 
ambitions to make a change, which included their aspirations to help others with consideration 
for environment/contextual factors that can influence addiction. Specifically, they discussed the 
need to increase treatment availability, to decrease stigma and judgment, to educate others 
(including doctors and pharmacists), and to establish and advocate for Suboxone® as a viable 
treatment option.
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Participants further described effective treatment as being supportive, fitting to the 
individual’s social milieu, and appropriately paced for each individual’s readiness to change. In 
this regard, participants emphasized how important it is for patients to be ready and self­
determined to achieve treatment success as described by participant 12:
That’s what being in recovery is. I  choose to be in recovery. I  want this. I  want 
this. I  think that’s the only way anybody’s ever going to .y o u ’re gong to have to 
want it to recovery, but definitely the Suboxone® and therapy definitely help. 
Participants also expressed their views on drug use and abstinence. They particularly 
emphasized that abstinence of all substances should not be forced if the patient is focused on a 
different goal (e.g., getting off of heroin), as participant eight explained:
I  will say as far as Suboxone® (treatment) goes, I  feel like I  have to lie about my 
smoking... I  want to quit, I  don’t want to smoke... even though I  want to quit 
smoking, somebody telling me that I  have to doesn’t (work).
Phase III. After completing Phases I and II, participants were invited to attend an 
interactive findings forum during which they could hear, discuss, and provide clarity to initial 
findings that emerged from analyzing the focus group and interview data. Four of the twelve 
individuals who participated in the focus group and/or an interview participated in the findings 
forum. Most were male (n = 3, 75%). Three were in the advanced group, and one was in the 
beginner group.
The findings forum lasted 90 minutes. During the first half of the forum, I used 
PowerPoint slides to present initial findings. During the presentation, participants also viewed 
and discussed a conceptual model of the findings as represented by the metaphor of a tree (see
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Figure 4.1). During the second half of the forum, participants further reflected on the findings 
and discussed how they wanted to see them used to create positive change.
All participants enthusiastically agreed with the findings. They further shared their 
feelings that being involved in the study was a rewarding experience. Most salient, participants 
were content that even if their own quotes were not presented, they still ‘heard’ their own stories 
in other participants’ words. For instance, several participants explained:
P8: Just to hear other people and what they said, it was interesting to find  
out...with each answer, a lot o f it related to me, even though it might not have 
been my answer. And there was a connection there with everybody I  see.
P4: You see yourself in all o f them; all o f us are in there.
P4: Every [theme] hit somebody in a certain way.
When asked which study findings participants wanted accentuated, they primarily 
focused on their desire for Suboxone® to be credited as being an important contributor to their 
success. As one participant explained, “[people] would have more success with Suboxone® than 
without and just doing whatever it may be doing, counseling or whatever, without the 
medication” (P8). Another participant noted, “This has been my only experience in treatment, so 
I have nothing to compare it too, but this one worked for me because Suboxone® got me started” 
(P3). As with participants who took part in Phases I and II, the sentiment of findings forum 
participants was that Suboxone® saved their lives, as succinctly stated by this participant: “I’d be 
dead if it wasn’t for Suboxone®” (P4).
Participants expressed their desire for the findings to be used to ensure knowledge that 
Suboxone® helps people achieve success. This desire was spurred by a fear that policy and 
decision-makers (e.g., legislation) would do away with this form of treatment. Participants also
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discussed their desires that the findings be used to educate doctors, providers, dentists, surgeons, 
and pharmacists about Suboxone®. To demonstrate the participants’ appeals to educate providers 
regarding opioid abuse, one participant stated, “The doctors aren’t educated at all” (P2), and 
another noted, “Ya, they give pain pills out like its candy” (P4). Participants noted that these 
medical practices are unhelpful and that they “test our willpower” (P4), suggesting that when 
faced with a medical provider who will prescribe them opioids, they are forced with the choice 
of whether or not to refuse the medication. The overall sentiment of participants was that doctors 
are generally uneducated about Suboxone®, will prescribe opioids to someone on Suboxone® 
treatment, and often hold stigmatizing beliefs about Suboxone®.
While findings forum participants expressed enthusiasm for the overall findings, they 
also had positive reactions to the integrated conceptual model. The process of developing the 
model, along with the specific components and participant reactions to the model are discussed 
below.
Success/Recovery Tree: An Integrated Conceptual Model
During the findings forum, a conceptual model was presented to participants to help tell 
the “cumulative story” of their findings. The integration of the Phase I and II data is represented 
within the metaphor of a success/recovery tree (see below).
The metaphor of a tree originally emerged during the Phase I focus group. While 
participants were engaging in the “All-on-the-wall” procedure (during which individuals were 
asked to write and share aspects of success on sticky notes), the cohesion of the group began to 
wear down as participants became confused about the methodological process and ceased 
communicating with each other. While the group reflected on the ideas written on the sticky 
notes, and while organizing them into categories, one participant shared how he saw success
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being represented as a tree. The spark given off by this comment ignited group cohesion, 
investment/buy-in, and enthusiasm for the project, as revealed by this interaction among several 
participants:
P7: In a tree they’d  [work and responsibility would] be the lower branches but
there’s one single branch [functioning] holding them together.
Investigator: Good!
P4: Draw a tree!
P3: That’s a good analogy. Best one I ’ve heard.
P2: I  like that. That makes sense.
As data analysis transferred from participants to researchers, the metaphor of a tree faded 
into the background as attention was afforded to initial, selective, and theoretical coding. In this 
analysis process, the data were broken apart and built back together. Yet, as the final stages of 
coding were being completed, the concept of the tree reemerged as the findings that emerged 
from the full data set (from Phases I and II) were integrated. The following conceptual model of 
a tree is grounded in the data and incorporates three of the research questions, which focused on 
participants being asked to define success, recovery, and the factors that act as facilitators and 
barriers to success. To clearly represent cumulative findings, each symbol denoted in the tree 
corresponds with the number of references in each concept, whereby larger symbols suggests 
concepts that were represented with greater frequency by participants.
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Figure 4.1. Success/Recovery Tree: An Integrated Conceptual Model. Participant-derived 
categories, themes, and concepts are represented in this model. The categories of success, 
recovery, and facilitators/barriers are represented by the branches, the trunk, and the 
sun/clouds/roots respectively.
Context. The facilitators and barriers (treatment factors, contextual factors, and 
psychological factors) are located in proximity to the success/recovery tree because participants 
did not indicate these factors within their definitions of success and recovery (the actual tree). 
Instead they were noted as contributing to the growth or deterioration of the success/recovery 
tree.
First, the contextual factor, life, represents setting or location. Participant’s emphasized 
the importance of context and the necessity of there being a fit between one’s context and one’s 
definitions of success and recovery. Therefore, if the individual tree is well suited in the setting
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(e.g., a palm tree on the beach, a birch tree in the woods), then it will facilitate its growth. 
However if there is a mismatch between the tree and the setting (e.g., a kapok tree in a desert, or 
a Mesquite in a rainforest), the tree may be inadequately nourished.
Other contextual facilitators and barriers (e.g., social support, external assumptions, 
relationships) are represented as the sun. Continuing with the metaphor, all trees require sunlight 
to grow, but sunlight that is too harsh (e.g., negative external assumptions) on a tree may cause it 
to wilt. In turn, insufficient sunlight (e.g., family/friends, support-connections) may weaken a 
tree because it must over-extend itself toward the sun.
Treatment factors (psychosocial treatment, Suboxone®, and availability-accessibility) are 
represented as three rainclouds as trees require rain to grow, but less than enough rain (e.g., lack 
of availability-accessibility) or too much rain (e.g., the wrong type of psychosocial treatment) 
will impede the growth of the success/recovery tree.
Finally, psychological facilitators and barriers (e.g., mindset, self-concept and feelings, 
and addiction) are represented as the roots of the success/recovery tree because they are internal, 
and often hidden or unseen. Strong roots, such as having a mindset oriented toward change, are 
illustrated as facilitating the growth process, while weaker roots that may have been 
contaminated by an external source (e.g., self-concept andfeelings) may make it more difficult 
for the tree to flourish.
Success/recovery tree. The actual (above ground) tree in the model metaphorically 
illustrates recovery and success. Recovery is represented as the sturdy, foundational trunk that is 
steadfast in its growth. As conveyed by participants, the tree trunk contains a process of 
growth/healing with a recovery attitude, such as a_desire to grow. Although the trunk eventually
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stops growing in height, it continues to expand in width, thereby providing a sturdy base for the 
branches of success.
The branches represent identified themes of success and are the most easily identifiable 
and measurable elements of the success/recovery tree. This corresponds with the participants’ 
distinction between recovery and success, where recovery is viewed as being a steadfast process, 
while success involves tangible outcomes. The highest branch represents success in terms 
of lifestyle (functioning lifestyle, cessation o f SUD symptoms, living life). The second highest 
branch represents accomplishing (progress, self-efficacy). The next branch down 
represents relationships (family, social functioning, restoring relationships). Finally, the lowest 
branch of the success/recovery tree represents the concept, psychological factors (emotional 
wellbeing, mental health).
Summary and reactions to model. The integrated model metaphorically conceptualized 
the ways participants shared their understanding of success in OBOT, including recovery as a 
process, the factors that facilitate and inhibit OBOT success and recovery, and the outcomes of 
success. This visual metaphor was instrumental to participants during the focus group, and 
resonated with participants during the findings forum, as these reactions from participants 
illustrate:
“I ’m impressed with it” (P2),
“I  thought it was excellent and well thought out ” (P3),
“It couldn’t be any different; i t ’s set up just perfect. I  wouldn’t change a thing”
(P4),
“Ya. It has all the factors ” (P8),
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“Everybody’s different, and it leaves room for everybody; i t ’s a really excellent 
piece o f work” (P3), and
“I  really like the tree because the tree covers just about everything and anything”
(P4).
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Chapter 5: Discussion
This study aimed to develop a substantive, patient-driven theory of in Office-based 
Opioid Treatment (OBOT) success and recovery using qualitative methodology. Overall, 
findings suggest that for 12 individuals in an OBOT program in rural Alaska, the concepts of 
success and recovery are related, yet distinct. Participants described facilitators and barriers to 
treatment success, and expressed ideas about how OBOT success should be measured.
Success
The first aim of this study was to understand how OBOT patients understand success in 
OBOT. The findings of this study suggest that patients’ definitions of success are much more 
nuanced than standard definitions of success that focus heavily or exclusively on consumption, 
and usually on complete abstinence (Butler Center for Research, 2011; McLellan et al., 2007; 
Miller & Miller, 2009; Tiffany et al., 2012; Witkiewitz, 2013). Specifically, four themes 
emerged from patients’ definitions of success: (a) lifestyle, which included a functioning/normal 
lifestyle, cessation o f substance use disorder [SUD] symptoms, and living life to the fullest; (b) 
accomplishing, which included progress and self-efficacy; (c) relationships, which included 
family, restoring relationships, social functioning; and (d) psychological factors, which included 
emotional wellbeing, mental health, and character. Each of the concepts is discussed vis-a-vis 
the literature below.
Lifestyle. Three lifestyle concepts emerged from the data. Participants mentioned the 
cessation o f substance use disorder symptoms, including but not limited to reduction in use, 
cravings, and drug seeking. While this is similar to some standard outcome domains (SAMHSA, 
2010b; White, 2007), this was just one among many ways participants defined success in OBOT. 
Our findings are consistent with another qualitative study conducted with patients in harm-
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reduction programs who identified reduced substance use as just one among several other factors 
related to successful treatment outcomes (Lee & Zerai, 2010).
The current study illustrates that factors other than cessation of substance use disorder 
symptoms are also important in OBOT patients’ definitions of success. Findings accentuate the 
role of a functional lifestyle, including fulfilling responsibilities and living a healthy and 
sustainable lifestyle, as a marker of success. The findings of the current study are similar to that 
of another study with patients with substance use disorders, who identified improved daily 
functioning as a beneficial outcome to psychosocial treatments such as psychodynamic therapy, 
motivational interviewing, applied relaxation, and cognitive-behavior therapy (Bergly, Grawe, & 
Hagen, 2014). In the current study, functional lifestyle was the most referenced concept, which 
suggests being able to function in society plays an important role in how patients define and 
experience success, and should likely be considered when measuring OBOT success. For 
instance, participants believed they were functional when they were able to contribute to society 
and do “normal” things, such as pay bills, maintain a safe place to stay, and own a car. While this 
study’s findings converge with recommendations to measure outcomes such as employment 
status and functioning (Butler Center for Research, 2011; SAMHSA, 2010b), citizenship (White,
2007), and housing stability (SAMHSA, 2010b; White, 2007) as treatment outcomes for 
substance use disorders, such domains often remain neglected in treatment outcome research.
Living life, which included fully experiencing life and having a sense of purpose, holds 
parallels to the concept of quality of life. Experts have expressed the need to consider quality of 
life in regards to treatment outcomes (Butler Center for Research, 2011; Miller & Miller, 2009; 
Tiffany et al., 2012; White, 2007). This study’s findings suggest that treatment success involved 
elements of “living life” to the fullest and fully engaging in life in a way that participants did not
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before in many realms of their lives, such as dedicating time to family and enjoying life beyond 
what they could do in addiction (e.g., vacationing, being more emotionally present). Similarly, a 
subjective sense of a good quality of life predicted sustained remission in the use of illicit drugs 
(Laudet et al., 2009) and was identified as relevant to harm-reduction patients in a qualitative 
study (Lee & Zerai, 2010). This suggests that quality of life may be an important consideration 
for understanding how patients experience treatment success. Moreover, this study adds to the 
literature on quality of life by accentuating how participants understand their quality of life in 
contrast to their life in addiction.
Accomplishing. Accomplishing concepts, which emerged from study findings, include 
progress and self-efficacy. As patients described it, progress includes bettering oneself and the 
reappraisal of life goals. Research on meaning making suggests that reappraisal of goals is a 
positive and healthy way to make meaning (Park & Folkman, 1997), and to minimize dissonance 
when events in a specific situation (in the case of this study, drug abuse) are misaligned with an 
individual’s beliefs and values (Skaggs & Barron, 2006). Again this finding is similar to what 
was found for substance abuse patients in a harm-reduction treatment program, who identified 
changes in future goals as an outcome they obtained from engaging in successful treatment (Lee 
& Zerai, 2010). The findings of this study add to the literature by suggesting that progress, and 
more specifically the reappraisal of life goals, is a relevant way for individuals in harm-reduction 
treatment programs, such as OBOT, to move toward treatment success.
In this study, having self-efficacy was described as contributing to participants’ process of 
engaging in treatment and to their sense of being able to manage life in the future. Self-efficacy is 
a well-known concept in substance use literature that has, in part, been shown to predict 
reduction in opioid use (Reilly et al., 1995). The findings of this study suggest that self-efficacy
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is likely important not only in assisting in positive treatment outcomes such as opioid use 
reduction and treatment engagement, but also in a patient’s perceived ability to accomplish 
responsibilities in the future.
Relationships. Participants in this study described the important role offamily, social 
support, and restoring relationships in regards to experiencing treatment success. Likewise, 
research suggests that having family and social support play important roles in treatment success. 
For instance, community reinforcement and family training (CRAFT) has been demonstrated to 
outperform therapy that is informed by NA philosophy in engaging unmotivated individuals to 
enter treatment (Meyers, Miller, Smith, & Tonigan, 2002). Similarly, Behavioral Couples 
Therapy (BCT) has ample evidence to support its effectiveness in improving outcomes, 
including reduced substance use and related problems and improved outcomes for family 
members (Fals-Stewart, O’Farrell, Birchler, Cordova, & Kelley, 2005). For patients in 
medication-assisted treatment, positive social support predicted the perception of enhanced 
family and social relationships, overall health, and ability to be abstinent from opioids (Cavaiola, 
Fulmer, & Stout, 2015). Moreover, social support has also been found to mediate positive 
treatment outcomes (see Black & Chung, 2014) Thus, the importance of family and 
social/communal support and engagement is well established as being related to substance 
misuse treatment outcomes.
This study’s findings suggest in addition to family and social support, it may also be 
important to repair relationship ruptures that were caused by opioid misuse. Therefore, solely 
assessing for family and social support may not address all of the relationship factors involved in 
success for OBOT patients, and it may behoove clinicians and researchers to also consider if 
patients have begun to mend relationships.
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Psychological. Participants described psychological concepts of emotional wellbeing, 
mental health, and character as important in treatment success. These patient derived themes are 
consistent with research that has found stress to be related to lower treatment engagement 
(Jaremko et al., 2015), using opioids to cope (Jones et al., 2014), opioid relapse, and craving 
(Sinha et al., 2007). Nevertheless, participants in this current study went beyond merely 
mentioning stress and mental health as they relate to treatment engagement and opioid use. They 
also noted how improved mental health enriched other areas of their life, such as being able to 
make better decisions.
Additionally, character, including feeling like a new person, was a psychological theme 
of success. Interestingly, character is frequently discussed in the recovery and NA literature (NA, 
1992), and is emphasized during NA programs, with a focus on poor moral character as a reason 
for substance misuse. Some participants in this study did describe character with attention to 
moral deficits, such as describing themselves as having a dependent personality, which might be 
influenced by embedded cultural assumptions about the morality of substance use. However, this 
study’s findings described character more with a focus on growth and overcoming, such as 
feeling good about being open and honest in life. It is possible that participants’ definition of 
success relating to character may have been influenced by their participation in NA-related 
programs.
Success summary. In sum, important nuances in the definition of success for OBOT 
patients can be derived from this study. Although cessation of substance use disorder symptoms 
is an element of success, findings accentuated other factors. For example, the ability to live a 
functional lifestyle, the progression of quality of life, the reappraisal of life goals, and the belief 
in one’s ability to be successful in the present and in the future are specific factors that parallel
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the literature and are also relevant for OBOT success. Other factors found in this study included 
how emotional wellbeing, mental health, and feeling like a new person enriched one’s life 
overall, not just in one’s ability to engage in treatment. Finally, restoring healthy family and 
social relationships was an important process related to OBOT success. As such, these factors 
may be important considerations for measuring OBOT success.
Recovery
The second aim of this study was to understand how OBOT patients define recovery. 
Findings revealed that recovery included a process of healing/growth with a specific recovery 
attitude, including having a desire to change, making the decision to do so, and having 
acceptance about oneself and others. The most frequently endorsed theme of recovery, 
healing/growth, is similar to some literature that suggests that personal growth (Laudet, 2007) 
and healing from trauma (White, 2007) are components of recovery. Interestingly, while this was 
the most endorsed recovery theme in this study, it has received less emphasis in the literature 
compared to the requisite of abstinence (ASAM, 1982; Dodge et al., 2010; Galanter, 2007; 
Laudet, 2007; McLellan et al., 2007). This could be due to the fact that participants, by virtue of 
being in the OBOT program, are not by some definitions, abstinent. It could also suggest that 
patients understand recovery as being more than abstinence. Nevertheless, this challenges the 
ideal that one must be abstinent to be in recovery.
Patient-defined recovery was found to be a lifelong process that should be approached 
day by day, and that involved a “chain reaction of positive” (P6). This is consistent with 
literature that suggests that process is an essential component of recovery (ASAM, 1982; 
Galanter, 2007; Laudet, 2007, 2008; McLellan et al., 2007; SAMHSA, 2012; White, 2007). 
Interestingly, although success and recovery were found to be distinct, yet related constructs, this
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study’s findings demonstrate that process was the only real distinguishing factor between 
recovery and success. This suggests that, when attempting to distinguish recovery and treatment 
success, it may be important to consider if participants are describing a process (as in recovery), 
or a specific outcome (as in success).
Participant definitions of recovery were also consistent with aspects of twelve-step 
philosophy (NA, 1992). Interestingly, none of the participants indicated that they currently attend 
Narcotics Anonymous meetings, and only 3 of the 12 participants had been to Narcotics 
Anonymous in the past and reported it was not helpful. One interpretation of this is that beliefs 
embedded in the exosystem, that is broader social influences (Bronfenbrenner, 1994), have 
infused their way into participant definitions of success. Alternatively, there may be some 
universal elements of recovery that are present for those who adhere to Narcotics Anonymous, 
and those who do not.
Finally, all three recovery themes identified in this study are in line with recovery- 
oriented systems of care that identify similar guiding principles, including recovery as a 
transformative, holistic, self-directed process of healing that involves hope, gratitude, and a 
trajectory of rebuilding community (Sheedy & Whitter, 2009). Therefore, findings support the 
application of using the guiding principles of recovery-oriented systems in OBOT.
Facilitators and Barriers
The third aim of this study was to understand what facilitators and barriers patients 
identify as relating to their definition of OBOT success. Three key facilitators and barriers to 
success emerged from this study: psychological factors, treatment factors, and contextual factors.
Psychological factors. Psychological facilitators and barriers to success included self­
concept/feelings, mindset, and addiction. In this study, self-concept/feelings could be a facilitator
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to success when it included heighted self-confidence, while it could also be a barrier when it 
included negative feelings such as “feeling dirty.” The literature suggests that perceived stress 
and maladaptive/avoidant coping styles (Hyman et al., 2009) and abnormal cortisol levels 
(Jaremko et al., 2015) negatively relate to opioid misuse and treatment engagement in methadone 
maintenance treatment. Similarly, participants indicated that they originally initiated opioid use 
to cope with stress (67%) and to escape something negative (58%). Alternatively, participants 
noted that positive feelings and self-concept facilitated OBOT success.
Mindset was found to be a facilitator of success that involved making the decision to 
change and working hard at making changes step-by-step. This concept maps on to motivation to 
change, an element of the transtheoretical model, which is established as a crucial component for 
behavioral change (DiClemente, 1999), and suggests that patients themselves also identify 
motivation as a crucial element to success in OBOT.
Addiction was primarily deemed to be a barrier to treatment success. Specific barriers 
included cravings, denial, mental dependency, relapse, enjoying using opioids, lying, and having 
low self-esteem because of drug use. Of these barriers, cravings were the most frequently 
endorsed, with participants noting that cravings were the hardest part of quitting opioids. This is 
consistent with evidence that cravings predict relapse in buprenorphine maintenance treatment 
(Tsui et al., 2014). Therefore, not only do cravings predict relapse, but they are also experienced 
by buprenorphine patients as challenging.
Treatment factors. Treatment facilitators and barriers included psychosocial treatment, 
Suboxone®, and availability and accessibility to treatment. Psychosocial treatment was described 
as a facilitator when it offered qualities such as support and accountability. It was described as a 
barrier when it was not aligned with patient goals or when patients felt judged. This study’s
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findings suggest that engaging in psychosocial treatment facilitated their success. For example, 
one participant noted, “I think it has a lot to do with the individual and the group therapy that we 
get here. It’s been really helpful for me” (P4). This concurs with existing research suggesting 
that treatment engagement is one of the best predictors of success (Mee-lee et al., 2010;
Orlinsky, Grawe, & Parks, 1994), and diverges from other research that suggested that 
psychosocial treatment does not improve outcomes for buprenorphine maintenance treatment 
(Amato et al., 2011; Moore et al., 2012; Weiss et al., 2011) and proposed that physician 
monitoring may be enough (Renner et al., 2014). For the participants of this study, psychosocial 
treatment was a necessary component of their success, suggesting that physician monitoring only 
may do a disservice to patients regarding their experiences of success.
The findings also highlight the importance of a respectful and non-judgmental treatment 
atmosphere as a facilitator to success. A similar concept was described in previous qualitative 
research where participants reported that de-marginalization, or being treated with respect by 
providers and having a trustworthy treatment environment, helped them achieve a successful 
treatment experience (Lee & Zerai, 2010). Thus, compassionate treatment approaches, rather 
than harsh, punitive moral models (Thombs, 2006) are likely to be more facilitative of treatment 
success with OBOT patients.
Similar to findings reported by Egan and colleagues (2011), participants in this study also 
described the importance of psychosocial treatment as a means of gaining self-esteem and 
connecting with others. Existing research has demonstrated that buprenorphine in conjunction 
with psychosocial treatment and/or mutual support groups is associated with longer treatment 
retention (Stein et al., 2005) and higher session attendance (Moore et al., 2012). Moreover, best 
practice recommendations advise the integration of psychosocial treatment and medication-
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assisted treatment (Kraus et al., 2011). The current study findings support this recommendation 
as participants endorsed the importance of combining medication such as Suboxone® with 
psychosocial treatment to achieve success.
In this study, Suboxone® was revealed to be a facilitator by helping patients transition out 
of their old lifestyle and supporting healthy lifestyle choices. It was also discussed as a barrier 
when individuals believed the “ultimate success” was abstinence from all substances, including 
Suboxone®. These views varied based on the participant, where some had a goal of complete 
abstinence of all substances while others had goals of moderate use of some substances, such as 
marijuana.
In other qualitative studies, individuals who have had experience with medication- 
assisted treatment also reported ambivalent and contradictory ideals regarding Suboxone® 
(Hewell et al., 2016b; Redden et al., 2013), at times describing it as a “life saver,” and at other 
times as a “crutch” or “liquid handcuffs” (Redden et al., 2013). As such, this study’s findings 
suggest that Suboxone® can serve as either a facilitator or barrier to treatment, depending on the 
patient’s treatment goals. Moreover, even when Suboxone® was discussed as a barrier, 
participants in this study still indicated that it was at some point in their lives a necessary 
facilitator for engaging in treatment, medically managing withdrawal and cravings, preventing 
relapse, and making positive life changes.
A final treatment barrier that emerged from this study was the availability and 
accessibility to treatment. This included references to waiting lists, limited treatment options, 
financial barriers, and individuals’ (patients’ and providers’) awareness/literacy of Suboxone® 
treatment. This is particularly relevant to accessing and receiving treatment in rural Alaska where 
there are limited resources and treatment options. Such barriers have been identified in other
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research, particularly in rural areas with individuals who would benefit from treatment for opioid 
misuse (Heil, Sigmon, Jones, & Wagner, 2008; Hewell et al., 2016a), and is particularly relevant 
to Suboxone® treatment, which has systemic barriers imposed related to the number of patients 
that providers can treat.
Contextual factors. This study revealed how contextual factors, including social 
relationships, life, and external assumptions, make it easier and harder to experience treatment 
success. Findings revealed social relationships facilitated success when individuals in treatment 
experienced encouragement and support from others. Similarly, one qualitative study 
demonstrated how individuals with hepatitis C virus in a psychosocial support group identified 
group cohesion and the group process as an agent that facilitated change (Woolhouse, Cooper, & 
Pickard, 2013). The current findings extend on Woolhouse and colleagues’ (2013) findings by 
emphasizing how patients in OBOT perceive social support between people in their treatment 
program as a facilitator to success.
Alternatively, social relationships could pose barriers to success, such as when people 
from participants’ addictive lifestyle would try to engage with them. Other research has 
demonstrated how family and social factors, such as delinquent influences, are related to 
substance misuse (Sharma, Sharma, & Barkataki, 2015) and how low social support relates to 
maladaptive coping and perceived stress (Hyman et al., 2009). Moreover, by cutting ties with 
substance users, individuals in one study reported increased rating of recovery identity (Dingle, 
Stark, Cruwys, & Best, 2015). Extending on this notion, participants in this study described the 
importance of cutting ties with negative influences in order to overcome this barrier and achieve 
success, suggesting that disengaging from unhealthy social networks is also important achieving 
success with OBOT patients.
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In this study, external assumptions by others were primarily identified as a barrier that 
includes judgments, stigma, and misguided expectations about what the patient’s behavior 
should be. Another study found that stigma could have an additive affect, where greater 
experienced stigma can create a heightened perception of stigma as a barrier (Conner & Rosen,
2008). More specific to medication-assisted treatment, stigma has also been identified as a 
barrier to the adaption of medication-assisted treatment (Roose et al., 2012). This study adds to 
the evidence of stigma as a barrier to treatment by demonstrating that stigma is also a barrier for 
OBOT.
Recovery-oriented systems of care emphasize the importance of observing the patient’s 
life context when considering what the patient needs (Sheedy & Whitter, 2009). For participants 
in this study, life, defined as qualities of living that make it easier or harder to obtain success 
such as balancing tasks, life in Alaska, and stressors, is an interesting contextual facilitator and 
barrier. Participants described how factors that are significant to life in Alaska, such as the rural 
setting and extreme seasonal variations, can make it easier or harder to be successful in OBOT. 
An example of the role of extreme seasonal variations is when treatment is facilitated in the 
summer because participants are energetic, productive, busy, and excelling at work due to the 
midnight sunlight, or when treatment is more challenging in the winter because of boredom and 
low mood due to minimal sunlight. Therefore, this study expands on the notion that context is 
important in patient care by adding specific contextual factors for individuals in this rural Alaska 
setting.
Other. Although some literature suggests that pain and physical functioning play 
important roles in opioid misuse (Jones et al., 2014), this was not discussed as being a facilitator 
or barrier for our participants. Although 33% of the participants indicated chronic pain was a
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health concern and 75% reported initiating opioid use because of pain, this was not described 
qualitatively as a predominant theme related to participants’ definition of success, nor as a 
barrier to their success. It could that individuals in the sample were finding non-addictive ways 
to manage issues of pain, or had recovered from the physical conditions that caused them to need 
pain relief in the first place, making pain less relevant as a barrier to success. Nevertheless, this is 
an important consideration that should be explored with future research.
Measurement
The final aim of this study was to understand what factors participants identify as being 
important to measuring OBOT success. When participants were asked what they thought 
providers and researchers should consider when assessing for success, they recommended having 
an individualized and flexible definition, recognizing the needs/traits of people who are addicts, 
paying attention to the patient’s progress, recognizing that success happens progressively, and 
considering other specific factors (e.g., personality changes, appearance of good health, financial 
stability, and relationships).
Guiding principles of patient-centered models of care suggest that there are many 
pathways to recovery and advocate for a person-centered approach to treatment (Sheedy & 
Whitter, 2009). This study’s findings expand on this notion by prioritizing patient-identified 
treatment outcomes. Notably, participants advocated for measurement that aligns with the 
patient’s goals, is flexible and individualized, pays attention to and recognizes progress, and 
attends to traits of people who are addicted (such as cravings, relapse, and honesty). Thus, this 
study expands on what has been described as a scant body of research (Sheedy & Whitter, 2009) 
by lending support to recovery-oriented systems of care for those in OBOT, particularly because 
the patients themselves reported factors that parallel this model.
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Additionally, this study’s findings emphasize the importance of considering honesty in 
reporting when attempting to assess for success. This parallels research that has highlighted the 
role of social desirability in measuring substance use related constructs, such as motivation to 
change and problem severity (Zemore, 2012). It also resonates with research that has suggested 
that using computerized, as opposed to paper-and-pencil questionnaires, may create 
unconstrained responding, thereby leading to more reporting of risky behavior (Booth-Kewley, 
Larson, & Miyoshi, 2007). Therefore, when deciding how to measure success, this study’s 
findings suggest it is important to take into account the individual’s definition of success in a 
manner consistent with recovery-oriented systems of care, while also considering the role of 
honesty and social desirability.
Research has established a need for a clear and consistent definition of treatment success, 
in part for the purpose of measuring outcomes (Betty Ford Institute Consensus Panel, 2007; 
Butler Center for Research, 2011; Dodge et al., 2010; Laudet, 2008; Laudet et al., 2006; White, 
2007; Witkiewitz, 2013). A few participants in this study referenced other specific factors that 
converge with common treatment outcome domains when discussing the factors that should be 
measured to determine success. For instance, participants recommended considering if the 
patient has relapsed, which is consistent with substance consumption (SAMHSA, 2010b; White, 
2007). They also recommended asking participants, “How they are doing financially” (P12).
This is consistent with assessing domains of employment status and the ability to support oneself 
(Butler Center for Research, 2011; SAMHSA, 2010b). Finally, they recommended keeping track 
to see if the patient goes to jail. This is consistent with criminal activity (Donovan et al., 2011; 
McClellan et al., 2007; SAMHSA, 2010b). However, these domains were only mentioned in a
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few instances, suggesting that they may not be as important to participants as developing ways to 
measure success that is salient to the individual patient’s situation.
The specific constructs that participants identified in their definitions of success may be a 
starting point for determining what should be measured in OBOT. These constructs are in line 
with some recommendations of what constructs to consider when measuring outcomes, including 
mental health (McLellan et al., 2007; White, 2007), psychosocial/family functioning and support 
(McLellan et al., 2007; SAMHSA, 2010b; Tiffany et al., 2012; White, 2007), cravings (Tiffany 
et al., 2012), and self-efficacy (Tiffany et al., 2012). Additionally, quality of life factors 
recommended in the literature, which parallel this study’s findings, include relationships, sense 
of meaning, self-esteem, and spirituality (Cummins et al., 2003; Wasserman et al., 2006). 
Importantly, while this study does provide some context to the specific content domains that 
might be used when measuring OBOT success, the most salient contribution of this study to the 
literature of substance misuse treatment measurement is the emphasis on individualized and 
patient-driven outcome markers for success.
Implications
This study provides a unique, in-depth understanding of how patients in OBOT define 
and experience success and recovery. The findings have implications for clinical practice, policy, 
and research.
Clinical practice. As has been discussed, traditional models of measuring success tend to 
focus on consumption-related outcomes (Butler Center for Research, 2011; McLellan et al.,
2007; Miller & Miller, 2009; Tiffany et al., 2012; Witkiewitz, 2013). As this study has 
demonstrated, these traditional models fail to capture the nuances of gains that people make in 
treatment. Although a reduction in SUD symptoms is one element of treatment success in this
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study, other factors that converge with other existing research, including functionality (Bergly et 
al., 2014; Butler Center for Research, 2011; SAMHSA, 2010b), quality of life (Butler Center for 
Research, 2011; Cummins et al., 2003; Laudet et al., 2009; Lee & Zerai, 2010; Miller & Miller, 
2009; Tiffany et al., 2012; Wasserman et al., 2006; White, 2007), self-efficacy (Reilly et al., 
1995), reappraisal of goals (Lee & Zerai, 2010; Park & Folkman, 1997; Skaggs & Barron, 2006), 
and improved relationships (Cavaiola et al., 2015) are particularly relevant.
This supports the notion that factors above and beyond consumption should be considered 
when measuring treatment outcomes (Butler Center for Research, 2011; Miller & Miller, 2009; 
Tiffany et al., 2012), particularly in OBOT. Findings of this study lend support for the need to 
reconstruct customary definitions of recovery to be more inclusive of non-abstinence oriented 
treatments and individuals, such as OBOT.
Similarly, this study’s findings provide some guidance about modes of assessing success. 
For instance, participants mentioned the importance of considering if people are being honest 
when you are attempting to assess for success. They also noted the importance of measuring 
success in a manner that takes into account the individual’s definition of success. These 
considerations in turn give credence to practices of incorporating anonymous assessment of 
success or bio-markers (such as urinalysis) to address the issue of honest disclosure, along with 
individualized behavioral indicators or interviews to address the importance of attending to the 
individual’s definition of success.
Participants’ definitions of success and understandings of facilitators and barriers were 
consistent with a biopsychosocial model of addiction (Miller & Carroll, 2006). This includes 
biological factors, such as using Suboxone® to medically manage withdrawal and cravings; 
psychological factors, such as emotional wellbeing, mental health, social stigma, motivation; and
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sociocultural factors, such as life in Alaska, family, social contexts. Notably, treatment outcomes 
(e.g., relapse, treatment non-compliance) are impacted by similar biopsychosocial factors that 
were noted by the participants in this study, such as poverty and family support, in other long­
term medical disorders (e.g., asthma and diabetes; McLellan, Lewis, O’Brien, & Kleber, 2000). 
This supports the need to emphasize these factors in treatment delivery and outcomes 
monitoring, while challenging some of the stigma that is often placed on substance use disorders 
that is not placed on other medical disorders. Additionally, patients identified facilitators to 
treatment that corroborate with recovery-oriented systems of care (SAMHSA, 2010a; Sheedy & 
Whitter, 2009; MHALA, 1995; VHA, 2011), including offering psychosocial treatment that is 
aligned with the patient’s goals, is encouraging, is non-judgmental, values the whole patient, and 
moves beyond solely treating symptoms. Also fitting with recovery-oriented models (Sheedy & 
Whitter, 2009), this study’s findings emphasized the importance of considering cultural and 
contextual variables, such as life in Alaska, when engaging patients in treatment.
Furthermore, when considering contextual variables, it should also be noted that, while 
only three participants reported going to Narcotics Anonymous and all three reported that this 
was not helpful, participant definitions of success echoed twelve-step philosophy. For instance, 
the notion that recovery is a process that happens day-by-day, and the embedded concept of a 
“dry drunk” (someone who has not healed), are also found in the Narcotics Anonymous literature 
(NA, 1992). One implication of this might be that the exosystem, such as the moral model of 
addiction prevalent in our society or the embedded practices and beliefs of Narcotics 
Anonymous, influence how treatment is delivered, thereby influencing how patients define 
success and recovery.
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The American Society of Addiction Medicine (2011) and the Substance Abuse and 
Mental Health Services Administration (2005) recommend considering the following factors 
when designing individual treatment plans using buprenorphine maintenance treatment: 
biopsychosocial needs, comorbidity of psychiatric, medical and other substance use disorders, 
legal issues, employment/financial issues, social and familial support, and somatic impacts of 
drug use (Kraus et al., 2011; SAMHSA, 2005). When comparing these recommendations to the 
findings of this study, participants did minimally endorse medical and other substance use 
disorders, somatic impacts of drug use, and legal issues. However other factors that were 
endorsed include: relational factors, such as social and familial support; lifestyle factors, such as 
employment, finances; and psychological factors, such as comorbidity and biopsychosocial 
needs. It seems that participants understand success more holistically and teleologically, which is 
inconsistent with a strict medical model that focuses almost exclusively on symptom reduction. 
Therefore, as suggested by other authors, a biopsychosocial model and recovery-oriented 
systems of care are appropriate for OBOT (Kraus et al., 2011; MHALA, 1995).
Policy. In this study, participants identified the lack of availability and accessibility to 
treatment as major barriers to OBOT. At the time of this study, federal policy restricted the 
number of buprenorphine patients that providers could treat. Providers can only treat 30 patients 
during their first year of receiving a waiver to prescribe, and this can only be increased to 100 
patients thereafter (SAMHSA, 2004). This policy serves as a significant treatment barrier by 
limiting access to treatment (National Alliance of Advocates for Buprenorphine Treatment 
[NAABT], 2015). This is a particular concern for individuals seeking OBOT in communities 
with limited availability of providers (Hewell et al., 2016a), such as in rural and/or low 
socioeconomic status contexts (Redden et al., 2013).
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Notably, several participants engaged in this study with the hope that their insights would 
have an impact on OBOT services at a policy level. They highlighted the need for more varied 
models of OBOT in Alaska, such as OBOT programs that align with the patient’s goals and 
readiness to change and do not force them into quitting other substances, such as cigarettes. They 
also expressed their fears about treatment being discontinued because of policy changes, 
conveyed a need for more providers and treatment programs, and noted the challenges they 
encountered because of provider limits on prescribing. For instance, participants described 
waitlists, having to travel far distances to receive treatment, and guilt associated with being in 
treatment when others are not permitted due to provider limits on prescribing. This speaks to the 
necessity of systematic change that increases accessibility to treatment. Moreover, in another 
study, program administrators who did not adopt medication-assisted treatment primarily noted 
systemic barriers, such as finances and availability of quality medical staff, (Knudsen, Abraham, 
& Oser, 2011), which further supports the need to address systematic barriers.
This study supports the importance of increasing availability and access to medication- 
assisted treatment combined with psychosocial treatment for opioid misuse, which is consistent 
with other recommendations (Kraus et al., 2011; SAMHSA, 2005). The Obama Administration 
announced a public health and safety initiative that, in part, aims to increase access to 
medication-assisted treatment (United States Executive Office of the President, 2015). This 
study’s findings highlight the importance of advocating for policy that will increase access to 
effective treatment.
Research. This qualitative study helps to illuminate some of the factors patients deem 
important for OBOT success. Future research is needed to develop ways to operationalize and 
validly measure some of the specific attributes patients identified in this study, particularly since
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these themes correspond with other factors identified in the literature. Specifically, it would be 
interesting to explore how psychological factors (emotional wellbeing, mental health, and 
character), accomplishing factors (progress and self-efficacy), lifestyle factors (functional 
lifestyle, cessation of SUD symptoms, and living life) and relational factors (family, restoring 
relationships, and social relationships) correlate with other OBOT outcomes. Moreover, 
definitions of success and recovery are necessarily influenced by experiences in treatment.
Future research should explores how individuals in a treatment program with a different 
philosophy, without Narcotics Anonymous exposure, or who have spontaneously recovered 
without treatment, define and experience success and recovery from addiction.
Future research could explore pain as a barrier to OBOT success, as there is evidence to 
support that it plays a role in opioid use, but was not described as a concept related to being a 
barrier to success by participants in this study. Additionally, exploring the meaning that restoring 
relationships has for patients in OBOT treatment might yield useful information related to 
patients’ process of obtaining OBOT success. For example, researchers might qualitatively 
explore how participants went about restoring relationships, and what about this process helps 
them feel successful in treatment.
Finally, it would be useful for future research to explore the role of character change as a 
component of OBOT success, as this typically is understood as having roots in a moral model of 
addiction, but still may remain an important feature of how individuals perceive their success. 
Comparing individuals in OBOT treatment who also ascribe to NA principles with those who do 
not might be one avenue for elucidating this.
Perhaps most importantly, this study’s findings have connotations for how future research 
should be conducted. Specifically, researchers should consider the impact of honesty and social
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desirability when conducting research. Anonymous measures, such as computerized surveys, 
may be one way to increase accurate reporting by study participants. It is also advisable that 
future researchers consider participant recommendations of having an individualized and flexible 
approach. With regard to both qualitative and quantitative research, using a collaborative 
approach, such as CBPR as was used in this study, would likely empower participants while 
gaining a more in-depth and nuanced understanding of treatment success.
Other Considerations, Limitations, and Strengths
This study uniquely contributes to the literature by providing an in-depth perspective into 
a phenomenon that has limited, and arguably misguided, understanding. This qualitative study 
may serve as a point of departure for future research, particularly within a political climate that 
warrants the need to understand, implement, and responsively evaluate patient’s definitions of 
success in the effective treatment for opioid misuse: buprenorphine. The limitations, challenges 
and strengths of this study are outlined below and reported in Table 5.1.
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Table 5.1
Study’s Challenges, Limitations, and Strengths
Component Challenges/Limitations Strengths
Study Design
I. Qualitative a) Small, non-representative sample a) Sample provided rich, in-depth, perspectives
b) Responses based on one treatment a) In-depth analysis of poorly researched topic
program b) Pre-study biases acknowledged and
c) Lack of generalizability
d) Researchers’ a priori knowledge 
and assumptions
determined prior to study
II. CBPR a) Time intensive a) Partnership with Sunshine Clinic ensured 
ethical and appropriate materials and processes
b) Study stakeholders identified and 
established
Sampling & Recruitment
n = 12 a) Sample size a) Adhering to recommended sample size and
b) Lack of diversity within sample theoretical sampling led to Theoretical 
Saturation
Data Collection
I. Demographic a) Long and time consuming a) Tool was pilot-tested
Survey
II. Focus Group a) FG primarily consisted of a) Process was pilot-tested
(FG) advanced participants b) Group process fostered: 
Participant interaction 
Diverse perspectives 
Trust and relationship building
III. Interviews a) Mode of data collection, a) Adherence to CBPR
telephone b) Enabled theoretical sampling
Data Analysis
I. Analysis a) Interview data were coded by one a) Focus group data coded by two researchers
researcher b) Data and information triangulation
II. Member- a) Low representation at findings a) Adherence to CBPR
Checking forum b) Data triangulation
c) Conceptual model of findings
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Study design. This study used a qualitative design informed by grounded theory, directed 
content analysis, and community-based participatory research principles. Strengths and 
limitations that emerged from this design follow below.
Qualitative design. Qualitative research is time-intensive and demanding (Singleton & 
Straits, 2010), which presented challenges for conducting this study. For example, participants 
were contacted at multiple time points and researchers dedicated extensive time to all stages of 
the study. The time required fostered qualitative trustworthiness, or rigor, which included a 
directive, yet open and flexible design. For more information on the rigor of this design, see 
Table 3.6.
Due to the small, non-representative sample, it is not possible to generalize findings (such 
as the definition of success). Additionally, this study was conducted exclusively with one OBOT 
program in rural Alaska. Therefore, it is necessary to consider that the findings may be related to 
the culture and procedures of this program. Nevertheless, findings will add to the existing 
research and understanding of how the field of substance abuse defines treatment success and 
increase knowledge in local communities. Furthermore, the small sample size is appropriate for a 
qualitative design that encourages exploration of dynamic experiences with an emphasis on the 
participants’ perspective (Singleton & Straits, 2010) by accruing in-depth data (Charmaz & 
Belgrave, 2012). Moreover, the iterative process of conducting the focus group and follow-up 
interviews with some participants assisted in verifying findings and saturating data (Charmaz & 
Belgrave, 2012).
Finally, the researchers’ background knowledge of the field of substance abuse may have 
fostered challenges to remaining open to new information and thus forcing participant responses 
into preconceived categories (Charmaz & Belgrave, 2012). To address this, researchers remained
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cognizant and reflexive about their biases. Specifically, they developed an a priori codebook to 
document literature-based expectations prior to conducting the study as a means to compare and 
contrast with data-driven findings.
Community-based participatory research. The CBPR approach required an intense time- 
commitment that was demanding for researchers and participants (Israel et al., 1998). For 
example, researchers met with participants at multiple time points, including before the study 
and after data were collected (during the findings forum). To address this challenge, time and 
communication processes were factored into the study schedule. As a positive, time committed 
to fostering partnership and participation fortified the collaboration between the OBOT program 
director and researchers. Having this collaboration served to lessen other study challenges 
(discussed later) and increased the likelihood that the study findings would be useful to 
stakeholders (Israel et al., 1998).
Sampling and recruitment. As discussed above, due to the relatively small sample size 
(n = 12) study findings should be interpreted with caution. Nevertheless, the goal of attaining in­
depth knowledge and theoretical saturation was achieved per following recommendations 
afforded by Guest and colleagues (2006). However, when reviewing the findings of this study, it 
is important to consider that the sample represents participants from one treatment program and 
their definitions of success and recovery were likely influenced by their experiences in this 
particular treatment program. The differences in goals for substance use between beginner and 
advanced group participants may attest to this with more advanced group participants having the 
goal of complete abstinence with more beginner group participants having the goal of moderate 
or controlled use of some substances (e.g., alcohol and marijuana). Although a comparison 
between beginner and advanced group participants was not a specific aim of this study,
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discrepancies in goals could be interpreted as suggesting that patients remain in treatment if their 
beliefs align with program philosophy, or that program philosophy influences how patients 
define success. As mentioned above, future research should be conducted to further clarify how 
programmatic group membership (e.g., beginner or advanced group) and time in treatment relate 
to individuals’ definitions of success.
Recruitment, particularly for the telephone interviews, was a challenge that was mitigated 
by the partnership with the OBOT program director that assisted in recruitment. After 
participants were recruited to the study, there remained a discrepancy in representation. For 
example, there was a low representation of beginner patients during the focus group. Theoretical 
sampling was used to target specific populations to address issues of representation (e.g., patients 
from the beginning group were targeted for interviews). Still, the study may be limited by its lack 
of ethnic diversity. While the sample is not representative of the overall United States 
population, it is representative of the population of this study (patients in Sunshine Clinic’s 
OBOT program). Nevertheless, it is important that future research aimed at understanding 
patient’s definitions of success include diverse samples.
Data collection: Demographics survey. The demographics survey was a relatively long 
and demanding component of data collection. The survey comprised 33 complex items that took 
participants approximately 20 minutes to complete. However, participants expressed 
appreciation for the detailed survey questions, and they conveyed that the survey encompassed 
many important aspects of their addiction. This was most likely due to the survey being co­
developed with professional advisors, and pilot-tested with multiple individuals and groups prior 
to data collection.
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Focus group. Limitations of the focus group include its length and participant 
composition, including primarily advanced treatment group participants. Nevertheless, the group 
format and All-on-the-wall procedure facilitated an interactive and creative process of gathering 
diverse perspectives and establishing relationships with and among study participants. 
Additionally, aspects of the focus group process were pilot-tested to refine question wording and 
the methodology of the All-on-the-wall procedures. Suggested revisions enabled researchers to 
strengthen the protocol and work through some procedural difficulties with the All-on-the-wall 
procedure. While the pilot testing enabled a smoother facilitation during the actual data 
collection, there was still some confusion amongst the group regarding the approach. This 
required researchers to remain flexible and open while adhering to the protocol.
Interviews. Due to geographical constraints, the in-depth interviews were conducted via 
telephone, rather than in person. While telephone interviewing increased convenience for both 
the researcher and participants, lacking were visual cues to develop and convey empathy, rapport 
and trust (Novick, 2008). However, by adhering to a CBPR design, the OBOT program director 
helped mitigate this challenge by helping to introduce the researcher to potential interview 
participants. Additionally, the researcher made efforts to contact participants multiple times to 
get to know them and to develop rapport. Moreover, telephone interviews may have actually 
increased comfort for participants, thereby helping them to disclose sensitive information 
(Novick, 2008). Other strengths of this study’s interviews include the in-depth data that were 
collected, the ability to collect information that clarified and verified data collected during the 
Phase I focus group, and that theoretical sampling was used to achieve theoretical saturation.
Data analysis. Although two people analyzed and coded the focus group data (a study 
strength), the interviews were coded solely by the lead researcher (a study limitation). This may
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have led to biases unintentionally guiding data interpretation. However, to mitigate this 
limitation, data and analysis were triangulated across data collection methods (focus groups and 
interviews) by using the existing literature to guide an a priori codebook to check assumptions, 
collecting diverse modes of data (transcripts of recorded focus group and interviews, process 
notes, photographs), having two researchers code the focus group transcript, connecting with 
academic and community advisors, and presenting preliminary findings to participants for the 
purpose of member-checking (described below).
Member-checking. A findings forum was conducted to verify and clarify findings. 
Although all participants from Phases I and II were invited and the forum was scheduled after 
their monthly treatment group meeting to be convenient and encourage participation, only four 
people participated. Still, the findings forum aligned with the CBPR approach as it enabled 
participants to be involved as partners and included an element of brainstorming future directions 
(Israel et al., 1998). The findings forum also provided a check for the data and findings, as 
participants were able to clarify misdirected findings (Charmaz, 2006), thereby further 
triangulating the data (as described above). A final strength that emerged during data collection 
and analysis, and then aided in presenting findings during the findings forum was the conceptual 
model (tree metaphor) that provided a meaningful and visual tool to enhance member checking.
Conclusion
This study provides an in-depth understanding of how OBOT patients understand and 
conceptualize success and recovery in their treatment. Despite the small sample size (n = 12) and 
the exclusivity of sampling from one OBOT program, findings offer useful information for 
treatment providers and researchers. A visual and conceptual model of OBOT success and 
recovery also emerged.
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Findings reveal the role of relationships, lifestyle factors, psychological factors, and 
accomplishing as aspects of success for OBOT patients. A notable barrier to achieving this 
success is the availability and accessibility of treatment, while psychosocial and Suboxone® 
treatment that was compassionate and nonjudgmental served as an important facilitator to 
success. Findings lend support for the use of a biopsychosocial approach within a role of 
recovery-oriented systems of care for OBOT patients. Furthermore, factors revealed in this study 
may be useful to consider when implementing OBOT programs and measuring success.
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Appendix A 
Glossary of Qualitative Terminology
Term Definition
Purposive Sampling Techniques (Patton, 2002)
Extreme or Sampling extreme/deviant cases that are not typical of the phenomenon
Deviant Case (e.g., overcoming extreme adversity to obtain success).
Intensity Intensely, but not extremely, represent the phenomena; information-rich.
Maximum Used to determine overarching patterns, this approach samples diversely
Variation* across conditions. In this study, maximum variation was used to get a 
representative sample of beginner versus advanced patients.
Homogeneous* Particularly useful in focus groups, this approach reduces variation and 
focuses the analysis. In this study, the focus group was primarily 
homogenous (advanced group participants).
Typical Case This approach is used to capture the “typical” case (e.g., someone who 
manifests the typical pathway to success).
Stratified Purposive Facilitates comparisons between groups by sampling within a subgroup.
Critical Case* This technique assists in theory generalization because “if it’s true of this 
one case, it’s likely to be true of all other cases” (1990, pg. 182). In this 
study, used when sampling person in the individual program.
Snowball* This technique asks “people who know people” to identify information- 
rich cases.
Criterion* This technique samples all people who meet some criterion. In this study, 
criterion included OBOT patients at Sunshine.
Theory-based or To elaborate on or examine the validity of an existing construct, this
Operational
Construct
approach samples individuals who embody the theory or construct.
Confirming/ Used to explore variation and seek out cases that disconfirm data, this
Disconfirming approach is used after the initial analysis to deepen the analysis. In this
Cases* study, it involved sampling a young beginner client who was struggling to 
be successful.
Opportunistic This flexible technique is used to follow new leads.
Random Purposive If this potential sample is too big, this approach can be used to credibly 
select cases.
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Politically Sensitive This technique keeps politically sensitive cases in mind when sampling to
Cases
Convenience
Combination or 
Mixed Purposive*
intentionally attract or detract attention from the study.
As the name connotes, this technique is efficient, yet lacks credibility and 
yields information-poor cases.
This technique combines different purposive sampling techniques to 
triangulate data and encourage a flexible stance.
General approach to analysis
Theoretical
Sensitivity
Reflexivity
Constant
Comparison
Exploring the data 
Coding
Quality of a researcher and his/her ability to have insight, be reflexive, and 
make meaningful inferences about the data. These qualities are developed by 
the literature, professional experiences, personal experiences, and the research 
project itself (Strauss & Corbin, 1990).
Process of being reflective and explicit about one’s biases 
Data is iteratively compared with other data, other categories, and other 
concepts to deconstruct and reconstruct theory (Bryant & Charmaz, 2007 
Charmaz, 2006; Glaser & Strauss 1967; Glaser, 1978; Strauss, 1987)
Codes outline the ‘skeleton’ of the theory (Charmaz, 2006) through the 
process of organizing data around ‘themes’ (Kelle, 2007).
Initial Coding Careful initial coding meets two goals of grounded theory—fit and
relevance—by using open coding, in-vivo coding, and diagraming (Charmaz, 
2003/2006).
In vivo Codes Codes that are symbolic markers of the language participants use (Charmaz,
2006)
Selective Coding Directed, active, and conceptual process where codes are discriminated based 
on the emerging theory (Charmaz 2003/2006). This process establishes “core” 
categories (Drauker et al., 2007).
Theoretical Development of relational codes that are weaved together around the “core”
Coding categories. This abstract process moves codes from literal to a symbolic and
theoretical (Charmaz, 2006).
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Theoretical
Sampling
Data Saturation
An evolving, systematic process that follows up on emerging data and 
examines relationships between categories to add clarity and refine categories 
until saturation is reached (Charmaz, 2006). This was the primary mode of
sampling for this study. It was also used to follow up on themes in order to
saturate data. After data were analyzed, gaps in the data and emerging themes 
were identified. Using this process, participants were selected for subsequent 
stages of data analysis accordingly (e.g., sampling individuals in the beginner 
group because of an underrepresentation in the focus group) until no new 
themes emerged.
Theoretical saturation occurs when the collection of more data does not reveal 
new data nor profit further theory development (Bryant & Charmaz, 2007). 
Dey (1999) critiques the feasibility of saturating data and points out that a 
more accurate term for what actually happens in grounded theory research is 
‘theoretical sufficiency’ (in Charmaz, 2006).
Organizing the data 
Codebook The codebook is a way to organize and structure the codes. In our codebook, 
the first column in the codebook represents grounded theory coding 
categories, which closely parallel Glaser’s coding families and Strauss and
Corbin’s coding paradigm  in that it groups together codes that are
conceptually similar (Bryant & Charmaz, 2007). Like coding families, this 
organizational strategy helps to “avoid being flooded by the data (Kelle, 
2007, p. 200-204).” The second column includes initial coding categories 
based on key concepts from existing research and theory as recommended by 
Potter and Levine-Donnerstein’s (1999). The third column includes 
operational definitions based on theory as suggested by (Hsieh & Shannon, 
2005).
Auditing/ Memo Auditing provides a thorough and explicit rationale for selecting participants 
Writing using theoretical sampling (Currie, 2009).
Memo writing is the process of taking thorough notes of the analysis process. 
Theoretical The creative and hands-on process of sorting data to allow for abstract
Sorting comparisons (Bryant & Charmaz, 2007).
Purposive sampling techniques that were used in this study*
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Appendix B 
Professional Advisor Memo
You are being asked to advise and partner in this study because you have extensive 
knowledge and understanding of the challenges and successes of OBOT, have connections with 
key community members (professionals, patients, and other stakeholders), and have 
demonstrated success in your OBOT program. This qualitative study is informed by Community- 
based participatory research (CBPR) principles and takes a constructivistic grounded theory 
approach in conjunction with directed content analysis principles.
By agreeing to advisor in this study, you are viewed as an expert, collaborator, co­
researcher, and shared decision-maker. The study design is reciprocally beneficial, 
empowerment-focused, and action-based. Therefore, you will be privy to knowledge that will 
assist your agency and community in increasing successful OBOT.
Five key pillars of CBPR based on Kemmis and McTaggart (2005) and Israel and colleagues
(2001) inform your involvement:
• Shared ownership of the project. This involves long-term commitment from both you 
and I, collaborative involvement through each step of the project, shared interpretation 
and dissemination of findings, and shared benefits of integrating knowledge with action.
• Community analysis of social problems. The topic for this study emerged from a 
preliminary CBPR study aimed at identifying and combatting barriers to Buprenorphine 
treatment in Interior Alaska. Multiple stakeholders were involved in the interpretation of 
findings and determination of future directions. This study emerged as a community- 
informed next direction.
• Emphasis on action in the community. This study emphasizes contextual variables and 
is committed to application-based research.
• Strength-based and empowerment-focus. This study focuses on the strengths of people 
who have been successful in OBOT. It intends to empower partners and stakeholders 
(you and your patients) to increase OBOT success.
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• Iterative and cyclical process. Using the grounded theory approach of theoretical 
sampling, data will be analyzed and interpreted as it is collected. As professional 
advisors, I will be looking to you to help interpret findings throughout the project to help 
‘hone in’ on the essence of patient success.
To accomplish this logistically, I  am asking the following from you:
• Willingness to provide ethical, cultural, and community oversight
• Willingness to participate in monthly meetings to guide the research (including project 
design, pilot testing study instruments and providing feedback, data interpretation and 
dissemination, and guidance of future directions)
• Willingness to recruit and screen participants based on eligibility criteria and selection of 
individuals who will provide rich information.
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Appendix C 
Demographics Survey
Thank you for taking the time to be involved in this study. We would like to start by asking you some 
questions about yourself and your history. Please complete all of the questions. Please indicate if you are 
unsure or if the question does not apply.
The first set of questions asks about your basic demographics.
1. What is your gender?
a. Male
b. Female
c. Other (please specify):___________________________________________________
2. Do you live in Alaska fulltime (aside from vacations/short travel)?
a. Yes
b. No
3. How would you describe where you live?
a. Urban (city/populated)
b. Rural (scarcely populated)
c. Remote (off the road system)
d. Other (please specify):___________________________________________________
4. What is your current living situation?
a. Living alone
b. Living with spouse or partner
c. Living with roommate(s)
d. Living with children (only)
e. Living with parents
f. Other (please specify):___________________________________________________
5. What is your age?_____________
6. Which of the following best describes your race/cultural tradition/ethnicity? Please check all that 
apply:
a. Caucasian
b. African American
c. American Indian or Alaska Native
d. Asian American
e. Native Hawaiian or other Pacific Islander
f. Russian
g. Hispanic/Latino
h. Other (please specify):___________________________________________________
7. What is your current employment status?
a. Employed: full time
b. Employed: part time
c. Student
d. Disabled (not able to work)
e. Unemployed
f. Retired
g. Other (please specify):___________________________________________________
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8. How would you describe your household income?
a. I struggle to meet my needs
b. I have enough to meet my needs
c. I have more than enough to meet my needs
9. What is your relationship status (please select one best answer)?
a. Single
b. In a relationship
c. Married
d. Divorced, separated, or widowed
e. Other (please specify):___________________________________________________
10. Do you have children?
a. Yes
b. No
The following questions are specific to your health WHILE IN ACTIVE ADDICTION.
11. Please rate your health while in active addiction in the following areas by marking ‘X ’ in the 
appropriate category (poor-excellent):______ ________________________________________
Poor Fair Good Very Good Excellent
Physical health
Mental health
Spiritual wellbeing
Social functioning
Other (please specify):
12. Please select how your active addiction impacts/impacted you in the following areas by marking
‘X ’:
Negatively No impact Positively
Physical health
Emotional health
Mental abilities/health
Spiritual wellbeing
Social functioning
My family relationships
My personal relationships
My behavior
My work or education
The way I feel about myself
My life as a whole
Other (please specify):
Increased No impact Decreased
Experience of pain
Life problems
Illegal activities
My household income
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13. Would you say you are currently in active addiction (e.g., using on a regular basis)?
a. Yes
b. No
The following questions are specific to your CURRENT health.
14. Please place ‘X ’ next to the health concerns that you currently experience.
 Abscesses or collapsed veins
 Arthritis and other rheumatologic problems
 Brain injury
 Breathing issues (such as COPD, asthma)
 Cancer
 Chronic pain
 Heart health issues
 Infectious disease (such as HIV, Hepatitis B and C)
 Liver and/or kidney issues
 Other (please specify):___________________________________________________
 None of the above
15. What, if  any, emotional concerns (for instance, depression, anxiety, stress) do you currently 
experience?
16. Please rate your current health in the following areas by marking ‘X ’ in the appropriate category 
(poor-excellent):_________________________________________________________________________
Poor Fair Good Very Good Excellent
Physical health
Mental health
Spiritual wellbeing
Social functioning
Other (please specify):
The following questions ask about your history with opioid use and treatment.
17. How did you begin using opioids (please check all that apply)?
 They were prescribed to me by a doctor
 I used opioids for fun or to enhance my mood
 I used opioids to get “high”
 I used opioids to escape something negative
 I used opioids to help me cope with a psychological issue (e.g., depression, anxiety)
 I used opioids to help me cope with stress
 I used opioids to help me manage my pain
 I used opioids because they were available
 I used opioids to fit in
 Other (please specify):___________
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18. What opioids have you used (check all that apply):
___Prescription opioids (as prescribed)
___Prescription opioids (not as prescribed)
___Morphine (as prescribed)
___Morphine (not as prescribed)
___Methadone (as prescribed)
___Methadone (not as prescribed)
___Medication-assisted treatment, such as Buprenorphine (as prescribed)
___Medication-assisted treatment, such as Buprenorphine (not as prescribed) 
 Heroin
___Other (please specify):
19. What is/was your opioid of choice?_____________________________________________________
20. What was your preferred way to take opioids (please select one best answer)?
a) Orally
b) Snorting
c) Inhalation/smoking
d) Intravenously
e) Other (please specify):___________________________________________________
21. At any time, would you consider your opioid use to have been “problematic” or “addictive”?
a) Yes
b) No
22. If yes: Approximately how long, excluding periods of abstinence, did you have “problematic” or 
“addictive” use of opioids?_______________________________________________
24. Have you ever experienced withdrawal symptoms?
a) Yes
b) No
24. Which of the following most accurately describes your current substance use?
No
Use
Moderate/Controlled Unrestricted/ 
Heavy Use
Nicotine
Alcohol
Marijuana
Opioids
Methamphetamine s/other 
stimulants
Other Drugs (please 
specify):
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25. What are your goals in regard to substance use?
No
Use
Moderate/Controlled Unrestricted/ 
Heavy Use
Nicotine
Alcohol
Marijuana
Opioids
Methamphetamine s/other 
stimulants
Other Drugs (please specify):
26. Including your treatment at Sunshine Community Health Center (outpatient), please indicate the 
instances, length, and helpfulness of each of the treatment types below.
Treatment type Separate number 
of instances in 
treatment
Length of 
treatment
How
many
were
helpful?
Did you 
stop
treatment
(Yes/No)
If yes, why did 
you stop 
treatment 
(voluntary, 
kicked out, etc)
Inpatient
NA/AA
Outpatient
Intensive Outpatient
Other (please specify):
27. Although this treatment is voluntary, is your treatment at Sunshine mandated in any way?
a) Yes
b) No
28. If yes, please check all that apply:
a) Court
b) Family
c) Work
d) Other (please specify):________________
29. What Sunshine program are you in?
a) Beginning group (every other Thursday)
b) Advanced group (third Friday of the month)
c) Individual program
30. Do you consider yourself in recovery?
a) Yes
b) No
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31. If yes, how long have you been in recovery?_____
32. Why do you feel like you are or are not in recovery?
33. Is there anything else you would like to share?
Thank you for taking the time to complete this survey.
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This focus group protocol corresponds with the three stages outlined in the proposal and 
includes the following material: (a) Welcoming Script; (b) Ground Rules for the Focus Group; 
and, (c) Focus Group Questions.
Stage 1: Welcome Script
> Introduce Valerie Hewell and Gabriel Cartagena: relevant personal information (such as 
years lived in Alaska), professional background, and interests/commitment related to the 
study
> Pass out flyers
> Introduce study: background and development, purpose (dissertation), aims, and research 
questions
> Introduce general methodology and approach: CBPR and qualitative approach, three 
phases, timeline, what is being asked of participants
> Read informed consent
> Open the floor for questions
Stage 2: Ground Rules for Focus Group
The following rules were written on a flip chart and discussed after the informed consents 
were signed. Participants were asked if other rules should be added:
1. Patience! Only one person talks at a time.
2. Confidentiality! “What happens in the room stays in the room.” Everything (including 
illegal activities such as drug use) will be kept in this room. Researchers are mandated 
reporters who must break confidentiality if there is a disclosure or risk of harm to self or 
others, especially children or elderly. Please respect the confidentiality of other group 
members.
3. Participate! Everyone is encouraged to participate. There are no right or wrong 
answers—we want to hear what you believe!
4. Balance! We want to hear both sides of the issue: positive and negative
5. Agree to disagree...respectfully! We want to respect diverse opinions of people from all 
backgrounds—gender, culture, age, etc.
Stage 3: Data Collection
The focus group questions, procedure for collecting the data, and corresponding research 
questions can be found in Table 3.D-1 (below).
Appendix D
Focus Group Protocol
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Table 3.D-1
Focus Group Questions
Procedure Research
Question
Questions
Flip chart 1 and 2: 
Defining 
Success & 
Recovery
Question Block 1:
1) How do you define success in Suboxone treatment? What does 
that mean to you?
2) How do you define “recovery?”
3) How does your definition of treatment success relate to, or differ 
from, your definition of recovery?
4) How did you come to define success and recovery like this?
(prompt: providers, family, support groups, friends) 
Participants were asked the first set o f  questions. Responses getting at participant’s broad 
definition o f  success were jo tted  down on a flip  chart and discussed as a group.
Naming 2 and 3: Question Block 2:
Domains: Elements of 5) Think about yourself in Suboxone® treatment. There may have been
Sticky Success times that you felt successful, and there may have been other times 
notes that you did not. What contributes to feeling successful, or not feeling
successful, in treatment?
( if  responses center around substance use): Are there any other things 
that could make you successful beyond whether you used or not? What 
did you do differently in those times that helped you not use? What 
things did you learn in treatment, or elsewhere, that helped you do this 
differently? What positive and negative changes resulted from
treatment?
6) What makes it easier or harder for you to achieve success in 
{domain}? What do you need?
(Prompt to get at different ecological levels, i.e., personally, in 
treatment, with important people in their lives, employment/school, on
societal level)
Participants were asked the second set o f  questions. They were asked to write down their thoughts 
about “successful treatment” on yellow sticky notes and their thoughts about “not successful 
treatment” on green sticky notes. They were asked to share and collaboratively discuss their 
responses with the group and then place their sticky notes on a blank wall. Participants
_____________________collaboratively sorted the sticky notes into domains._____________________
Flip Debriefing 1) Compared to when you arrived, do you feel better, the same, or 
Chart worse?
2) How would you describe your experience during the focus group 
overall?
3) Would you be interested in future research related to health and 
wellness in rural Alaska?
4) Is there anything else you would like to share or feel I should know 
_______________________before you leave?_________________________________________________
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Appendix E
Interview Protocol
After obtaining informed consent, participants were first asked the demographics survey 
questions. Then, the following semi-structured interview questions were asked with 
prompts (depending on the participant) to further illuminate themes.
Research Questions
Question____________________________________________
1 and 2: Question Block 1:
Defining 1) How do you define success in Suboxone® treatment? What does that mean
Success & to you?
Recovery 2) How do you define “recovery?”
3) How does your definition of treatment success relate to, or differ from, your
definition of recovery?
4) How did you come to define success and recovery like this?
(prompt: providers,  ^family, support groups,  ^friends)
Question Block 2:
5) Think about yourself in Suboxone® treatment. There may have been times 
that you felt successful, and there may have been other times that you did not. 
What contributes to feeling successful, or not feeling successful, in treatment?
( if  responses center around substance use): Are there any other things that 
could make you successful beyond whether you used or not? What did you do 
differently in those times that helped you not use? What things did you learn in 
treatment, or elsewhere, that helped you do this differently? What positive and 
negative changes resulted from treatment?
6) What makes it easier or harder for you to achieve success in {domain}?
What do you need?
(Prompt to get at different ecological levels, i.e., personally, in treatment, with 
important people in their lives, employment/school, on societal level)
4: Question Block 3:
Measuring 7) How do we know when there has been success? What should we be asking
Success to assess or measure if  you have been successful?
Debriefing 8) Compared to when you arrived, do you feel better, the same, or worse?
9) How would you describe your experience during the interview overall?
10) Would you be interested in future research related to health and wellness in 
rural Alaska?
11) Is there anything else you would like to share or feel I should know before 
______________you leave?____________________________________________________________
2 and 3: 
Elements of 
Success
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Appendix F
Participant Debriefing Procedure and Resource Sheet
After participants finished the focus group or interview, the researcher offered participants the 
referral sheet (below) and said:
During this group (interview), the topics we discussed may have evoked strong reactions. These 
reactions are normal. I f  you would like help working through some o f these reactions, there are 
services available to you. You can talk to your counselor at Sunshine Community Health Center. 
Alternatively, there are also support groups, like Narcotics Anonymous, that are available. 
Finally, i f  there is immediate discomfort for which you feel at risk o f hurting yourself or others, 
you may call crisis hotlines or go to Providence hospital. These services are included in this 
resource sheet. Do you have any questions or concerns at this time?
Resource Sheet
Sunshine Community Health Center
> Outpatient medical and mental health services
> (907) 733-2273
> www.sunshineclinic.org
Anchorage Narcotics Anonymous
> Free 12-step support group for people in recovery
> (907) 277-5483
> www.akna.org
Anchorage Community Mental Health 24/7 Crisis Hotline
> Consumer-driven behavioral health care
> (907) 563-3200
> www.acmhs.com
Providence Crisis Recovery Center
> Professional help managing acute psychotic symptoms
> (907)563-5006
Providence Alaska Medical Center
> If you or someone you know is a danger to themselves or others, you can contact the 
Providence Alaska Medical Center Hospital 24 hour/7 day a week
> (907) 562-2211
> www.providence.org
*The person seeking services is responsible for any financial costs that accrue.
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Appendix G 
a priori Codebook
Category Code Description/ Justification for 
Inclusion
Recovery (Research Question 1)
Recovery Allegiance to those in recovery
An active process or state of being, without a
fixed endpoint
Abstinence is a prerequisite
Addresses shame
Cultural
Contributing to society 
Healing from trauma 
Health/wellness 
Holistic
Improved relationships/social functioning 
Life skills/self-care 
Many pathways
Meaning-making process toward self­
actualization 
Personal growth
Personal recognition of need to change 
Physical or biomedical functioning 
Psychiatric and psychological improvements 
Self-determination 
Spirituality 
Self-directed 
Supported by peers 
OBOT Success (Research Question 2 & 4)
Consumption Abstinence
Reduction in opioid-use 
Reduction in the use of AOD
ASAM, 1982; Dodge et al., 2010; 
Galanter, 2007; Laudet, 2007, 
2008; McLellan et al., 2007; NA, 
1988, 1992; SAMHSA, 2012; 
Sheedy & Whitter, 2009; White, 
2007
Merges “chemical 
dependency” and “psychiatric” 
category of Dodge et al., 2010; 
APA, 2013; Lee & Zerai, 2010
192
Appendix G Table continued
Functional
Factors
Health
Psychological
Health
Psychosocial 
and Family 
Functioning
Other
Addiction and 
Opioid- 
Specific 
Factors
Citizenship 
Criminal activity
Employment status and functioning 
Reduction in other mental health symptoms 
Stability in one’s housing environment 
Healthcare use patterns 
HIV risk-taking behavior 
Improvement in physical health
Cognitive impairment
Mental health
Psychological adjustment
Stress, Coping, and emotional volatility
Self-efficacy
Community engagement and connectedness
Relationship with significant others
Social functioning
Social interactions
Social pressures
Coping skills
Cravings
Other addictive behavior (e.g., drug seeking) 
Drug consumption and intoxication 
Pain
Poor response to medication 
Addiction and problematic medication use 
Enhancement expectancies 
Relapse
APA, 2013; Butler Center for 
Research, 2011; Lee & Zerai, 
2010; McClellan et al., 2007; 
SAMHSA, 2004, 2012; White, 
2007
Butler Center for Research, 
2011; Dodge et al., 2010; 
McLellan, et al., 2007; 
SAMHSA, 2012; White, 2007 
Dodge et al., 2010; McLellan, 
et al., 2007; SAMHSA, 2012; 
White, 2007; Reilly et al.,
1995
Dodge et al., 2010; SAMHSA, 
2012; Lee & Zerai, 2010; 
McLellan et al., 2007; 
SAMHSA, 2004; Tiffany et 
al., 2012; White, 2007 
Ashrafioun et al., 2015; Darke 
et al., 1992; Jones et al., 2014; 
Tiffany et al., 2012
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Quality of Safety and security Butler Center for Research,
Life* Relationships 2011; Cummins et al., 2003;
Health Laudet, 2007; Laudet et al.,
Connectedness with the community 2009; Lee & Zerai, 2010;
Spirituality (connectedness with higher power) Miller & Miller, 2009; NA,
Self-esteem 1988; SAMHSA, 2012;
Sense of meaning Tiffany et al., 2012;
Creativity Wasserman et al., 2006;
Reappraisal of goals White, 2007
Process Access to treatment Lee & Zerai, 2010; McClellan
Factors Demarginalization et al., 2007; Reisnger et al.,
Before Identification 2003
Treatment Initiation
Process “Any positive change” Amato et al., 2011; Connors et
Factors in Fit between patient and treatment al., 1997; Lee & Zerai, 2010;
Treatment Navigation of treatment Luborsky et al., 1997;
Patient satisfaction McLellean et al., 2007; Mee-
“Planting a seed” lee et al., 2010; Orlinsky et al.,
Quality of services 1994; Reisinger et al., 2003;
Therapeutic relationship 
Treatment compliance 
Treatment engagement 
Treatment retention
SAMHSA, 2004
Facilitators and Barriers (Research Question 3)
Facilitators & Beliefs about treatment Ashrafioun et al., 2015; Miller &
Barriers Craving Carroll, 2006; Hyman et al.,
Motivation & Self-efficacy 2009; Ilgen et al., 2005; Jaremko
Pain et al., 2015; Jones et al., 2014;
Physical and psychological functioning Reilly et al., 1995; Sinha et al.,
Social support 2007; Tiffany et al., 2012; Tsui et
Stress al., 2014; Tonigan, 2004; Redden
Substance use expectancies 
Suboxone®
et al., 2013
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Barriers Financial Hewell et al., 2016a; Redden et
Not ready to stop using al., 2013
Did not know where to go for treatment 
Transportation
Might have negative impact on job 
Could handle problem w/o treatment 
Didn’t need treatment 
Time
Access to treatment/availability
Health literacy
Stigma
Structural and systemic 
Suboxone®
Note. Table was established by the literature reviewed in chapter 2. This a priori codebook 
consists of categories and codes that facilitated constant compassion with the analysis process.
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Institutional Review Board Approval Letter
(907) 474-7800 
(907) 474-5444 fax 
uaf-irb@alaska.edu 
www.uaf.edu/irbA L A S K A
Institu tiona l Review Board
909 N Koyukuk Dr. Suite 212, P.O. Box 757270, Fairbanks, Alaska 99775-7270
May 29,2015
To: Ellen Lopez, PhD
Principal Investigator
University of Alaska Fairbanks IRB
[738121-3] Exploring Success in Buprenorphine Treatment
From:
Re:
Thank you for submitting the Amendment/Modification referenced below. The submission was handled by 
Expedited Review under the requirements of 45 CFR 46.110, which identifies the categories of research 
eligible for expedited review
Required Information:
The reviewer congratulates the research team on succesfully obtaining external funding for this important 
project After careful review of all the materials submitted via IRBnet the reviewer finds that all the 
necessary modifications have been satisfactorily made to reflect and acknowledge this funding As 
well, the additional review and revision of the interview questions sharpens the focus of the inquiry and 
strengthens the research considerably. The modifications are approved
This action is included on the June 3, 2015 IRB Agenda.
No changes may be made to this project without the prior review and approval of the IRB. This includes, 
but is not limited to, changes in research scope, research tools, consent documents, personnel, or record 
storage location.
T itle :
Received:
Expedited Category: 
Action:
Effective Date: 
Expiration Date:
APPROVED 
May 29, 2015 
April 30, 2016
Exploring Success in Buprenorphine Treatment
May 23, 2015 
7
196
Appendix I 
Informed Consent Forms
Informed Consent Form
Success in Buprenorphine Treatment: Group Discussion
IRB # 738121-3
Date Approved: 5/29/2015
What is the purpose of this study?
The purpose of this study is to better understand success in Buprenorphine treatment from the point 
of view of people going through treatment.
We are asking you to take part in this group discussion because you are in the Buprenorphine 
treatment program at Sunshine Community Health Center. If this sounds like you, please read this 
form carefully. We encourage you to ask questions before you decide if you would like to 
participate.
What does the study involve?
This study involves sharing your opinion during a two-hour small group discussion. We would like 
you to share how you view success in Buprenorphine treatment. How much you share is up to you.
What you say is important! We will audio record the group discussion to make sure we capture 
what you share.
What are the risks and benefits of being in the study?
We cannot say that you will directly benefit from this study. You may appreciate sharing your 
story and knowing what you share may help others to better understand treatment success.
Remember, you can choose what and how much you share. At times, you may feel uncomfortable 
sharing your story or hearing the stories of group members. If you ever feel too uncomfortable, 
please let the researchers know. You can take a break or stop the discussion at any time. We will 
discuss how it was to participate at the end of the group.
Will I get anything from participating?
We value your time and willingness to share your story. We will offer light refreshments during 
the group discussion. We will also offer you $20 Fred Meyer gift card.
Please note: If you choose to leave the group early, we will not be able to offer you the 
Fred Meyer gift card. Also, Sunshine Community Health Center and the University of
197
Alaska Fairbanks are not responsible for any financial costs related to seeking additional 
medication or mental health services.
Will my story be private?
We value your confidentiality and privacy. Researchers will remove any information that may 
identify you (such as names or places) when we take notes. We will securely store research 
records and securely dispose of paperwork.
Please note: The researchers are required to report serious risk of danger to group 
members or other people, especially children or elderly. Please know that researchers 
will keep all other information, including illegal activity and drug use, confidential.
We ask that you respect the privacy of other group members. We cannot guarantee group 
members will keep your privacy. However, we will come up with ground rules at the beginning 
of the discussion to encourage respect to group members’ privacy.
We may use the study results in reports, publications, presentations, and to inform future 
research. All findings from this project will be reported on a group basis. Your name and other 
information that could identify you will never be connected with any information we report.
Are there others ways I can participate in this study?
Yes! There are two other ways you can participate. First, we will conduct phone interviews to get 
an in-depth understanding of success in Buprenorphine treatment. Second, we want to make sure 
we accurately tell your story. Before we report findings, we will have a Findings Forum where 
we will give participants another chance to verify findings. If you are interested in participating 
in either one of these, please initial and provide your contact information on the next page.
Do I have to participate?
You do not have to participate in this group discussion. You may choose to stop the group 
discussion at any time for any reason. Whether or not you take part will not affect your ability to 
get services from Sunshine Community Health Center.
Who can I contact if I have questions?
If you have questions, feel free to ask the researchers now or anytime during the group discussion. 
If you have questions later, you may contact (Principal Investigator) Valerie Hewell at 
vmhewell@alaska.edu or (907) 474-7007.
If you have questions or concerns about your rights as a participant, you can contact the UAF 
Office of Research Integrity at 474-7800 (Fairbanks area) or 1-866-876-7800 (toll-free outside the 
Fairbanks area) or fyirb@uaf.edu.
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Statement of Consent:
I understand this study and the procedures described above. By signing my name below, I 
agree that my questions have been answered, and I agree to participate in this study. I also 
agree that I am 18 years or older and have been provided a copy of this informed consent 
form.
Please initial for all that apply:
Required:
 I agree to participate in the study
 I understand that the group discussion will be audio-recorded
Optional:
 I consent to being contacted to participate in a follow-up phone interview
 I would like to be invited to the Findings Forum
 I would like to be contacted about future research related to Buprenorphine treatment
Signature of Participant & Date Signature of Researcher & Date
Contact Information (Phone) Contact Information (Email)
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Informed Consent
Success in Buprenorphine Treatment: Phone Interview Script
IRB #738121-3
Date Approved: 5/29/2015
Thank you for showing interest in doing this phone interview! I imagine you have a few 
questions about the study. I will answer some questions now. I encourage you to ask other 
questions before you decide if you would like to participate.
Before we begin, I  would like to let you know that this phone conversation is being recorded. Is 
this alright with you?"
You may be wondering about the purpose of this study.
The purpose of this study is to better understand success in Buprenorphine treatment from the 
point of view of people going through treatment.
I am asking you to take part in this phone interview because I heard you are in the Buprenorphine 
treatment program at Sunshine Community Health Center. Is this correct? I f  yes: Great! Let’s 
continue.
I f  no: Thank you for showing interest in our study. Unfortunately, you are no longer eligible.
You may be wondering what this study involves.
This study involves sharing your opinion during a one-hour phone interview. We would like you 
to share how you view success in Buprenorphine treatment. How much you share is up to you.
What you say is important! We will audio record and type-up the phone interview to make sure 
we understand what you share.
What are the risks and benefits of being in the study?
I cannot say that you will directly benefit from this study. You may appreciate sharing your story 
and knowing that what you share will help others to better understand treatment success.
Remember, you can choose what and how much you would like to share. At times, you may feel 
uncomfortable sharing your story. If you ever feel too uncomfortable, please let me know. You 
can take a break or stop the interview at any time. We will discuss how it was to participate at 
the end of the interview.
You also may want to know if you will get anything from participating.
We value your time and willingness to share your story. If you complete a phone interview, we 
will offer you a $20 gift certificate to Fred Meyer. You can pick this up with Cici after the 
completion of this phone interview. Sunshine Community Health Center and the University of
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Alaska Fairbanks are not responsible for any financial costs related to seeking additional 
medication or mental health services.
It is important to know about your privacy.
We value your confidentiality and privacy. Research team members will remove any information 
that may identify you (such as names or places) when typing-up the audio recording. We will 
securely store research records and securely dispose of paperwork.
Please note: I am required to report serious risk of danger to participants or others, especially 
children or elderly. But please know that all researchers will keep all other information, 
including illegal activity and drug use, confidential.
We may use the study results in reports, publications, presentations, and to inform future 
research. All findings from this project will be reported on a group basis. Your name and other 
information that could identify you will never be connected with any information we report.
We want to make sure we accurately tell your story.
Before we report the findings, we will have a Findings Forum where we will give participants 
another chance to verify our findings. If you are interested in participating, please initial and 
provide your contact information on the next page.
You do not have to participate in this interview.
You may choose to stop the interview at any time for any reason. Whether or not you take part 
will not affect your ability to get services from Sunshine Community Health Center.
Finally, I want to give you some contact information in case you have questions.
If you have questions, feel free to ask me now or anytime throughout the interview. If you have 
questions later, you may contact (Principal Investigator) Valerie Hewell at 
vmhewell@alaska.edu or (907) 474-7007.
If you have questions or concerns about your rights as a participant, you can contact the UAF 
Office of Research Integrity at 474-7800 (Fairbanks area) or 1-866-876-7800 (toll-free outside 
the Fairbanks area) or uaf-irb@alaska.edu.
Statement of Consent:
We will now ask for your verbal consent:
(All answers require a response o f “yes ”)
□  Do you understand this study and the procedures described above?
□  Have all of your questions been answered?
□  Have you received a copy of this informed consent form?
□  Are you 18 years or older?
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□  Do you agree to participate?
□  Do you understand that this interview will be audio-recorded and transcribed?
We would also like to know if you are interested in participating in future research:
□  Would you like to be contacted to participate in another follow-up phone interview?
□  Would you like to be invited to the Findings Forum?
□  Would you like to be contacted about future research related to Buprenorphine treatment?
Contact information:
Phone number:
Email address:
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Appendix J 
Focus Group Recruitment Flyer
Help us define Suboxone 
treatment SUCCESS!
A re  you:
I 8 years o r older?
In Sunshine’s Suboxone  
tre a tm e n t program ?
Get a  
$20 Fred M eyer 
Gift Card  
fo r partic ipating*
W e will be hosting a 
D IS C U S S IO N  g r o u p !
W h o ? Sunshine Suboxone c lien ts  
W h e n ? July 17 ,2 0 15 fro m  2-4 pm  
W h e r e ? Sunshine C o m m u n ity  H e a lth  C e n te r 
24091 Long Lake R o ad ,W illow ,A laska
If you are interested in sharing 
your ideas about success, 
please contact:
C ic i S choenberger at:
cschoenberger@sunshineclinic.org 
(907) 733-2273
Valerie  Hew ell at:
vmhewell@alaska.edu
*Funded  by: 
A laska M enta l 
H e a lth  Trust 
A u th o rity
VHF
U N I V E R S I T Y  O F
A L A S K A
F A I R B A N K S
F o r questions about the study or 
your rights as a p articipant, contact:
U A F Office of 
Research In teg rity  
474-4800 or 
uaf-ori@ alaska.edu
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Appendix K
Alaska Mental Health Trust Authority Funding Agreement
(first two pages)
Trust
Alaska Mental Health  
Trust Authority
FY15 Authority Grant Funding Agreement
Project Title: Partnership: Exploring Success in Suboxone Treatment (FY15)
Total: $2,000.00
Term: 5/21/2015 - 6/30/2016
Authority Grant Type: Partnership
GIFTS ID: 6 6 0 4 (P le a se  use th is number in all grant correspondence)
Alaska Mental Health Trust Authority Agency Contact: Valerie Hewell
3745 Community Park Loop, Suite 200 Title: PhD student in clinical
Anchorage, AK 99508 psychology
Phone: 269-7960 Organization Name: Sunshine Community
Fax: 269-7966 Health Center Inc
www.mhtrust.ora Address: HC 89 Box 8190
Trust Program Contact: Michael R. Baldwin Talkeetna, Alaska 99676
Phone: (907) 733-9229
I. General Agreement
The purpose of this agreement is to provide Sunshine Community Health Center Inc with $2,000.00 
from the Alaska Mental Health Trust Authority (the Trust) for the Partnership: Exploring Success in 
Suboxone Treatment (FY15).
Sunshine Community Health Center Inc and the Trust, in consideration of the funding of this project, 
establish the following agreed upon conditions.
II. Project Description
This qualitative design study will use community-based participatory research principles to explore how 
suboxone patients define suboxone treatment success, and to understand how these patients believe 
suboxone treatment success should be measured. It intends to involve beneficiaries as partners in the 
study with the understanding that they are experts on their own treatment success. It also intends to 
inform treatment providers, researchers, evaluators, and other beneficiaries about what factors are 
involved in suboxone treatment success. This aims to improve the way suboxone treatment is delivered 
and evaluated with an emphasis on the beneficiaries needs.
Sunshine Community Health Center Inc will negotiate and monitor contracts for the project. Invoices 
from contractors are to be submitted to Sunshine Community Health Center Inc for payment by 
Sunshine Community Health Center Inc
III. Project Performance Measures
The grantee will submit a final project report that provides:
• A copy of the final research report that includes a summary of findings, implications and 
recommendations for policy and systems changes to improve the quality of treatment and life 
for Trust beneficiaries impacted by opioid dependence.
• A presentation of the study results and recommendations to the Alaska Mental Health Trust 
Authorities Board of Trustees Planning Committee within six months of project completion if
_______ scheduling permits.__________________________________________________________________
204
• A final copy of any presentations or articles that result from professional presentation or 
publication of data and results from this project.
• Documentation that the Alaska Mental Health Trust Authority is acknowledged as a funder on 
any professional publication or presentation of the project results.
IV. Budget Agreement
The Trust agrees to fund Sunshine Com m unity Health Center Inc in the amount of $2,000.00 with the 
understanding that funding is as outlined below:
Project Budget
Personnel Services $800.00
T ravel $200.00
Equipment $100.00
Supplies $300.00
Other $600.00
Grant Total fo r FY15 $2,000.00
It is understood that the Trust cannot advance funds or reimburse Sunshine Com m unity Health Center
Inc for any anticipated or actual expenditures that has not been documented and agreed to pursuant to 
this agreement.
V. Payment Provisions
Grant funds will be advanced upon the Trust’s receipt of the signed Grant Agreement and the signed 
Request for Advance form. Billings for the first year are not to exceed $2,000.00
Estimates, contracts, or receipts and other required information will be submitted to:
Lucas Lind, Grants Administrator 
Alaska Mental Health Trust Authority 
3745 Community Park Loop, Suite 200 
Anchorage, AK 99508
VI. Reporting Requirements
Program and Fiscal Reports
Sunshine Com m unity Health Center Inc will submit to the Trust, program and fiscal information as 
determined in this agreement.
A comprehensive final grant report will be due within 60 days of the conclusion of the project, on or 
before August 31, 2016
All grant reports are to be submitted online through IGAM, the Trust’s online grant reporting 
application/reporting system. This report can be found at the Trust’s website, www.mhtrust.org. in the grant 
opportunities section. The address for the online report is:
https://www.qrantrequest.com/SID 259/Default.asp?CT=CT&SA=AM&FID=&SESID=21953&RL-
The link to online reports can also be found at the Trust’s grant opportunities webpage: 
http://wwwmhtrustorq/index.cfm?section=Trust-Fundinq&paqe=Grant-Opportunities
Please contact Carrie Predeger, Grants Accountability Manager (907-269-7965) with any questions about
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Appendix L 
Analysis Tables
Table 4.K-1
All-on-the-wall Themes and Concepts
Theme Concepts (Sticky notes)
Family/ Family—being with, having the respect of, having close relationships, etc (7)
Close Being a parent (3) or grandparent (1)
Relationships Being a spouse (2)
Having better relationships (kids, family, God)
Friends Friends—can make it easier, or harder (2) 
Strangers—make it harder (1)
Mental Health Psychosocial Treatment Group (4) 
Counseling (2)
Stability/ Being able to function in society (2)
Functioning/ To live normal (1)
Functioning & Life No shame (1)
Hard to balance life, kids, and do everything expected in group (1)
“Bettering College/school (1)
Yourself’ Hard to balance work [with life tasks] (1)
Job—enjoying job, getting promotion/good job (3)
Emotional/Spiritual Happiness— for no reason, happier than before (2) 
Feeling more spiritually connected (1)
“Doing it for Discussed as an overarching theme. When the tree model emerged, this was
M yself’ discussed as the trunk
“Term ites’ of Tree Felt lame (1)
Physical dependence on Suboxone® (4)
Unnamed I don’t have to go to the doctors and get med pain pills. (line separating this 
and): and lie to doctors (potentially moral?)
Take better care of myself i.e. woman’s health, dentist, mental, all of above 
Having better healthy lifestyle
Note. This table details the themes and concepts participants developed using the All-on-the-wall 
procedure. Concepts (right column) represent the sticky notes participants wrote, while themes 
(left column) represent how the group organized these concepts through discussion. Numbers in 
the Concepts column represent the number of sticky notes that mentioned the corresponding 
concept.
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Table 4.K-2
Comparison between Final Analysis and Focus Group Themes
Final Analysis Theme FG Theme Focus Group Description
Success
Lifestyle
Functional Lifestyle
Functional Lifestyle
Functional Lifestyle 
Cessation o f  SUD 
Symptoms
Accomplishing
Self-Efficacy
Psychological
Emotional Wellbeing 
Mental Health
Relationships
Family
Functioning -Can be past, present, or future
-Not taking from society/giving back to society 
-Being able to do routine daily activities (e.g., 
employment, school, take care of kids), vacation, and 
dealing with challenges 
Normalcy -Normalcy is how they feel about their ability to be in the
world, whereas functioning is the “output” or result of this 
-“Clear-headed”
-“Acceptable life”
Physical health -Effects on physical health
Cessation of -No more lying/stealing/chasing to get drugs
“addict” -Less relapse
behavior -Less quantity of drug use (e.g., not using 70+pills)
Psychological -Emotional wellbeing, feeling happy for no reason,
wellbeing improved self-esteem, coping, less social fear, and self­
efficacy
-Getting off antidepressants
-Attitude or belief that you can be successful, rather than 
the actually doing it (which is the code “Doing it for 
yourself”)
-“I like that I’m able to go into public. Before I feared 
going into public because I was always using, so I never 
went into public.”
-“I will get there eventually”
Family -Relational
-Role you play in family
-To be part of the family (participate, engage, build 
relationships)
-“Getting to be a wife and a mother again”
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Table 4.K-2 continued
Final Analysis Theme FG Theme_________________ Focus Group Description
Social Functioning
Psychological
Character
Facilitators/Barriers
Treatment
Psychosocial
Treatment
Psychosocial
Treatment
Psychosocial
Treatment
Availability/ 
accessibility 
Suboxone®
Social -Any reference where participants discuss their relation to
Relationships people outside of their family (e.g., work, school, friends,
and people in group when they’re referred to as “friends”) 
-Can include positive or negative impacts on relationships 
“My relationship with friends is better”
-“I’ve lost relationships again”
Morality -Moral behavior (not lying, stealing)
-Innate moral compass (sense of morality)
Counseling/ -Encouragement, accountability, honesty, support,
Treatment: problem-solving, sharing ideas, goal-setting, & help;-
current Coping
-Being accepted and valued, having friendship, increasing 
motivation
-vital and “key” to success 
Other -Participants discuss prior encounters with substance abuse
Treatment treatment or NA—could be positive or negative
Structure of -Process and policies in place in treatment setting
treatment -Can be positive (not “another drug dealer”; taking the
time to talk; listening) or negative (struggle balancing 
treatment with life; “bringing down the hammer”)
-“See that’s something I really struggle with. Being told 
choose your job or your treatment, and without that job I 
can’t have treatment”
-“And it’s sad how many of those people don’t even want 
to be there that are taking up space for other people.” 
Access to -No access to quality treatment; waitlists; expense
treatment -Unmet need for treatment
Personal -Accepting oneself for being in Suboxone® treatment, or
beliefs about being conflicted/guilty about being on Suboxone®
being on -Some people may be maintained on Suboxone®
Suboxone® -Stigma-induced sense that you’re “Trading one drug for
another”; Beliefs that there needs to be psychosocial 
component for medication-assisted treatment (MAT)
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Table 4.K-2 continued
Final Analysis Theme FG Theme Focus Group Description
Suboxone
(Frequently overlaps 
with) Suboxone®
Contextual factors
External
Assumptions
External
assumptions
Psychological factors
Self-concept and 
feelings
Addiction
Mindset
Benefits of 
Suboxone® 
Gratitude for 
treatment
Stigma
Provider 
awareness of 
Suboxone® 
Psychological 
distress
Denial
Realization
-Any reference to benefits of Suboxone
-Strong sense of appreciation for treatment; discuss 
treatment as pivotal
-“If it weren’t for this treatment, I ’d be dead”
-“We’re just really lucky to have this”
-Judgment for being on Suboxone®
-Negative attitudes or beliefs about Suboxone®
-Desire to address misconceptions to decrease stigma in 
others
“Maybe getting them to really realize what it is, and that 
it’s different. I don’t know, it made me feel kind of good. 
To make them be not so stigmatic about it for lack of a 
better word.”
-Discusses awareness, or lack of awareness, that providers 
and pharmacists have
-Guilt/Doubt/Shame
-Not wanting to be on Suboxone®
-Shameful to get treatment
-Feeling like a loser; low Self-esteem/ self-worth; not 
feeling worthy to be in treatment
-Fearful that others will find out about treatment and judge 
-“Yeah, and I’ve always worried about my family’s 
judgment and whatever, and it took me a long time to just 
not worry and just do me and what’s good for me and my 
daughters.”
-Avoidance of reality; specifically apples to addiction 
-Personal awareness of problem/addiction; hitting rock 
bottom
-Facing what you’ve denied 
-“Admitting it is half the battle”
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Table 4.K-2 continued
Final Analysis Theme FG Theme_________________ Focus Group Description
Recovery
Recovery Attitude
Healing/Growth
Healing/Growth
Healing/Growth
and
Success: 
Accomplishing 
Progress 
Participants Reactions
Not Applicable (NA)
NA—Incorporated in
Different
Themes/Concepts
NA—Incorporated in
Different
Themes/Concepts
Decision/
Desire
Healing
Recovery is 
more than 
sobriety 
Growth/ 
progress
Hopes for the 
research 
Powerful 
quotes 
Spirituality
-The personal choice the participants makes or has made 
concerning their treatment, life, and/or recovery -Mediator 
between self-efficacy (the belief you can) and actually 
doing it (whether for yourself or others)
- Intention/desire to get “clean”
-Can be intrinsic motivation or court-ordered, for family, 
or for God
-“Recovery starts when you decide to be healthy”
-“But it was my desire to please God that gave me the 
desire
-Whereas success is being clean, recovery is healing 
-Holistic process; refers to mending/healing relationships ; 
“Chain reaction of positive”
-“Recovery is a mental, physical, spiritual part of you that 
all comes in and somewhat works together.”
-Notion that there is more involved in “recovery” than
quitting the substance
-In contrast to a “Dry drunk”
-Constant process of improving self involves 
improvements made from past until now and also 
goals/ideas about how they might improve themselves in 
the future
-Reappraisal of goals; self-actualization 
-Participants discuss their hopes for the research
-Heart-felt moments
-Any reference to spirituality/religion 
(May overlap with personal growth)
Addiction prior -Discuss what life was like when using (e.g., lying to 
to treatment doctors)
-“I was just a warm body in case there was a fire”
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Table 4.K-2 continued
Final Analysis Theme FG Theme_________________ Focus Group Description
NA—Incorporated in Challenge/ -Any difficulties described by participants in all aspects of
Different Struggle recovery, treatment, addiction, and life
Themes/Concepts
Note. This table includes a comparison of the final analysis themes (first column) to the initial 
focus group codebook with open codes (second column), and definitions and examples (third 
column). Categories (bolded), themes (underlined), and concepts (italicized) are represented in 
the first column.
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Table 4.K-3
Actual versus Predicted Themes
Actual Themes and Categories that 
Emerged from Participants
Predicted Themes 
Based on the Literature
Success
Lifestyle
Cessation o f  SUD 
Symptoms
Functional Lifestyle
Living Life
Accomplishment
Progress
Self-Efficacy
Relationships
Family
Social Functioning
Restoring Relationships 
Psychological
Emotional Wellbeing
Mental Health 
Character
-Consumption: Abstinence, reduction in opioid-use, reduction in the 
use of AOD
-Addiction and opioid-specific factors: Coping skills, cravings, other 
addictive behavior (e.g., drug seeking), drug consumption and 
intoxication, pain*, poor response to medication, addiction and 
problematic medication use, enhancement expectancies, relapse 
-Functional Factors: Citizenship, criminal activity, Employment status 
and functioning, reduction in other mental health symptoms, stability 
in one’s housing environment
-Health: Healthcare use patterns, HIV risk-taking behavior, 
improvement in physical health
-Quality of life: Safety and security, relationships, health, 
connectedness with community, spirituality (connectedness with 
higher power), sense of meaning, creativity
-Quality of life: reappraisal of goals 
-Psychological health: self-efficacy
-Psychosocial and family functioning: relationship with significant 
others
-Psychosocial and family functioning: Community engagement and 
connectedness, social functioning, social interactions, social pressures
(No predicted theme)
-Psychological Health: Psychological adjustment, Stress, Coping, and 
emotional volatility
-Psychological Health: Cognitive impairment, Mental health 
-Quality of life: self-esteem
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Table 4.K-3 continued
Actual Themes and Categories that 
Emerged from Participants
Predicted Themes 
Based on the Literature
Recovery
Healing/Growth
Process
Recovery Attitude
(No Actual Theme)
Facilitators and Barriers 
Treatment factors
Psychosocial Treatment
Addresses shame/discrimination 
Contributing to society
Cultural; Supported by peers; Rebuilding community
Healing from trauma
Health/wellness
Improved relationships/social functioning 
Life skills/self-care
Meaning-making process toward self actualization 
Personal growth
Psychiatric and psychological improvements 
Spirituality
An active process or state of being, without a fixed endpoint
Many pathways
Holistic
Hope and gratitude
Personal recognition/decision to change
Self-determination
Self-directed
Allegiance to those in recovery 
Abstinence is a prerequisite (*for some)
Physical or biomedical functioning*
-Process factors in treatment: “Any positive change”, fit between 
patient and treatment, navigation of treatment, patient satisfaction*, 
“Planting a seed” *, quality of services, therapeutic relationship, 
treatment compliance, treatment engagement, treatment retention* 
Beliefs about treatment; Could handle problem without treatment*; 
Didn’t need treatment*
Time
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Table 4.K-3 continued
Actual Themes and Categories that Predicted Themes
Emerged from Participants_____________________ Based on the Literature
Suboxone® Suboxone®
Availability/Accessibility Process factors before treatment: Access to treatment,
demarginalization, identification, initiation*
Access to treatment/availability
Did not know where to go for treatment
Financial
Psychological factors Motivation
Mindset Readiness to change
Self-efficacy
Psychological functioning
Self-concept and Feelings Stress
Addiction Cravings
Substance use expectancies
Contextual Factors
Social Relationships Social support
Life Transportation
Might have negative impact on job*
External Assumptions Health literacy
Stigma
Structural and systemic
Other Themes that do not Pain*
Correspond with Findings Physical functioning*
Note. This table includes actual themes emerging from the study findings (first column) 
compared to predicted themes identified within the literature (second column).
Themes in the a priori codebook that did not correspond with qualitative themes in this study.
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Appendix M 
Findings Forum PowerPoint
Thanks!
I
■ A special thanks to you all for participating and sharing your 
story with me!
■ Thanks to Cici lo r her commitment to this project! Thanks 
also to Sunshine Clinic!
■ Thanks to the Alaska Mental Health Trust Authority lor 
funding this project!
What will w e do in this group?
■ Welcome!
■ Presentation of Findings
■ Discussion
■ Closing
Welcome
I
■ Purpose of this group:
■ l b  sh are  w hat yon  sh ared
■ Tb m ake ra re  I u n d e n t  an d  w hat you sh a re d  a n d  w hat is im portan t 
to  you
■ Tb d iscu ss  w hat w e shou ld  d o  w ith th e  find ings
■ Other important information:
■ T he g ro u p  sh o u ld  last ab o u t 2 ho u rs
■ In fo rm ed  C onsent a n d  C onfidentiality
■ W hen  w e are  d o n e , te ll C id  an d  sh e  will g iv e  you  a  F red  M eyer 
gift card!
What’s this project about?
I■ Goal: answer these research questions:
■ 1) How d o  OBOT p a tien ts  defin e  recovery?
■ 2) How d o  OBOT p a tien ts  defin e  OBOT su cc ess?
■ 3) W hat facilitators a n d  b a r r ie rs  d o  th e se  p a tien ts  identify  as  re la tin g  to 
th e ir defin ition  of OBOT success?
■ 4) W hat facto rs do  th e se  p a tien ts  identify  as  im portan t fo r m ea su rin g  OBOT
■ Why:
■ OBOT is un ique! C u rren t defin itions of su c c ess /rec o v ery  are  too narrow. 
inconsisten t, an d  m ay not fit for OBOT
■ W e need patient-driven definitions of su cc ess  in  OBOT to CTeale 
appropriate treatment outcomes
■ How: By conducting a focus group and follow-up interviews
Let’s take a quick break.
If you want to stay, please come tell 
me you understand the purpose of the 
group and want to participate.
If you do not want to participate, you 
may leave at this time.
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What I did after conducting the 
interview/focus group
■ Listened to and 
typed up your 
interview/ focus 
group
■ Read the transcripts, 
over and over and 
over!!!
■ Looked for things 
that were common 
and not so common
+ About the folks that participated:
R ange 22-72 
M edian  36
I
1 R a c e /E th n ic ity G e n d e r |
C au casian  100% M ale 98%
Russian 8% fe m a le  42%
42%
A dvanced  90%
8%
B eg an  u s in g  o p io id s ...
P resc rib ed  b y  docto r 03%
F u n /e n h an c e  m ood 79%
To g e t "h igh" 79%
To e sc a p e  som eth ing  nega tive 98%
To c o p e  w ith psycho log ica l issue 30%
To c o p e  w ith stress 67%
To m an a g e  pain 73%
B ecause they  w ere availab le 90%
To fit in 33%
O ther: to  co p e  w ith ce rta in  social 8%
I
In a c tiv e  addic tion 0%
E x p erien ce d  w ithdraw al 100%
C onside r them selves in 100%
recovery
A verage  t im e  In ...
Active
A ddiction
9 years
(2-20 y e a r range)
Recovery 38.29 m onths 
(2 m onths-9 years)
About the folks that participated:
I
| L iv in g L iv in g
U rban 3 (29% ) sp o u se /p a r tn e r  9 (42%  1)
Rural 9 (42% ) W ith ch ild re n  3 (2 9 % )
Rem ole 2 (17% ) W ith p a ren ts  3 (2 9 % )
U rban  & Rural 2 (1 7 ) 2 (16% )
L iv in g  T ab le  2
U rban 3(2 9 % )
R ural/R em ote 7(98% )
7(3 8 % ) 
S (42% )
U rban  & Rural 2(17% )
+
About the folks that participated 
(current health):
B reathing 4
C hron ic p ain
H eart hea lth 1
Infectious d isease 1
Liver/k idney 2
N one 4
A b sc esses /co llap sed  
veins
2
O th er (high b lood  
p re ssu re  & sm oking)
2
+
Questions:
Defining Success & Recovery
■ 1) How do you define success in Buprenorphine treatment? 
What does that mean to you?
■ 2) How do you define '‘recovery?"
■ 3) How does your definition of treatment success relate to. or 
differ from, your definition of recovery?
■ 4) How d id  you come to define success and recovery like 
this?
I
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Questions:
Elements of Success and Recovery
■ 5) Think about yourself in Suboxone treatm ent There may 
have bee n  tunes that you felt successful, and there may have 
been  other tunes that you d id  not feel successful. What 
contributes to feeling successful, or not feeling successful, in 
treatment?
■ 6) What makes it easier or harder for you to achieve success?
I
Questions:
Measuring Success
■ 7) How do we know when there has been  success? What 
should counselors and researchers ask about when they want 
to know if you have been  successful in treatment? What 
should we be  asking to assess or measure if you have been  
successful?
I
Now, let's look at what you 
said!
Questions:
Debriefing
■ 1) Com pared to when you arrived, do you feel better, the 
same, or worse?
■ 2) How would you describe your experience during the 
interview overall?
■ 3) Is there anything else you would like to share or feel 1 
should know before you leave?
Spiritual/Psychological
+ What is Success in Suboxone 
treatment?
■ Stall itu A l/P av trh o lo m e& I
■ Emotional wellbeing, mental h t ih h  spirituality, clear-headed, 
character
•  C o n n ec tio n
■ Family, social relationship*, healing lost relationships
■ L ifesty le
■ Functioning’normal life, healthy lifestyle, em ploym ent.job .school, 
money
■ Treatm ent/counseling. Suboxone, cessation of SUD symptoms, 
abstinence t s  not
■ G ro w th
■ Sslf-sfficacy, progress, hops to r future, grateful, transformation, bring
Ids
I
Emotional
wellbeing
"Feeling happy for no reason, 
nothing major has to happen. I'm just 
generally happy now, where I was 
miserable before." -6
Mental health "I’m off antidepressants” -4
Spirituality “I feel more spiritually connected" -6
Clear-headed "My mind is a lot more clear. I think 
more positively.” -11
Character "I feel like a whole new person" -4 
"Before. I didn't want to share. I hid 
everything." -4
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Connection
Lifestyle
Family "Okay. Just having better relationships 
in general. #  1 My kids, my family, 
gaining all that trust back and 
everything really started with group 
and being on Suboxone and being in 
recovery, relationships & family"-2
Social "My relationships with my friends are
Relationships/ better." -1
Functioning
Healing lost 
Connections
"So I’m making connections that I've 
lost and that feels pretty damn good.'* 
-4
Functioning/normal life *'.. .things like going to work and keeping  a 
regular schedule and paying bills. Maintaining a 
safe place to stay. Being able to keep 
possessions that are necessary to maintain a 
lifestyle, like a car or work equipm ent.. .and 
sustainable lifestyle."-*
Healthy lifestyle ‘‘A healthier lifestyle. All that stuff like going to 
the doctor and taking care of yourself and  going 
to the dentist. You know the little things that I 
probably slacked off on when 1 was getting high 
and not taking care of myself.“ -2
Em ployment/job/ 
school
And I'm  m ore on top of jobs. I m ean with this >ob. 
I'm a (promotion). If 1 was using, 1 wouldn't even 
have a job. -6
Money “you're bettering yourself by having money to 
take care of things" -3
T r e a t m e n t Growth
Cessation of substance 
use disorder 
symptoms
“I don’t have any cravings or anything/' -5 
“With Suboxone. you take it and ... I'm  not 
always chasing d rugs like 1 was before. That
-3
Suboxone “If I wasn’t on Suboxone. I'd b e  dead." -3 
“If I had  to take it the rest of my life, IU be 
willing to do iL" -6
Treatment/counseling “treatm ent does not work as far as quitting 
unless you want it to work" -12 
“a  little bit more success to that was being on 
the OBOT program  treatment." -11
Abstinence vs not “I'd like to b e  abstinent on my own ability, not 
on Suboxone." -3
“I wouldn't like to say that I'm not successful 
because I haven't s topped smoking weed, but I 
think that I'm successful because I’m not doing 
heroin."-10
S e lf-e ff ic a c y  "B ecause I 'm  a b le  to  accom plish  the th ings tha t I
w ant to  a n d  d irec t th e  c o a rse  of m y  h ie ."  -9
P ro g re s s T o r m e. a t th e  beg in n in g , sm all su cc esses  w ere 
g e ttin g  p a s t  th e  poin t w h e re  I ac tually  w as a b le  to 
s to p  tak ing  so m eth in g  for long  en o u g h  to  tak e  the 
su b o x o n e ." -11
H o p e  fo r  fu tu re "I have got, I fe e l like I’v e  go t so  m u ch  m o re  life 
a h e a d  of m e. an d  righ t th ere  that's abou t su cc ess  for
m e." -4
G r a te fu l  "I am . I am  so ...  you  Ye g o in g  to m ak e  m e  c ry ...  I am  
so  gra te fu l b e c a u s e  if I d id n 't h a r e  it. m y so n  w ould 
not have a  m o th er anym ore . I w ould b e  dea d ."  -4
T ra n s fo rm a tio n " I  s e e  it as  a  life-chang ing  e x p e r ie n c e  . It h e lp s  m e  
s tay  focused  on  m y goals .Ya so  it h e lp s . . .ya my
L iv in g  l i f e  T m  sta rtin g  m y  h ie  a n d  I'm  liv ing  m y life  m o re  than
I w as befo re ."  -11
+
How do you define “recovery”?
"/ think it"s a chain reaction o f  positive -  it hap p en s in fo u r  life  
I b ec a u se  on ce  you  start rem ain ing  in recovery  then yo u r health g ets  
b e tter  mentally, physically. " -6
■ Healing/Growth
■ Pi ocean
■ D e s ire
■ P e a c e /a c c e p ta n c e /b a la n c e d  v iew
■ C o n n e c tio n  
. ■ Freedom/living life to the fullest 
I  don 't know  /g u e s s  it was ju st a ser ies  o f  false  starts . It was a few  ye a rs  o f  falling  
ba ck into old  habits a nd  destroying  the progress I  h a d  m a d e ... >ou know  I  g o t to
want it too. Actually want i t  (Before), 1 n e e d e d  to  d o  th ese  things, b u t actually 
wanting to d o  th e m ..th a t is  what I  wouM  term  as the recovery p hase . I  g u ess  you  
__________________________ c -  u.'d s jv  ."m sSlf jr. " 3__________________________
+
Success vs. Recovery
■ Success can be PART of Recovery:
■ "Directly related, bu t separate" -4
■ "O nce yo u  have success, you 're reco very  starts"  - J
■ "Recovery is no t (just) b e in g  sober. ~ -6
■ "A nybody w ho's g o in g  through recovery is  g o in g  to su c c e e d  in life. "  
-It
■ Success is  the outcom e/behavior; Recovery is  the 
process/m indset:
■ "R ecovery  is th e  po in t w h e re  you 're  g e ttin g  b e tte r .. .su c c e s s  is 
m o re  that you’r e  ac tually  d o in g  w hat yo u 're  su p p o se d  to d o ” -11
“Success can be being clean lor a day.. .success is just 
being on a path to better myself I guess it would be 
and recovery would be that long-term...you’re not 
going back out there.’’-10
I
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+ How did you come to define success
and recovery like this?
Q*R>u ajways have an idea in  jrour h e a d  a t  whai righ t and w rong  is." -10  J  
■ Innate knowledge
I
■ Experience
■ External infringement
■ Realizing what's right for you
03: D oing it so  m a n y  times. 
04: S tep  b y  step.
02: Trial an d  error.
"It's all about how  yo u  fe e l about yourself. I f  yo u  fe e l like you 're go ing  
r igh t direction ."-10
in  the
Easier/Harder: Treatment factors
• Treatment
■ H eld  acco u n tab le , su p p o rt, a c ce p ta n ce , m atterin g
■ M ism atch b e tw e e n  patien t a n d  trea tm en t goals, trea tm en t po licy
■ Availahihtv-acefeaaibilitv
■ “7T*eroi nev er enough ro o m " -3
■ *right righ t to he lp  p e o p le  out there understand  it. Because they  
really d o n 't  a lot o f  p e o p le  1 talk to never h ea rd  o f  it. nothing." -4
■ “T h e  Suboxone h elp s  yo u  beca u se  it takes away the sickness  that 
m a k es y o u  want to g o  b a c k  an d  aliena te the pa in .”-4
■ ~Um, th e  only th ing  tim e I  have no t felt successfu l in this program  is 
when I  was dou b tin g  m y se lf fo r b e in g  on Suboxooe."  -6
■ "if allow ed m e  to kn o w  that this is  attainabie. It's like a h elp e r  to start 
with a nd  it h e lp e d  m e  g et to this point now  w here I  can s e e  that I  
can do  it. or  it can b e  done."  -3
I
Easier/Harder: Internal Factors
I
■ D ecislon-desire-m lndset
■ It defin itely was a struggle. But in the e n d  I  ju s t h a d  to p u t m in d  over 
m atter and  ju s t p u t  m y  w illpow er in  there.” -11
■ Internalised feelings
■ "the only thing I  dan  t  l ik e  about Suboxone is I  have a gu ilt fee lin g  
taking  it. a n d  I  don 't know  why." -5
■ *1 am  so  gra te fu l b e c a u se  if  I d id n 't hav e  it, m y son  w ould  no t h a r e  
a  m o th er anym ore . I w ou ld  b e  d ea d ."  -4
■ Self-concept
■ fe e l  like  a d irty  p e rso n  w hen yo u  start, y o u  know  what I  m ean?"
-10
■ *1 b e lie v e  that I d o  h av e  h o p e  that I c a n  b e  not d e p e n d e n t on  
anything." -3
+
Easier/Harder: External Factors
■ Fhmily-friends
■ m o v e d  ou t h e re ...b e c a u se  I w anted  to g e t away b o m  a ll o f  the 
p e o p le ..."  -8
■ External m n m n lla m
■ “T here "s a stigm a that's grown on th e  physicians s id e  o f  it, the 
doctors s id e  o f  it. A s they b e c o m e  aware o f  suboxone: they lo o ke d  at 
the no tes  and  s e e  that w e w ere addicts, there's a stigm a as far as our 
character." - J
•  Support-connection
■ "And I  de fin itely  have  the su p p o r t o f  o thers a n d  that is  h u g e . I  g u ess  
the b ig g es t w ould  b e  m y  wife, bu t fam ily a lso  A n d  the trea tm en t 
The understanding  o f  (counselor) has  b e e n  huge. The h e lp  o f  others 
really h e lp s  a lot "-9
I
+
Easier/Harder: Other
■ U fe
I
■ "Like, having  a jo b  a n d  b e in g  a s in g le  m o m  an d  g o in g  down to 
(rural A K  town) ev ery  other w eek , it  d o esn ’t so u n d  like a lo t b u t it 
was really hard  for m e  to even  do  th e  s tu ff I  was su p p o se d  to  d o  to 
even stay  in this group . " -2
■ (d iscusses changes m  living situation): “So it’s  b e e n  a  v e ry  d ifferen t 
ro ad , it’s  v e ry  n ice . I 'm  very  h a p p y  w h e re  I am  in  m y  life righ t 
now. Pm  h a p p ie r  th an  I've e v e r  b e e n ."  -4
■ Alaska?
■ Time?
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A few thing that I was wondering 
about...
■ Is there something about being m Alaska that warrants life 
own category? Or could it b e  considered more of another 
theme. like “life":
/  think the difference is just the season. I'm going through 
(Current treatment), it* winter time. And when 1 was with (past 
treatment). it was through the summer, starting like in March and 
to have that all through the summer. So, it's just... there "s a lot 
more things to do in the summer. It helped. 1 don‘t 'know Hit was 
Dip-Oopped and I was with (current provider ) during the summer 
and (previous provider) during the winter, ltd  probably be the 
same problem. -12
And especially in Alaska, people get bored and what not -10
Also...
■ Is time a separate factor, o r is it included in  “life1*
I
I know this isn't really what you're looking lor but time. The 
biggest thing is time. Ybu never have enough time. But itls not 
really something that 1 can do anything about But it's definitely 
related to the whole situation because 1 feel like 1 lost 10,12 years 
and 1 should have maybe been trying to do more to make up for 
lost time. -9
II
Measuring Success/ 
Recovery
How should we measure or assess 
success?
I
■ Individualised & Flexible Definition
■ Recognizing needs/traits of peop le who are addicted
■ Other factors to consider
■ Pay attention
the
w orse b e in g  arres ted , b e in g  in jaH, b e in g  in a 
h o u se/lo ck ed  word treatm ent program . A nd  
those are so m e  o f  th e  ways that are kin d  o f 
obvious b u t t o m  there , it w ould  have to com e  
with th e  p a tie n t  " •9
'T h e r e  a n  so  m any o th e r facto rs like  is your p a rtic ip a n t b e in g  h o n est. W hat is  
y o u r partic ip a n t's  id e a  o f su cc ess?  A re y ou  d e e m in g  su cc ess  b a s e d  o n  th e  
s tereo typ ica l so cie ta l definition? W hat k in d  of su cc ess  a re  y ou  look ing  lor?  Are 
y ou  g o in g  to  b a s e  it on  w h e th e r o r not they see m  like you? A re yo u  b a s in g  it on 
w h e th e r o r no t th ey  oomfocm to  your defin ition  of recovery, b e c a u se  I don 't 
know that that w ould  b e  th e  rig h t w ay to  g o  ab o u t it e ith er . -8
Is there anything else you'd like to 
share?
■ Desire to help/m ake change
■ Educate
■ Views of treatm ent/drug use
■ Remove stigma
■ insight/ awareness.' gratitude
I
"don 1 try  to  take this 
m edication away b o m  p e o p le  
who a re  actually trying to  
ch a n g e their  fives. It works. It 
really helps. N ot fo r everybody.
it m ig h t no t w ork for 
everybody, b a t I  th ink fo r the  
m ajority o fp e o p le  it does."
■12
"So ju s t availability, m isunderstanding  about bow  to 
g e t into them, or advertising for them . So I definitely  
those are so m e  o f  the main, k e y  issues." -8
Debriefing
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+
How do you feel after participating 
in the study?
I
■ Positive ox hopeful mood
■ Sharing
■ Desire to change things
“I f e e l  I  f e e l  it's g o o d  to—it*  like  a therapy session  a lm ost...
It g e ts  m y  fee ling  out into the air to m yself.
W hich it's im portant to know  how  you  fe e l and what m akes you  fee l what, 
so ...it*  g o o d  to d o  things like this, f m  in a positive m o o d ." -10
" f fe e l  better.
I  fe e l  b e tte r  h o p in g  that m aybe this can h e lp  in som e
•] 
: J d a l
w ay"\
iJ
In Sum..
I
■ Success includes spiritual/psychological components, 
growth, lifestyle, treatment, and connection
■ Recovery is more related  to the process, and success the 
outcome; recovery is more long-term, success can b e  “small 
successes*'
■ Primary facilitators/barriers include treatment factors (e.g., 
availability-accessibility. treatment, suboxone), internal 
factors (e.g., self-concept, internalized feelings), external 
factors (e.g.. su p p o rt family-friends), and life
+ What do you think? 
Discussion Questions: I
1) What are your general Im pressions of the findings?
2) What was most intar*«tiiuy? Did anything surprise you?
3) Are there findings you may not agree with and would like to 
clArihr?
like to highlight?
5) How would you like to m »  lhl» r»«««reh?
6) How did you fee l about the process of doing this research? 
If you d id  the focus group, how d id  you feel about the sticky- 
notes?
Closing:
I
1) How helpful was it to hear other people 's stories?
2) How was it to participate in this forum using distance 
technology?
3) Any final thoughts/reactions?
Thanks again!!
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